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A B S T R A C T
Background
Depression is an important morbidity associated with stroke that impacts on recovery yet o(en undetected or inadequately treated. This
is an update and expansion of a Cochrane Review first published in 2004 and updated in 2008.
Objectives
Primary objective
• To determine whether pharmacological therapy, non-invasive brain stimulation, psychological therapy, or combinations of these
interventions reduce the prevalence of diagnosable depression a(er stroke
Secondary objectives
• To determine whether pharmacological therapy, non-invasive brain stimulation, psychological therapy, or combinations of these
interventions reduce levels of depressive symptoms, improve physical and neurological function and health-related quality of life, and
reduce dependency a(er stroke
• To assess the safety of and adherence to such treatments
Search methods
We searched the Specialised Registers of Cochrane Stroke and Cochrane Depression Anxiety and Neurosis (last searched August 2018), the
Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 1), in the Cochrane Library, MEDLINE (1966 to August 2018), Embase
(1980 to August 2018), the Cumulative Index to Nursing and Alllied Health Literature (CINAHL) (1982 to August 2018), PsycINFO (1967 to
August 2018), and Web of Science (2002 to August 2018). We also searched reference lists, clinical trial registers (World Health Organization
International Clinical Trials Registry Platform (WHO ICTRP) to August 2018; ClinicalTrials.gov to August 2018), and conference proceedings,
and we contacted study authors.
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Selection criteria
Randomised controlled trials comparing (1) pharmacological interventions with placebo; (2) one of various forms of non-invasive brain
stimulation with sham stimulation or usual care; (3) one of various forms of psychological therapy with usual care and/or attention
control; (4) pharmacological intervention and various forms of psychological therapy with pharmacological intervention and usual
care and/or attention control; (5) non-invasive brain stimulation and pharmacological intervention with pharmacological intervention
and sham stimulation or usual care; (6) pharmacological intervention and one of various forms of psychological therapy with placebo
and psychological therapy; (7) pharmacological intervention and non-invasive brain stimulation with placebo plus non-invasive brain
stimulation; (8) non-invasive brain stimulation and one of various forms of psychological therapy versus non-invasive brain stimulation
plus usual care and/or attention control; and (9) non-invasive brain stimulation and one of various forms of psychological therapy versus
sham brain stimulation or usual care plus psychological therapy, with the intention of treating depression a(er stroke.
Data collection and analysis
Two review authors independently selected studies, assessed risk of bias, and extracted data from all included studies. We calculated mean
diNerence (MD) or standardised mean diNerence (SMD) for continuous data, and risk ratio (RR) for dichotomous data, with 95% confidence
intervals (CIs). We assessed heterogeneity using the I2 statistic and certainty of the evidence according to GRADE.
Main results
We included 49 trials (56 comparisons) with 3342 participants. Data were available for: (1) pharmacological interventions with placebo
(with 20 pharmacological comparisons); (2) one of various forms of non-invasive brain stimulation with sham stimulation or usual care
(with eight non-invasive brain stimulation comparisons); (3) one of various forms of psychological therapy with usual care and/or attention
control (with 16 psychological therapy comparisons); (4) pharmacological intervention and various forms of psychological therapy with
pharmacological intervention and usual care and/or attention control (with two comparisons); and (5) non-invasive brain stimulation
and pharmacological intervention with pharmacological intervention and sham stimulation or usual care (with 10 comparisons). We
found no trials for the following comparisons: (6) pharmacological intervention and various forms of psychological therapy interventions
versus placebo and psychological therapy; (7) pharmacological intervention and non-invasive brain stimulation versus placebo plus non-
invasive brain stimulation; (8) non-invasive brain stimulation and one of various forms of psychological therapy versus non-invasive brain
stimulation plus usual care and/or attention control; and (9) non-invasive brain stimulation and one of various forms of psychological
therapy versus sham brain stimulation or usual care plus psychological therapy.
Treatment eNects observed: very low-certainty evidence from eight trials suggests that pharmacological interventions decreased the
number of people meeting study criteria for depression (RR 0.70, 95% CI 0.55 to 0.88; 1025 participants) at end of treatment, and very
low-certainty evidence from six trials suggests that pharmacological interventions decreased the number of people with less than 50%
reduction in depression scale scores at end of treatment (RR 0.47, 95% CI 0.32 to 0.69; 511 participants) compared to placebo. No trials of
non-invasive brain stimulation reported on meeting study criteria for depression at end of treatment. Only one trial of non-invasive brain
stimulation reported on the outcome <50% reduction in depression scale scores; thus, we were unable to perform a meta-analysis for this
outcome. Very low-certainty evidence from six trials suggests that psychological therapy decreased the number of people meeting the
study criteria for depression at end of treatment (RR 0.77, 95% CI 0.62 to 0.95; 521 participants) compared to usual care/attention control.
No trials of combination therapies reported on the number of people meeting the study criteria for depression at end of treatment. Only one
trial of combination (non-invasive brain stimulation and pharmacological intervention) therapy reported <50% reduction in depression
scale scores at end of treatment. Thus, we were unable to perform a meta-analysis for this outcome.
Five trials reported adverse events related to the central nervous system (CNS) and noted significant harm in the pharmacological
interventions group (RR 1.55, 95% CI 1.12 to 2.15; 488 participants; very low-certainty evidence). Four trials found significant
gastrointestinal adverse events in the pharmacological interventions group (RR 1.62, 95% CI 1.19 to 2.19; 473 participants; very low-
certainty evidence) compared to the placebo group. No significant deaths or adverse events were found in the psychological therapy group
compared to the usual care/attention control group. Non-invasive brain stimulation interventions and combination therapies resulted in
no deaths.
Authors' conclusions
Very low-certainty evidence suggests that pharmacological or psychological therapies can reduce the prevalence of depression. This
very low-certainty evidence suggests that pharmacological therapy, psychological therapy, non-invasive brain stimulation, and combined
interventions can reduce depressive symptoms. Pharmacological intervention was associated with adverse events related to the CNS and
the gastrointestinal tract. More research is required before recommendations can be made about the routine use of such treatments.
P L A I N   L A N G U A G E   S U M M A R Y
Pharmacological, psychological, and brain stimulation treatments for depression aer stroke
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Do pharmacological treatments, non-invasive brain stimulation, psychological treatments, or combination treatments reduce the
proportion of people with depression or the extent of depressive symptoms a(er stroke?
Background
Depression is common a(er stroke yet o(en is not detected or inadequately treated.
Search date
We identified studies by searches conducted on 13 August 2018.
Study characteristics
We included trials that reported on the use of pharmacological, non-invasive brain stimulation, psychological, and combination therapy
interventions to treat depression a(er stroke. Mean age of participants ranged from 54 to 78 years. Studies were from Asia (30), Europe
(11), North America (6), and Australia (2).
Key results
We included 49 trials (56 treatments) involving 3342 participants. Pharmacological treatments resulted in fewer people meeting the study
criteria for depression and less than 50% reduction in depression scale scores at end of treatment. Psychological therapy reduced the
number of people meeting the study criteria for depression at end of treatment. More people in the pharmacological treatment group
reported central nervous system (in five trials) and gastrointestinal side eNects (in four trials) than in the placebo groups. Information on
side eNects of other treatments was not provided.
Certainty of the evidence
Estimates of treatment eNects were imprecise due to small numbers in most studies and recruitment of people with very diNerent baseline
characteristics. We rated the certainty of evidence as very low due to these and other limitations in study design.
Conclusion
Antidepressant drugs may benefit people with persistent depressive symptoms a(er stroke, but care is required in their use, as little is
known about their side eNects. Psychological therapy may oNer a treatment option. Future research should include a broader group of
people with stroke.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Pharmacological intervention compared to placebo for treating depression aer stroke
Pharmacological interventions compared to placebo for treating depression after stroke
Patient or population: people with depression after stroke
Setting: inpatient, outpatient, or mixed
Intervention: pharmacological intervention
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes












Study populationDepression: meeting study criteria for de-
pression at end of treatment (Analysis 1.1)









Study populationDepression: < 50% reduction in scale scores
at end of treatment (Analysis 1.2)









Depression: mean scores at end of treatment (Analysis 1.4) - - - - No totals
Neurological function: mean scores at end of treatment (Analysis
1.13)
SMD 0.95 lower









Study populationAdverse events: death - at end of treatment
(Analysis 1.14)









Study populationAdverse events: all - central nervous system
events (e.g. confusion, sedation, tremor)












































































































































































Study populationAdverse events: all - gastrointestinal effects
(e.g. constipation, diarrhoea) (Analysis 1.15)









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; SMD: standardised mean difference
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the quality of evidence as several studies were rated as high or unclear risk for multiple risk of bias domains.
bWe downgraded the quality of evidence due to substantial heterogeneity (50% to 89%) observed.
cWe downgraded the quality of evidence as the confidence intervals were wide.
dWe downgraded the quality of evidence due to moderate heterogeneity (30% to 49%) observed.
eWe downgraded the quality of evidence as the confidence intervals were very wide.
 
 
Summary of findings 2.   Non-invasive brain stimulation compared to sham non-invasive brain stimulation and/or usual care for treating depression
aer stroke
Non-invasive brain stimulation compared to sham non-invasive brain stimulation and/or usual care for treating depression after stroke
Patient or population: people with depression after stroke
Setting: inpatient, outpatient, or mixed
Intervention: non-invasive brain stimulation
Comparison: usual care and/or sham non-invasive brain stimulation
Anticipated absolute effects* (95% CI)Outcomes















Depression: meeting study criteria for depression at end of treatment
(Analysis 2.1)





































































































































































Depression: < 50% reduction in scale scores at end of treatment
(Analysis 2.2)
- - - - No totals
Depression: mean scores at end of treatment (Analysis 2.3) MD 6.63 lower






Depression: mean scores at end of follow-up (Analysis 2.4) MD 2.60 lower






Neurological function: mean scores at end of treatment (Analysis 2.7) SMD 2.21 lower






Adverse events: death - at end of treatment (Analysis 2.8) - - - - No data avail-
able
Adverse events: all - central nervous system events (e.g. confusion, se-
dation, tremor) (Analysis 2.9)
- - - - No data avail-
able
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; SMD: standardised mean difference.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the quality of evidence as several studies were rated as high or unclear risk in multiple risk of bias domains.
bWe downgraded the quality of evidence as the confidence intervals were very wide.
cWe downgraded the quality of evidence due to considerable heterogeneity (90% to 100%) observed.
dWe downgraded the quality of evidence as the confidence intervals were wide.
 
 
Summary of findings 3.   Psychological therapy compared to usual care and/or attention control for treating depression aer stroke
Psychological therapy compared to usual care and/or attention control for treating depression after stroke
Patient or population: people with depression after stroke





































































































































































Comparison: usual care and/or attention control
Anticipated absolute effects* (95% CI)Outcomes














Study populationDepression: meeting study criteria for de-
pression at end of treatment (Analysis 3.1)









Depression: < 50% reduction in scale
scores at end of treatment (Analysis 3.2)
- - - - - No data avail-
able










Depression: mean scores at end of treatment (Analysis 3.4) - - - - No data avail-
able
Study populationDepression: meeting study criteria for de-
pression at end of follow-up (Analysis 3.5)









Study populationAdverse events: death - at end of treat-
ment (Analysis 3.17)









Study populationAdverse events: leaving the study early
(including death) - all dropouts and with-









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.




































































































































































Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the quality of evidence as several studies were rated as unclear or high risk in multiple risk of bias domains.
bWe downgraded the quality of evidence as confidence intervals were wide.
cWe downgraded the quality of evidence as confidence intervals were very wide.
 
 
Summary of findings 4.   Pharmacological intervention and a form of psychotherapy (combination) compared to pharmacological intervention and
usual care or attention control (single) for treating depression aer stroke
Pharmacological intervention and a form of psychotherapy (combination) compared to pharmacological intervention and usual care or attention control (single)
for treating depression after stroke
Patient or population: people with depression after stroke
Setting: inpatient, outpatient, or mixed
Intervention: pharmacological intervention and a form of psychotherapy (combination)
Comparison: pharmacological intervention and usual care or attention control (single)

















Depression: meeting study criteria for depression at end of treatment
(Analysis 4.1)
- - - - No data avail-
able
Depression: < 50% reduction in scale scores at end of treatment
(Analysis 4.2)
- - - - No data avail-
able
Depression: mean scores at end of treatment
(Analysis 4.3)
MD 1.53 lower






Activities of daily living: mean scores at end of treatment (Analysis 4.5) MD 11.83 higher






Neurological function: mean scores at end of treatment (Analysis 4.6) - - - - No totals





































































































































































Adverse events: all - gastrointestinal effects (e.g. constipation, diar-
rhoea) (Analysis 4.8)
- - - - No totals
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the quality of evidence as both studies were rated as unclear risk in multiple risk of bias domains.
bWe downgraded the quality of evidence as substantial heterogeneity (50% to 89%) was observed.
cWe downgraded the quality of evidence as the confidence intervals were very wide.
dWe downgraded the quality of evidence as considerable heterogeneity (90% to 100%) was observed.
 
 
Summary of findings 5.   Non-invasive brain stimulation and pharmacological intervention (combination) compared to pharmacological intervention
and sham stimulation or usual care (single) for treating depression aer stroke
Non-invasive brain stimulation and pharmacological intervention (combination) compared to pharmacological intervention and sham stimulation or usual care
(single) for treating depression after stroke
Patient or population: people with depression after stroke
Setting: inpatient, outpatient, or mixed
Intervention: non-invasive brain stimulation and pharmacological intervention (combination)
Comparison: pharmacological intervention and sham stimulation or usual care (single)
Anticipated absolute effects* (95% CI)Outcomes
Risk with pharmacological in-
tervention (single)
Risk with non-invasive brain
stimulation and pharmaco-
logical intervention and sham












Depression: meeting study criteria for depression at end of treat-
ment (Analysis 5.1)






































































































































































Depression: < 50% reduction in scale scores at end of treatment
(Analysis 5.2)
- - - - No data avail-
able
Depression: mean scores at end of treatment (Analysis 5.3) MD 4.09 lower






Activities of daily living: mean scores at end of treatment (Analysis
5.6)
SMD 2.03 higher






Neurological function: mean scores at end of treatment (Analysis
5.8)







Adverse events: death - at end of treatment (Analysis 5.9) - - - - No data avail-
able
Study populationAdverse events: leaving the
study early (including death)









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio; SMD: standardised mean difference.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the quality of evidence as the confidence intervals were very wide.
bWe downgraded the quality of evidence as several studies were rated as unclear or high risk in multiple risk of bias domains.
cWe downgraded the quality of evidence as substantial heterogeneity (50% to 89%) was observed.
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B A C K G R O U N D
Description of the condition
Depression and anxiety disorders are important sequelae of stroke.
These mood disorders occur in up to half of people during
the first year a(er onset of stroke, although estimates diNer
between studies due to varying definitions, populations, exclusion
criteria, and timing of assessments (Ayerbe 2013; Hackett 2014).
Inconsistent research findings are also due to the complexity of
recognition, assessment, and diagnosis of an underlying mood
disorder associated with acute stroke and cognitive, language,
and other impairments. In addition, people with stroke may
experience a variety of behavioural syndromes that are more
specific to brain injury, including indiNerence, emotional lability,
disinhibition, unawareness of illness (anosognosia), and diNiculties
with verbal emotional expression (aprosody). In particular, much
of the controversy surrounding 'stroke-associated depression' as
a specific type of depressive syndrome hinges on concern about
whether the tools normally used for diagnosis of major depression
and other depressive illnesses may mis-attribute features of
ischaemic brain injury to depression (House 1987; Johnson 1991).
Although several depression screening tools have been validated
(against a structured clinical interview) for use in people with stroke
(Turner 2012), in practice, researchers use a range of methods to
diagnose depression - a psychiatric interview to apply standard
diagnostic criteria such as those provided in the Diagnostic and
Statistical Manual of Mental Disorders (e.g. DSM-IIIR, DSM-IV, DSM
V) (APA 1987; APA 1994; APA 2013), or psychiatric rating scales
such as the Montgomery Åsberg Depression Rating Scale (MADRS)
(Montgomery 1979), or a rating scale of mood based on self-
assessment.
Although controversy continues about whether depression a(er
stroke is predominantly caused by physical factors (such as stroke
lesion location) (Carson 2000), or by a person's psychological
response to stroke, evidence suggests that clinically diagnosed
stroke-associated depression is similar in frequency and nature
to depression among older people with other chronic illnesses
(Burvill 1996; Burvill 1997; Sharpe 1990). Although it was previously
thought that the period of greatest risk appeared to be within
the first few months of stroke onset (Burvill 1995a; Herrmann
1998; House 1991), this was not apparent in systematic reviews of
high-quality observational studies (Hackett 2014). Although some
people recover spontaneously, apparently undergoing a grief-
like depressive adjustment reaction, up to one-third of people
have depression that persists during the first year or longer a(er
stroke onset (Astrom 1996; Herrmann 1998). Those with 'anxious
depression' and those with more severe symptoms at presentation
appear less responsive to treatment and have a worse long-term
prognosis (Astrom 1996).
Evidence of a causal relationship between stroke-associated
depression and adverse outcomes is complicated by potential
confounding factors such as age, gender, social class, physical
disability, and comorbid conditions. However, evidence provided
by Parikh 1990 and Sinyor 1986 suggests that abnormal mood
may impede rehabilitation by impairing physical function (Ayerbe
2013), as well as cognitive function (Robinson 1986), and by
contributing to stress on carers (Anderson 1995a). Furthermore,
stroke-associated depression may be associated with increased
risk of death (House 2001; Morris 1993b), including death by suicide
(Stenager 1998). Depressive illness among older people, in general,
is associated with greater morbidity and dependency, higher use of
drugs and alcohol, increased use of healthcare resources, and poor
compliance with treatment of comorbid conditions (Katona 1995).
Description of the intervention
We considered three broad interventions.
• Pharmacological interventions designed to treat depression:
several classes of relevant pharmacological agents include
selective serotonin reuptake inhibitors (SSRIs) (e.g. fluvoxamine,
fluoxetine, sertraline, citalopram, paroxetine), serotonin-
norepinephrine reuptake inhibitors (SNRIs) (e.g. venlafaxine,
milnacipran, sibutramine), monoamine oxidase inhibitors
(MAOIs) (e.g. moclobemide), tricyclic antidepressants (TCAs)
(e.g. nortriptyline, imipramine, clomipramine), and other
antidepressant medications including psychostimulants (e.g.
methylphenidate), mood stabilisers (e.g. lithium), or
benzodiazepines.
• Non-invasive brain stimulation: electroconvulsive therapy (ECT)
involves the brief passage of an electrical current through
the brain via electrodes applied to the scalp to induce a
generalised seizure (i.e. a fit or convulsion). The seizure
comprises two components: a central element - the ictus
involving depolarisation (i.e. discharge of neurotransmitter
chemicals) of brain cells - and a peripheral element consisting of
convulsive, jerking movements of the body, although this is now
modified due to use of a short-acting anaesthetic and muscle
relaxant, as part of what is called modified ECT. Modified ECT
replaced the crude equipment and techniques of unmodified
ECT used in the mid-1950s. The seizure is detected by electrodes
placed on the scalp to monitor brain electrical activity (i.e.
EEG). The ECT electrodes can be placed on both sides of
the head (bilateral placement), or on one side - usually the
right side of the head (unilateral placement). Passage of an
electrical current through the skull to the brain is necessary to
trigger a seizure. In this update, we broadened the review to
include other non-invasive brain stimulation techniques such as
(1) transcranial magnetic stimulation or repetitive transcranial
magnetic stimulation (TMS or rTMS, where a magnetic 'coil'
is placed near the head of the person receiving the treatment
without making physical contact); (2) transcranial direct current
stimulation (tDCS, where a constant, low current is delivered
directly to the brain area of interest via small electrodes); (3)
cranial electrotherapy stimulation (CES, where a small, pulsed
electrical current is applied across a patient's head); and (4)
magnetic seizure therapy (MST), a type of convulsive therapy
that involves replacing the electrical stimulation used in ECT
with a rapidly alternating strong magnetic stimulation.
• One of various forms of psychological therapy (talking therapy)
designed to treat depression: as many therapies are available,
we included any psychological therapy that involved direct
patient-professional interaction. The content of the interaction
could vary from counselling to specific psychotherapy, provided
it was directed at helping people develop their social problem-
solving skills and adjust to the emotional impact of stroke. All
interventions had to have a psychological component - talking,
listening, support, advice; they had to be based on a theory
of talking therapy; had to be structured and time-tabled as a
talking therapy; and had to be delivered by somebody with
some explicitly stated training in and supervision of therapies.
The person-professional interaction could take place in person,
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via telephone, or through other media. We did not include
web-based interventions even if mediated by a healthcare
professional. We did not include interventions based upon self-
management or supported self-management.
We further considered these combinations of three broad
interventions.
• Pharmacological intervention and one of various forms of
psychological therapy versus pharmacological intervention plus
usual care and/or attention control.
• Non-invasive brain stimulation and pharmacological
intervention versus pharmacological intervention plus sham
stimulation or usual care.
• Pharmacological intervention and one of various forms of
psychological therapy versus placebo plus psychological
therapy.
• Pharmacological intervention and non-invasive brain
stimulation versus placebo plus non-invasive brain stimulation.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus non-invasive brain stimulation
plus usual care and/or attention control.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus sham brain stimulation or usual
care plus psychological therapy.
How the intervention might work
Pharmacological interventions are thought to alter the
synaptic transmission process within the brain to increase
neurotransmission, for example, SSRIs are intended to block the
resorption of serotonin, SNRIs are designed to increase the levels of
serotonin and norepinephrine, and TCAs are designed to block the
reuptake of norepinephrine.
During modified ECT, a small amount of electrical current is passed
briefly across the brain to cause an artificial epileptic fit that
aNects the entire brain. Repeated ECT is believed to alter chemical
pathways in the brain that are responsible for depression. The
exact mechanism of action of rTMS, tDCS, and CES remains unclear.
They are thought to induce intracerebral current flow and increase
or decrease neuronal excitability and/or activate nerve cells in
the specific area being stimulated. rTMS involves replacing the
electrical stimulation used in ECT with a magnetic stimulus, which
is purported to produce similar clinical eNects but without the
cognitive side eNects.
Psychological therapy focuses on changing thinking, emotional,
behavioural, and relationship patterns. During psychological
therapies, trained therapists work with individuals to help them see
patterns in their thoughts, emotions, behaviours, or relationships
that may be problematic. The therapist's role is to help a person
understand these patterns while assist that person in developing
ways to overcome them.
Why it is important to do this review
Although depression may influence recovery and outcomes
following stroke, many (perhaps most) people with stroke do
not receive eNective treatment because their mood disorder is
undiagnosed or is inadequately treated. The UK National Sentinel
Audit found that 25% of patients were not screened for depression,
and only 60% of those identified as needing support received
it. Ebrahim 1987a found that few people with stroke-associated
depression had been given antidepressants following discharge
from hospital, and House 1989 reported that general practitioners
and hospital doctors had a passive attitude toward therapy. On the
other hand, some more recent studies have found antidepressant
prescribing persisting long term but with little attempt to match
prescribing to need (Paul 2006). Although this variability may reflect
problems with the diagnosis of a 'significant' mood state among
older people with disability, it may also reflect uncertainty among
clinicians as to the balance of benefits and risks (including side
eNects) of therapies in this setting. For example, it is not clear that in
other settings, antidepressants are of benefit for mild or moderate
depression of the sort that is common a(er stroke (Fournier 2010).
Indirect evidence of the eNectiveness of pharmacological and
psychological treatments for depression (and anxiety) for older
people in general, and for those with associated physical illness, is
available in several published reviews (Gill 2000; Kirsch 2008; Lima
2001; McCusker 1998; Mittmann 1997; Wilkinson 1997). However,
because of the possibility that depression a(er stroke may diNer in
important ways, it may be inappropriate to extrapolate these data
to people with stroke. Use of rTMS, tDCS, and CES in people with
stroke is relatively new, and few data are available to guide clinical
decision-making.
We undertook and updated a systematic review of all
randomised controlled trials (RCTs) (published and unpublished)
of pharmacological agents, non-invasive brain stimulation,
psychological therapies, or their combination for treatment of
depression a(er stroke. This is an update of a Cochrane Review first
published in 2004 and last updated in 2008.
O B J E C T I V E S
Primary objective
• To determine whether pharmacological therapy, non-invasive
brain stimulation, psychological therapy, or combinations of
these interventions reduce the prevalence of diagnosable
depression a(er stroke
Secondary objectives
• To determine whether pharmacological therapy, non-invasive
brain stimulation, psychological therapy, or combinations of
these interventions reduce levels of depressive symptoms,
improve physical and neurological function and health-related
quality of life, and reduce dependency a(er stroke
• To assess the safety of and adherence to such treatments
M E T H O D S
Criteria for considering studies for this review
Types of studies
We restricted the review to all relevant randomised controlled trials
(RCTs) only. There was no restriction on eligibility of RCTs on the
basis of language, sample size, duration of follow-up, or publication
status. Trials that met all inclusion criteria, but from which no
outcome data were available (neither from the report of the trial
nor from the study authors), could not contribute meaningfully to a
pooled estimate of eNect. These trials were regarded as 'dropouts'
rather than as ineligible.
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Types of participants
We defined stroke according to clinical criteria, including cerebral
infarction, intracerebral haemorrhage, and 'uncertain' pathological
subtypes. We excluded trials of people with subarachnoid
haemorrhage (SAH) only, as this entity has a diNerent natural
history and management strategy from other stroke subtypes.
However, we did include trials with mixed stroke subtypes,
including small numbers of people with SAH. There were no
restrictions on the basis of age, sex, or other characteristics.
Participants were required to have depression (diagnosed by
psychiatric interview, mood scale, or treating clinician) on
recruitment. We excluded trials with participants who were not
depressed at recruitment, but that measured depression as the
primary outcome at follow-up. These trials were included in a
review of interventions for preventing depression a(er stroke
(Hackett 2008a).
The diagnostic categories of depression considered were:
• depressive disorder, as defined by symptom scores on a
standard screening instrument - scoring above a pre-defined
scoring threshold;
• major depression, as defined by the American Psychiatric
Association Diagnostic and Statistical Manual of Mental Disorders
(DSM-IIIR, DSM-IV, DSM-V; APA 1987; APA 1994; APA 2013), or
similar diagnostic criteria; and
• dysthymia or minor depression, as defined by DSM or other
standard diagnostic criteria.
Trials that included mixed populations (such as those with stroke
and head injury or other central nervous system (CNS) disorders)
were excluded unless separate results for people with stroke
could be identified. Trials were excluded if participants were being
treated primarily for a stroke-associated pain syndrome, even if
depression was measured as a secondary outcome.
Types of interventions
We included the following interventions.
• Comparison between a pharmacological intervention and
placebo for treatment of depression a(er stroke. Specific
pharmacological agents included tricyclic antidepressants
(e.g. nortriptyline, imipramine, clomipramine), selective
serotonin reuptake inhibitors (SSRIs) (e.g. fluvoxamine,
fluoxetine, sertraline, citalopram, paroxetine), monoamine
oxidase inhibitors (MAOIs) (e.g. moclobemide), and other
antidepressant medications. Trials of mood stabilisers (e.g.
lithium) or of benzodiazepines and psychostimulants (e.g.
methylphenidate) were analysed separately.
• Comparison between non-invasive brain stimulation and sham
stimulation or usual care for treatment of depression associated
with stroke.
• Comparison between psychological therapy and usual care and/
or attention control for treatment of depression a(er stroke.
We included any psychological therapy that involved direct
person-professional interaction. The content of the interaction
could vary from counselling to specific psychological therapy,
provided it was directed at helping people develop their social
problem-solving skills and adjust to the emotional impact of
stroke. All interventions had to have a psychological component
- talking, listening, support, advice - and had to be based on a
theory of talking therapy; had to be structured and time-tabled
as a talking therapy; and had to be delivered by somebody with
some explicitly stated training in and supervision of therapies.
Alternatively, we included their combinations.
• Pharmacological intervention and one of various forms of
psychological therapy versus pharmacological intervention plus
usual care and/or attention control.
• Non-invasive brain stimulation and pharmacological
intervention versus pharmacological intervention plus sham
stimulation or usual care.
• Pharmacological intervention and one of various forms of
psychological therapy versus placebo plus psychological
therapy.
• Pharmacological intervention and non-invasive brain
stimulation versus placebo plus non-invasive brain stimulation.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus non-invasive brain stimulation
plus usual care and/or attention control.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus sham brain stimulation or usual
care plus psychological therapy.
Exclusions included the following.
• Interventions with an agent or therapy that was being evaluated
primarily for other reasons (e.g. to improve physical function, to
provide neuroprotection, to facilitate neuroregeneration), even
if the intervention was a recognised treatment for depression,
and even if a standardised depression scale was administered at
baseline and at outcome assessment (these trials are included
in a separate systematic review, with depression as a secondary
endpoint (Mead 2012)).
• Interventions provided with the sole purpose of educating or
providing information.
• Occupational therapy (including leisure therapy and other
rehabilitation services).
• Acupuncture or electro-acupuncture.
• Herbal medicines.
• Interventions that involved visits from stroke support workers,
unless there was a clearly defined psychological component.
Attention control in psychological therapy trials can include
non-specific interventions such as relaxation classes or follow-
up with a clinician who has no psychological training.
Types of outcome measures
Primary outcomes
Primary analyses focused on remission and included the following.
• Meeting the criteria for depression at end of treatment, as
defined by DSM or similar standard diagnostic criteria.
• Less than 50% reduction in depression scale scores at end of
treatment.
Secondary outcomes
• Depression scores as measured on scales such as the
Hamilton Depression Rating Scale (HDRS; Hamilton 1960),
the Montgomery Åsberg Depression Rating Scale (MADRS;
Montgomery 1979), the Geriatric Depression Scale (GDS;
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Gompertz 1993), the Beck Depression Inventory (BDI; Beck
1961), and the Hospital Anxiety and Depression Scale (HADS
Depression subscale; Zigmond 1983) at end of treatment and at
follow-up
• Meeting the criteria for depression at end of follow-up, as
defined by DSM or similar standard diagnostic criteria
• Less than 50% reduction in depression scale scores at end of
follow-up
• Psychological distress scores, as measured on composite scales
such as the General Health Questionnaire (GHQ; Goldberg 1972)
at end of treatment
• Anxiety scores, as measured on scales such as the Hamilton
Anxiety Scale, the Beck Anxiety Inventory, and the Hospital
Anxiety and Depression Scale (HADS Anxiety subscale; Zigmond
1983) at end of treatment
• Cognitive function scores, as measured on scales such as the
Mini-Mental State Examination (MMSE; Folstein 1975) at end of
treatment
• Activities of daily living scores, as measured on scales such as
the Barthel Index (BI; Mahoney 1965) at end of treatment
• Disability scores, as measured on scales such as the Functional
Independence Measure (FIM; Deutsch 1997)
• Neurological function scores, as measured on scales such as the
National Institutes of Health Stroke Scale (NIHSS; Lyden 2001)
• Disadvantages of treatment recorded as adverse events,
grouped by death, all, and leaving the study early (including
death)
Participants' reasons for withdrawal from trials were examined as
a marker of acceptance.
Search methods for identification of studies
This review is an update of a previously published Cochrane Review
update (2008) (Hackett 2008; Appendix 1). The first review was
published in 2004 (Hackett 2004). For this update, we searched
all databases from inception until August 2018. We searched for
relevant trials in all languages and arranged for translation of trial
reports when necessary.
Specialised Register of Cochrane Stroke
See the methods for the Cochrane Stroke Group Specialised
register; the Cochrane Stroke Group Information Specialist
searched the Specialised Register of Cochrane Stroke on 13 August
2018.
Electronic searches
We searched the following bibliographic databases.
• Cochrane Depression Anxiety and Neurosis Trials Register (last
searched August 2018).
• Cochrane Central Register of Controlled Trials (CENTRAL; 2018,
Issue 1), in the Cochrane Library (Appendix 2).
• MEDLINE (OVID): 1966 to August 2018 (Appendix 3).
• Embase (OVID): 1980 to August 2018 (Appendix 4).
• PsycINFO (OVID): 1967 to August 2018 (Appendix 5).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCO): 1982 to August 2018 (Appendix 6).
• Science Citation Index - Expanded (SCI-EXPANDED), Social
Sciences Citation Index (SSCI), and Arts & Humanities Citation
Index (A&HCI) within Web of Science: 2002 to August 2018
(Appendix 7).
Biological Abstracts has now been superseded by ISI Web of
Science, which includes the Arts and Humanities Index. Several
databases/citation indexes (Applied Science and Technology Plus;
Biological Abstracts; BIOSIS Previews; General Science Plus;
Dissertations and Theses) listed in Appendix 1 were not used for this
update.
Searching other resources
We searched the following resources using "stroke" or "brain
infarction" or "depression" or "low mood" from inception to August
2018.
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (www.who.int/ictrp/en/).
We also searched abstracts and conference proceedings from the
following international conferences for relevant studies.
• European Stroke Organisation Conference (2015 to 2018).
• Stroke Society of Australasia Annual Scientific Meetings (2008 to
2018).
• World Stroke Congress (2000 to 2016).
• Asia Pacific Stroke Conference (2011 to 2017).
The full search strategies for other resources are provided in
Appendix 8.
Personal communications
We contacted the study authors to ask for information on ongoing
studies or to request additional study data and, in some instances,
additional analyses.
Reference lists
We searched the reference lists of relevant trials, systematic
reviews, and reviewed chapters in books on the prevention and
treatment of depression and management of stroke, including
but not limited to, reviews of the management of stroke, books
specifically directed at treatment or prevention of depression, and
writings on stroke and old age.
Data collection and analysis
Selection of studies
Two review authors (SA, KC) reviewed all new citations and
discarded those that were irrelevant based on the title of the
publication and its abstract. When any suggestion was made that
an article was possibly relevant, we retrieved the full-length article
for further assessment. Two review authors (SA, KC) independently
selected the new trials for inclusion in the review from the culled
citation list. Potentially relevant Chinese articles were translated
by another study author (C-FH). We resolved disagreements by
discussion, and MH and AH confirmed the final list and adjudicated
any persisting diNerences of opinion. The selection process is
presented in a PRISMA flow diagram (Figure 1). Due to changes in
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the inclusion criteria for this update, records were re-screened from
the point of inception. Although we have tried our best to reflect
this in the PRISMA flow diagram, it is likely that the numbers will
not add up. We listed the included studies under Characteristics
of included studies and studies that we ultimately excluded under
Characteristics of excluded studies, and we provided the primary
reasons for exclusion.
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Figure 1.   Study flow diagram. Eligibility criteria were changed to include non-invasive brain stimulation
interventions in this update. The 2015 search was rerun from the point of inception to screen for non-invasive brain
stimulation and combination interventions.
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Figure 1.   (Continued)
 
Data extraction and management
Five review authors (SA, KC, C-FH, HL, MH) independently extracted
study characteristics and outcome data from included studies and
entered them on specially designed forms. We cross-checked and
entered the data into Review Manager 5 (Review Manager 2014).
We resolved disagreements by discussion or through consultation
with two other review authors (AH or MH). We obtained missing
information from the study authors when possible. Information
on funding sources is mentioned in the notes sections of the
Characteristics of included studies table.
We collected data on:
• the report: author, year, and source of publication;
• the study: sample characteristics, social demography, and
definition and criteria used for depression;
• the participants: stroke sequence (first ever vs recurrent), social
situation, time elapsed since stroke onset, history of psychiatric
illness, current neurological status, current treatment for
depression, and history of coronary artery disease;
• the research design and features: sampling mechanism,
treatment assignment mechanism, adherence, non-response,
and length of follow up;
• the intervention: type, duration, dose, timing, and mode of
delivery; and
• the eNect size: sample size, nature of outcome, estimate, and
standard error on x dy = SD.
To allow for intention-to-treat (ITT) analysis, we sought the data
irrespective of adherence and fidelity of the intervention, and
regardless of whether participants were subsequently deemed
ineligible or were otherwise excluded from treatment or follow-up.
When study authors used multiple measures to assess depression,
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we extracted data from the measure the study authors stated
was used to assess the primary outcome. For measures assessing
secondary outcomes, we extracted data from the most commonly
used measure. When data for the same trial endpoint were
conflicting across multiple publications, we extracted data from the
first publication reporting data for that outcome.
We checked all extracted data for agreement between review
authors. We obtained missing information from the primary
investigators whenever possible. To avoid introducing bias, we
obtained this unpublished information in writing, on forms
designed for the purpose, and entered it into RevMan.
Assessment of risk of bias in included studies
Three review authors (SA, KC, C-FH) independently assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by consultation
with another review author (MH). Although a number of scales
have been devised to assess the quality of RCTs, no convincing
evidence shows that complex and time-consuming scales are more
eNective than simple scales (Verhagen 2001). We assessed risk of
bias according to the following domains.
• Random sequence generation.
• Allocation concealment: if allocation was performed using
opaque envelopes, we also categorised this as 'high risk' as it is
not tamper-proof.
• Blinding of participants and personnel: for psychological
interventions, we recognise that participants are unlikely to
remain blinded; however we also categorised this as 'high risk'.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting: if a published trial had no
corresponding published or registered protocol, this was
assessed as unclear risk.
• Other bias.
We also provided a quote from the study to justify our judgement
in the Risk of bias in included studies table. When considering
treatment eNects, we have taken into account the risk of bias for
studies that contributed to that outcome.
Measures of treatment e;ect
Dichotomous data
For all dichotomous outcomes, we calculated risk ratios (RRs) with
95% confidence intervals (CIs) when appropriate, using random-
eNects analyses.
Continuous data
For continuous data, if ordinal scale data appeared to be normally
distributed, or if the analysis suggested that parametric tests were
appropriate, we treated outcome measures as continuous. If at
least two studies reported the same outcomes, then we calculated
a mean diNerence (MD) with 95% CI across trials. When diNerent
outcome measures were used, we calculated a standardised mean
diNerence (SMD) with 95% CI.
Unit of analysis issues
We predicted that randomisation would occur at the level of
the individual participant in most, if not all, trials. Outcomes are
reported at end of treatment and at end of follow-up when data
are available. When trials included two or more active intervention
arms and only one control arm (placebo, attention control, or usual
care), we compared data from each treatment arm with data from
the total number of participants in the control arm divided by the
number of active intervention arms. Comparisons are presented as
separate trials.
Dealing with missing data
We wrote to the authors of all included, ongoing, and dropout trials
to request data that were unavailable or ambiguous in published
articles. We also wrote to all pharmaceutical companies known to
produce, or having a licence to produce, antidepressants in 2004.
We received nine replies identifying no new trials, so we did not
repeat this in the 2008 update nor in the current update.
Assessment of heterogeneity
Clinical and methodological heterogeneity were assessed by
examining the study characteristics. We used the I2 statistic to
measure heterogeneity among the trials in each analysis (Deeks
2011). If at least two trials reported the same outcomes, we
reviewed the data for appropriateness of pooling. We interpreted
the amount of heterogeneity as low (0% to 29%), moderate
(30% to 49%), substantial (50% to 89%), and considerable (90%
to 100%) using I2 values. We reported similarities between
interventions, participants, design, and outcomes in the Included
studies subsection.
Assessment of reporting biases
We assessed publication bias by using a funnel plot only if 10
or more trials were included (Higgins 2011). We attempted to
avoid language bias by including trials irrespective of language of
publication, and we provided translation when needed by native
speakers of that language.
In some cases, similarities between trial reports indicated the
possibility of multiple publications from the same trial. We
contacted study authors to check whether these publications
were duplicates. In the absence of a response and explicit cross-
referencing, we judged articles to be from the same trial if they
met the following criteria: (1) evidence suggested overlapping
recruitment sites, trial dates, and grant funding numbers, and (2)
similar or identical patient characteristics were reported by trial
authors.
Data synthesis
We analysed data using Review Manager so(ware and pooled
data for meta-analysis when studies assessed similar treatments
and had similar outcomes (Review Manager 2014). We conducted
a meta-analysis using available or calculated MD or SMD for
continuous outcomes, and RR for dichotomous outcomes. We
included measures of uncertainty in the results, such as 95% CIs and
estimates of I2.
'Summary of findings' and certainty of the evidence
We assessed the certainty of evidence according to GRADE by
constructing a 'Summary of findings' table for the outcomes below,
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per comparison, using the GRADEPro tool (GRADEproGDT 2015)
(Atkins 2004; Schunemann 2011).
These data were available for comparison: (1) pharmacological
interventions versus placebo; (2) one of various forms of
non-invasive brain stimulation versus sham stimulation or
usual care; (3) one of various forms of psychological therapy
versus usual care and/or attention control; (4) pharmacological
intervention and various forms of psychological therapy
versus pharmacological intervention and usual care and/or
attention control (with two comparisons); and (5) non-invasive
brain stimulation and pharmacological intervention versus
pharmacological intervention and sham stimulation or usual care
(with 10 comparisons).
For comparison 1, 'pharmacological intervention versus placebo',
we reported certainty of evidence for the following outcomes:
meeting study criteria for depression at end of treatment, < 50%
reduction in depression scale scores at end of treatment, mean
neurological function scores at end of treatment, adverse events
related to CNS and gastrointestinal tract and death at end of
treatment.
For comparison 2, 'non-invasive brain stimulation versus sham or
usual care', we reported certainty of evidence for the following
outcomes: mean depression scores at end of treatment, mean
depression scores at end of follow-up, mean neurological function
scores at end of treatment, and death at end of treatment.
For comparison 3, 'psychological intervention versus usual care
or attention control', we reported certainty of evidence for the
following outcomes: meeting the study criteria for depression at
end of treatment, average change in depression scores between
baseline and end of treatment, meeting the study criteria for
depression at end of follow-up, death, and leaving the study early
(including death) at end of treatment.
For comparison 4, 'pharmacological intervention and a form
of psychological therapy (combination) versus pharmacological
intervention and usual care or attention control (single)', we
reported certainty of evidence for mean depression scores at end of
treatment, mean activities of daily living at end of treatment, and
death at end of treatment.
For comparison 5, 'non-invasive brain stimulation
and pharmacological intervention (combination) versus
pharmacological intervention and sham stimulation or usual care
(single)', we reported certainty of evidence for the following
outcomes: mean depression scores at end of treatment, mean
activities of daily living scores at end of treatment, mean
neurological function scores at end of treatment, death, and
leaving the study early (including death) at end of treatment.
We found no trials for these comparisons: (6) pharmacological
intervention and various forms of psychological therapy
interventions versus placebo and psychological therapy; (7)
pharmacological intervention and non-invasive brain stimulation
versus placebo plus non-invasive brain stimulation; (8) non-
invasive brain stimulation and one of various forms of
psychological therapy versus non-invasive brain stimulation plus
usual care and/or attention control; and (9) non-invasive brain
stimulation and one of various forms of psychological therapy
versus sham brain stimulation or usual care plus psychological
therapy.
Subgroup analysis and investigation of heterogeneity
We planned to undertake subgroup analyses for all outcomes
when feasible to explore the influence of date of publication,
sample size, duration of follow-up, treatment type, high (over
20%) number of dropouts, and blinded versus unblinded outcome
assessors. If at least two trials reported the same outcomes, we
reviewed the data for appropriateness of pooling. If we found
definitive evidence of heterogeneity (I2 > 50%), we explored
potential reasons for diNerences by performing subgroup analyses
and meta-regression (Normand 1999). If heterogeneity could not be
explained, we combined trials using random-eNects analyses with
cautious interpretation, or we did not combine them at all. When
possible, we performed subgroup analyses to examine the impact
of treatment type and duration, and of stroke severity.
Sensitivity analysis
We explored the sensitivity of the combined estimate of individual
trials for all outcomes when feasible by leaving one study out if
we noted high risk of bias and methodological diNerences. We
then calculated the combined eNect of the remaining trials and
compared these results with the combined eNect based on all trials.
R E S U L T S
Description of studies
Results of the search
In total, we identified 23,228 records; of these, we retrieved 22,748
through database searching. We found 480 additional references by
searching other resources. A(er 14,128 duplicates were removed,
we screened 9100 titles and abstracts and excluded 8967 irrelevant
records. We retrieved full-text reports for the remaining 133 studies.
A(er reading the full texts, we excluded 44 trials as they did not
meet the review eligibility criteria. We have provided the primary
reasons for exclusions in the Characteristics of excluded studies
table and in Figure 1. We identified 10 trials that met the inclusion
criteria (Chang 2011; Hadidi 2014; Jorge 2004; Jorge 2008; Kim
2017; Kim 2017a; Kootker 2012; RaNaele 1996; Robinson 2000;
Valiengo 2017). However, data were not available for depressed
participants only (Chang 2011; Hadidi 2014; Jorge 2004; Jorge 2008;
Kim 2017; Kim 2017a; RaNaele 1996; Robinson 2000; Valiengo 2017),
or were not in a format suitable for meta-analysis (Kootker 2012).
These trials are considered 'dropouts' (Table 1). In the previously
published version of this review (Hackett 2008), eight trials met
the inclusion criteria but were considered 'dropouts' (Bramanti
1989; Choi-Kwon 2006; Delbari 2011; Downes 1995; Mauri 1988;
Meara 1998; Ohtomo 1985; Sun 2000), as outcome data were not
available at all (Downes 1995), or outcome data were not available
for depressed participants only (Choi-Kwon 2006; Delbari 2011;
Ohtomo 1985; Sun 2000), or outcome data were not presented in
a format suitable for meta-analysis (Bramanti 1989; Meara 1998;
Mauri 1988). See Table 1 for more detailed information on these
studies.
We contacted the study authors to ask for information on ongoing
studies or to request additional study data and, in some instances,
additional analyses. We received responses with additional data
regarding seven trials (Andersen 1994; Downes 1995; Fruehwald
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2003; Lincoln 2003; Murray 2002; Reding 1986, Towle 1989). In 2008,
we received responses with additional data from the authors of
two trials (Lai 2006a; Watkins 2007). We received responses with
additional data or information from the authors of seven new trials
(Cullen 2018; Fang 2017; HoNmann 2015; Kerr 2018; Kirkness 2017a;
Mitchell 2002; Robinson 2008a).
Included studies
From the first published version of this review, a total of
nine included trials included 671 participants (Andersen 1994;
Fruehwald 2003; Lincoln 2003; Lipsey 1984; Murray 2002; Ohtomo
1991; Reding 1986; Towle 1989; Wiart 2000). Seven additional trials
(eight comparisons) with 864 participants were included in the
2008 update of this review (Jiang 2001a/Jiang 2001b; Lai 2006a;
Ponzio 2001; Rampello 2005; Watkins 2007; Yang 2002; Zhao 2004).
Lincoln 2003 compared an active treatment with an attention
control (time spent by participants in the treatment group with
a trained therapist was controlled in the attention control group
by participants spending an equal amount of time in focused
conversation), as well as another control (standard care). We
combined data from the attention control and control groups, and
we compared these with data from the treatment group. Jiang
2001a compared two active treatment arms versus a placebo arm.
We compared data from both treatment arms against data from half
the number of participants in the placebo arm and presented the
results as two separate comparisons (Jiang 2001a; Jiang 2001b).
More detailed information is provided in Characteristics of included
studies.
This present review includes 33 trials (39 comparisons) with 2807
participants. Cao 2009a and Jiang 2014a were parallel RCTs with
four arms. We compared data from both treatment arms with
their respective control arms and presented the results as separate
comparisons (Cao 2009a; Cao 2009b; Jiang 2014a; Jiang 2014b).
Gao 2017a and Kirkness 2017a compared two active treatment
arms versus a usual care or attention control arm. We compared
data from both treatment arms with data from half the number
of participants in the usual care or attention control arm and
presented the results as separate comparisons (Gao 2017a; Gao
2017b; Kirkness 2017a; Kirkness 2017b). Similarly, Robinson 2008a
compared two active treatment arms against a placebo arm. Data
from both treatment arms were compared with data from half
the number of participants in the placebo arm (Robinson 2008a;
Robinson 2008b). Yang 2014a compared two active treatment arms
versus a sham non-invasive brain stimulation arm. We compared
data from both treatment arms with data from half the number of
participants in the sham non-invasive brain stimulation arm (Yang
2014a; Yang 2014b).
Participants
All trials in this review included men and women. The mean age
of participants ranged from 55 to 77.5 years. Most trial authors
reported the time since stroke and randomisation into the trial,
with the range covering 'within a few days' to 36 months post
stroke. Most trials included participants with ischaemic stroke,
diagnosed via a combination of standard clinical and computed
tomography (CT) criteria. For more detailed information on each
included trial, please refer to the Characteristics of included studies
table.
Interventions and comparators
We reported results from the following comparisons: (1)
pharmacological intervention versus placebo; (2) non-invasive
brain stimulation versus sham non-invasive brain stimulation; (3)
one of various forms of psychological therapy versus usual care
and/or attention control; (4) pharmacological intervention and one
of various forms of psychological therapy versus pharmacological
intervention and usual care and/or attention control; and (5)
non-invasive brain stimulation and pharmacological intervention
versus pharmacological intervention and sham stimulation or
usual care. In 18 trials, 20 pharmacological comparisons were
assessed against placebo (Andersen 1994; Fruehwald 2003; Gao
2017a; Huang 2002; Jiang 2001a/Jiang 2001b; Kong 2007; Lai 2006a;
Li 2008; Lipsey 1984; Murray 2002; Ohtomo 1991; Ponzio 2001;
Rampello 2005; Reding 1986; Robinson 2008a/Robinson 2008b;
Wang 2005; Wiart 2000; Yang 2002). Seven trials (eight comparisons)
reported on non-invasive brain stimulation comparisons versus
sham or usual care (Chen 2005a; Gu 2016; Jiang 2014a; Meng
2015; Yang 2013; Yang 2014a;/Yang 2014b; Zheng 2016), and the
authors of 15 trials (16 comparisons) assessed various forms
of psychological therapy compared to usual care or attention
control (Alexopoulos 2012; Cao 2009b; Cullen 2018; Fang 2017;
Gao 2017b; HoNmann 2015; Kerr 2018; Kirkness 2017a/Kirkness
2017b; Lincoln 2003; Mitchell 2002; Thomas 2007; Towle 1989; Wang
2004a; Watkins 2007; Zhao 2004). In two trials (two comparisons),
a combination of pharmacological interventions and psychological
therapy was assessed against pharmacological intervention and
usual care and/or attention control (Cao 2009a; Wang 2005a). In
10 trials (10 comparisons), a combination of non-invasive brain
stimulation and pharmacological intervention was compared to
pharmacological intervention and sham stimulation or usual care
(Du 2005; Fan 2014; Jiang 2014b; Jin 2013; Li 2013; Li 2014; Liu 2015;
Lu 2016; Sun 2013; Zhang 2013).
We found no trials for the following comparisons: (6)
pharmacological intervention and one of various forms of
psychological therapy compared to placebo and psychological
therapy; (7) pharmacological intervention and non-invasive brain
stimulation versus placebo plus non-invasive brain stimulation;
(8) non-invasive brain stimulation and one of various forms of
psychological therapy versus non-invasive brain stimulation plus
usual care and/or attention control; and (9) non-invasive brain
stimulation and one of various forms of psychological therapy
versus sham brain stimulation or usual care plus psychological
therapy.
Pharmacological interventions
Among the trials of pharmacological interventions, 12 compared
an SSRI against placebo (citalopram: Andersen 1994; Gao 2017a;
fluoxetine: Fruehwald 2003; Huang 2002; Kong 2007; Li 2008;
Wang 2005; Wiart 2000; paroxetine: Lai 2006a; Ponzio 2001;
Yang 2002; sertraline: Murray 2002); two trials compared a
tricyclic antidepressant against placebo (amitriptyline: Jiang
2001a; nortriptyline: Lipsey 1984); and six trials compared
other treatments with antidepressant eNects (Deanxit: Jiang
2001b; Aniracetam: Ohtomo 1991; reboxetine: Rampello 2005;
trazodone: Reding 1986; nefiracetam: Robinson 2008a; Robinson
2008b). We found no trials of mood stabilisers (e.g. lithium) or
benzodiazepines. We found one trial of psychostimulants (e.g.
methylphenidate), which was considered a 'dropout' as outcome
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data for those with depression at entry could not be separated from
data for those without (Delbari 2011).
Non-invasive brain stimulation
Among trials reporting on non-invasive brain stimulation
interventions, seven compared rTMS versus sham rTMS or usual
care (no changes to antidepressant dosage and medication) (Chen
2005a; Gu 2016; Meng 2015; Yang 2013; Yang 2014a; Yang 2014b;
Zheng 2016). In only one trial, TMS was compared with usual care
(Jiang 2014a). Two trials compared high-frequency rTMS versus
sham or usual care (Yang 2013; Yang 2014a), and one trial compared
low-frequency rTMS versus sham stimulation or usual care (Yang
2014b). We found no trials of ECT. Any future trials will be included
but analysed separately.
Psychological therapy
Forms of psychological therapy included structured cognitive-
behavioural therapy delivered by trained psychologists or nurses
(Gao 2017b; HoNmann 2015; Lincoln 2003; Mitchell 2002; Thomas
2007); motivational interviewing (MI) delivered by nurses or non-
clinical psychologists (Kerr 2018; Watkins 2007); psychosocial
therapy delivered by psychosocial nurse practitioner therapists
in person or via telephone (Fang 2017; Kirkness 2017a; Kirkness
2017b); group psychotherapy (Cao 2009b); and psychotherapy
with an ecosystem aspect (Alexopoulos 2012); treatments focused
on psychological support (Wang 2004a), problem-solving therapy
with counselling delivered by social workers (Towle 1989),
and a supportive psychological intervention including education
delivered by special personnel (Cullen 2018; Zhao 2004).
Combination therapy
In two trials, a combination of psychotherapy and an SSRI was
compared with an SSRI alone (fluoxetine: Cao 2009a; paroxetine:
Wang 2005a). In six trials, rTMS and an SSRI were compared with
an SSRI (fluoxetine: Du 2005; Li 2014; Zhang 2013; citalopram: Liu
2015; sertraline: Jiang 2014b; Jin 2013). In two trials, rTMS and an
SNRI were compared with an SNRI alone (duloxetine: Fan 2014; Lu
2016). In one trial, rTMS and another antidepressant medication
were compared with an antidepressant alone (mirtazapine: Li
2013). Only one trial compared rTMS and a combination of
antipsychoactive agents and tricyclic antidepressants (flupenthixol
and melitracen: named Deanxit) versus Deanxit alone (Sun 2013).
Outcomes
Primary outcome - depression
In 14 trials (15 comparisons), outcome data for meeting the study
criteria for depression at end of treatment were assessed and
reported (Alexopoulos 2012; Andersen 1994; Fang 2017; Fruehwald
2003; Kirkness 2017a/Kirkness 2017b; Lincoln 2003; Lipsey 1984;
Mitchell 2002; Murray 2002; Ohtomo 1991; Ponzio 2001; Watkins
2007; Yang 2002; Zhao 2004). For the outcome less than 50%
reduction in depression scale scores at end of treatment, six trials
contributed data (Andersen 1994; Lai 2006a; Li 2008; Murray 2002;
Wiart 2000; Yang 2002).
Secondary outcomes
A variety of additional outcomes were assessed in each trial.
Several trials assessed and reported outcome data for depression
scores (Alexopoulos 2012; Andersen 1994; Cao 2009b; Chen 2005a;
Cullen 2018; Fruehwald 2003; Gu 2016; HoNmann 2015; Huang
2002; Jiang 2001a; Jiang 2001b; Kerr 2018; Kong 2007; Lai 2006a;
Li 2008; Lincoln 2003; Lipsey 1984; Mitchell 2002; Murray 2002;
Rampello 2005; Robinson 2008a; Robinson 2008b; Thomas 2007;
Wang 2004a; Wiart 2000; Yang 2013; Yang 2014a; Yang 2014b; Zhao
2004), psychological distress scores (Lincoln 2003; Watkins 2007),
anxiety scores (Cullen 2018; Fang 2017; HoNmann 2015; Kerr 2018;
Wang 2005a), cognitive function scores (Du 2005; Gao 2017a; Gao
2017b; Wang 2005; Wiart 2000), activities of daily living scores
(Cao 2009a; Cao 2009b; Du 2005; Fan 2014; Gao 2017a; Gao 2017b;
HoNmann 2015; Kerr 2018; Kirkness 2017a; Kirkness 2017b; Kong
2007; Li 2008; Li 2014; Lincoln 2003; Meng 2015; Mitchell 2002; Yang
2013), disability scores (Alexopoulos 2012; Chen 2005a; Fruehwald
2003; Lu 2016; Sun 2013; Wang 2004a; Watkins 2007; Wiart 2000),
and neurological function scores (Huang 2002; Jiang 2001a; Jiang
2001b; Jiang 2014a; Jiang 2014b; Jin 2013; Kong 2007; Liu 2015;
Meng 2015; Zheng 2016). In 24 trials (28 comparisons), study
authors reported having systematically measured and reported
adverse events (Alexopoulos 2012; Andersen 1994; Du 2005; Fang
2017; Fruehwald 2003; Gao 2017a/Gao 2017b; Gu 2016; Huang 2002;
Jiang 2001a/Jiang 2001b; Jiang 2014a/Jiang 2014b; Li 2008; Lincoln
2003; Lipsey 1984; Liu 2015; Meng 2015; Mitchell 2002; Murray
2002; Ponzio 2001; Robinson 2008a/Robinson 2008b; Thomas 2007;
Towle 1989; Wang 2005a; Watkins 2007; Wiart 2000). Adverse event
data o(en were not collected, were not reported, or were reported
poorly.
Excluded studies
We excluded a total of 44 trials at the full-text review stage for
a variety of reasons, including (1) depression not the primary
outcome of the study (n = 22); (2) data not available for depressed
participants only (n = 20); or (3) data not available in a suitable
format for meta-analysis (n = 2). See Characteristics of excluded
studies.
Ongoing studies
Five trials are ongoing (Kirkevold 2018: psychological therapy;
NCT03056287: non-invasive brain stimulation; Tang 2017: non-
invasive brain stimulation; Thomas 2016: psychological therapy; Xu
2016: pharmacological intervention).
Studies awaiting classification
From the previously published version of this review, four trials are
listed as awaiting classification (Evans 1985; Hanspal 2007; Katz
1998; Pearson 2005). We were unable to obtain more information
or outcome data from these trials despite multiple attempts to
contact the study authors. In the present review, 13 trials (17
comparisons) are awaiting classification (Chen 2002a/Chen 2002b;
Ding 2005; Finkenzeller 2009; He 2003; He 2005; Huang 2005; Latow
1983; Lee 2005; Liu 2010; Razazian 2016; Tang 2002; Wang 2015;
Yan 2010a/Yan 2010b/Yan 2010c/Yan 2010d). We were unable to
obtain more information or outcome data for three of these despite
multiple attempts to contact the study authors (He 2003; Latow
1983; Lee 2005). For two trials (three comparisons), we were unsure
if depression was the primary outcome (Chen 2002a/Chen 2002b;
Razazian 2016). In eight trials (11 comparisons), no information
was provided for the psychotherapy component of the intervention
to help us determine if it meets our review criteria (Ding 2005;
Finkenzeller 2009; He 2005; Huang 2005; Liu 2010; Tang 2002; Wang
2015; Yan 2010a/Yan 2010b/Yan 2010c/Yan 2010d).
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Dropout studies
From the previously published review, eight trials met the inclusion
criteria for this review (Bramanti 1989; Choi-Kwon 2006; Delbari
2011; Downes 1995; Mauri 1988; Meara 1998; Ohtomo 1985; Sun
2000). However, no outcome data were available in one trial
(unpublished data only: Downes 1995); in others, data were not
presented on depressed participants at baseline (Choi-Kwon 2006;
Delbari 2011; Ohtomo 1985; Sun 2000), or data were not presented
in a suitable format for inclusion in the meta-analysis (Bramanti
1989; Mauri 1988; Meara 1998).
In this review, 10 additional trials met the inclusion criteria
(Chang 2011; Hadidi 2014; Jorge 2004; Jorge 2008; Kim 2017; Kim
2017a; Kootker 2012; RaNaele 1996; Robinson 2000; Valiengo 2017).
However, data were not presented on depressed participants only
at baseline (Chang 2011; Hadidi 2014; Jorge 2004; Kim 2017; Kim
2017a; RaNaele 1996; Robinson 2000), or data were not presented in
a suitable format (Kootker 2012; Valiengo 2017), or we were unable
to verify if any participants had a diagnosis of stroke or if there were
duplicate data from another trial (Jorge 2008). We considered these
trials as 'dropouts' and have provided more detailed information in
Table 1.
Risk of bias in included studies
We present a graphical summary of risk of bias assessments
performed by review authors for the included trials in Figure 2,
based on the seven risk of bias domains. Figure 3 provides a
summary of risk of bias for each included trial. We have provided
the reasons for judgements in the Risk of bias in included studies
tables.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
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Figure 3.   (Continued)
 
 
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews
Figure 3.   (Continued)
 
Allocation
The randomisation sequence was appropriately generated in 25
trials (29 comparisons); thus we rated then as low risk (Alexopoulos
2012; Cullen 2018; Fang 2017; Fruehwald 2003; Gao 2017a/Gao
2017b; HoNmann 2015; Jiang 2014a/Jiang 2014b; Kerr 2018;
Kirkness 2017a/Kirkness 2017b; Kong 2007; Li 2008; Li 2014; Lincoln
2003; Lipsey 1984; Lu 2016; Meng 2015; Mitchell 2002; Murray 2002;
Rampello 2005; Reding 1986; Robinson 2008a/Robinson 2008b;
Thomas 2007; Towle 1989; Watkins 2007; Zhang 2013). However, 21
trials (24 comparisons) did not describe their method of sequence
generation, and so we rated them as unclear risk (Andersen 1994;
Cao 2009a/Cao 2009b; Fan 2014; Gu 2016; Huang 2002; Jiang
2001a/Jiang 2001b; Jin 2013; Lai 2006a; Li 2013; Liu 2015; Ponzio
2001; Sun 2013; Wang 2004a; Wang 2005; Wang 2005a; Wiart
2000; Yang 2002; Yang 2013; Yang 2014a/Yang 2014b; Zhao 2004;
Zheng 2016). We rated three trials as high risk, as generation of
sequence was controlled by the investigators (Ohtomo 1991), or the
method was drawing lots (Chen 2005a; Du 2005), which could be
manipulated.
We rated 12 trials (13 comparisons) as low risk, as an appropriately
generated and clearly concealed allocation procedure was used
in the study (Cullen 2018; Fruehwald 2003; Kerr 2018; Kong
2007; Li 2008; Lipsey 1984; Murray 2002; Rampello 2005; Reding
1986; Robinson 2008a/Robinson 2008b; Thomas 2007; Wiart 2000).
Twenty-nine trials (33 comparisons) did not describe adequate
concealment allocation, and we rated them as unclear risk
(Alexopoulos 2012; Cao 2009a/Cao 2009b; Chen 2005a; Du 2005;
Fan 2014; Gu 2016; Huang 2002; Jiang 2014a/Jiang 2014b; Jin 2013;
Kirkness 2017a/Kirkness 2017b; Lai 2006a; Li 2013; Li 2014; Liu 2015;
Lu 2016; Meng 2015; Mitchell 2002; Ohtomo 1991; Ponzio 2001;
Sun 2013; Wang 2004a; Wang 2005; Wang 2005a; Yang 2002; Yang
2013; Yang 2014a/Yang 2014b; Zhang 2013; Zhao 2004; Zheng 2016).
We rated eight trials (10 comparisons) as high risk for allocation
concealment, as they used sealed opaque envelopes, which could
be tampered with (Andersen 1994; Fang 2017; Gao 2017a/Gao
2017b; HoNmann 2015; Jiang 2001a/Jiang 2001b; Lincoln 2003;
Towle 1989; Watkins 2007) .
Blinding
The authors of nine trials (10 comparisons) reported that
participants and personnel were blinded to the treatment
allocation, and so we rated these trials as low risk for
performance bias (Andersen 1994; Fruehwald 2003; Kong 2007;
Lipsey 1984; Murray 2002; Ohtomo 1991; Reding 1986; Robinson
2008a/Robinson 2008b; Wiart 2000). We rated 22 trials (25
comparisons) as unclear risk, as they did not provide information
about blinding of participants and personnel (Cao 2009a/Cao
2009b; Cullen 2018; Fan 2014; Gu 2016; Huang 2002; Jiang
2014a/Jiang 2014b; Jin 2013; Lai 2006a; Li 2013; Li 2014; Liu 2015;
Lu 2016; Ponzio 2001; Sun 2013; Wang 2004a; Wang 2005; Wang
2005a; Yang 2002; Yang 2013; Yang 2014a/Yang 2014b; Zhang 2013;
Zheng 2016). We rated 15 trials (18 comparisons) as high risk for
performance bias, as participants or personnel were not blinded to
treatment allocation (Alexopoulos 2012; Chen 2005a; Du 2005; Fang
2017; Gao 2017a/Gao 2017b; HoNmann 2015; Jiang 2001a/Jiang
2001b; Kerr 2018; Kirkness 2017a/Kirkness 2017b; Li 2008; Lincoln
2003; Rampello 2005; Towle 1989; Watkins 2007; Zhao 2004).
We rated 19 trials (24 comparisons) as low risk for detection
bias, as outcome assessors were blinded to treatment allocation
(Andersen 1994; Chen 2005a; Cullen 2018; Fang 2017; Fruehwald
2003; Gu 2016; HoNmann 2015; Jiang 2014a/Jiang 2014b; Kirkness
2017a/Kirkness 2017b; Li 2008; Lipsey 1984; Mitchell 2002; Murray
2002; Ohtomo 1991; Rampello 2005; Reding 1986; Robinson
2008a/Robinson 2008b; Wiart 2000; Zhao 2004). Twenty-four trials
(27 comparisons) did not provide information about blinding of
outcome assessors, and we rated them as unclear risk of detection
bias (Cao 2009a/Cao 2009b; Fan 2014; Huang 2002; Jin 2013; Kong
2007; Jiang 2001a/Jiang 2001b; Lai 2006a; Li 2013; Li 2014; Liu
2015; Lu 2016; Meng 2015; Ponzio 2001; Sun 2013; Thomas 2007;
Towle 1989; Wang 2004a; Wang 2005; Wang 2005a; Yang 2002; Yang
2013; Yang 2014a/Yang 2014b; Zhang 2013; Zheng 2016). We rated
six trials (seven comparisons) as high risk because they did not
use blinded outcome assessment (Alexopoulos 2012; Du 2005; Gao
2017a/Gao 2017b; Kerr 2018; Lincoln 2003; Watkins 2007).
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Incomplete outcome data
We rated 26 trials (29 comparisons) as low risk, as they provided ITT
analyses (Andersen 1994; Chen 2005a; Du 2005; Fan 2014; HoNmann
2015; Huang 2002; Jiang 2001a/Jiang 2001b; Jin 2013; Lai 2006a;
Li 2013; Li 2014; Liu 2015; Meng 2015; Ponzio 2001; Rampello
2005; Reding 1986; Sun 2013; Wang 2004a; Wang 2005; Watkins
2007; Wiart 2000; Yang 2013; Yang 2014a/Yang 2014b; Zhang 2013;
Zhao 2004; Zheng 2016). We rated 18 trials (22 comparisons) as
high risk for attrition bias, as they reported per-protocol analyses
only (Cullen 2018; Fang 2017; Fruehwald 2003; Gao 2017a/Gao
2017b; Jiang 2014a/Jiang 2014b; Kirkness 2017a/Kirkness 2017b;
Kong 2007; Li 2008; Lincoln 2003; Lipsey 1984; Lu 2016; Mitchell
2002; Murray 2002; Ohtomo 1991; Robinson 2008a/Robinson 2008b;
Thomas 2007; Towle 1989; Yang 2002). The method of analysis was
unclear in four trials (five comparisons) (Alexopoulos 2012; Cao
2009a/Cao 2009b; Kerr 2018; Wang 2005a).
Selective reporting
We rated 45 trials (51 comparisons) as unclear risk for reporting
bias, as no trial protocol was available to compare a priori outcomes
versus those reported in publications (Alexopoulos 2012; Andersen
1994; Cao 2009a/Cao 2009b; Chen 2005a; Cullen 2018; Du 2005;
Fan 2014; Fang 2017; Fruehwald 2003; Gao 2017a/Gao 2017b; Gu
2016; HoNmann 2015; Huang 2002; Jiang 2001a/Jiang 2001b; Jiang
2014a/Jiang 2014b; Jin 2013; Kirkness 2017a/Kirkness 2017b; Kong
2007; Lai 2006a; Li 2008; Li 2013; Li 2014; Lincoln 2003; Lipsey 1984;
Liu 2015; Lu 2016; Meng 2015; Murray 2002; Ohtomo 1991; Ponzio
2001; Rampello 2005; Reding 1986; Sun 2013; Towle 1989; Wang
2004a; Wang 2005; Wang 2005a; Watkins 2007; Wiart 2000; Yang
2002; Yang 2013; Yang 2014a/Yang 2014b; Zhang 2013; Zhao 2004;
Zheng 2016). We rated four trials (five comparisons) as high risk,
as one or two outcomes mentioned in the study protocol or trial
registry information page were not reported in the primary results
publication (Kerr 2018; Mitchell 2002; Robinson 2008a/Robinson
2008b; Thomas 2007).
Other potential sources of bias
We rated 38 trials (44 comparisons) as low risk for other
bias, as baseline demographics and depression scores were
balanced between groups (Alexopoulos 2012; Andersen 1994; Cao
2009a/Cao 2009b; Chen 2005a; Cullen 2018; Du 2005; Fan 2014;
Fruehwald 2003; Gao 2017a/Gao 2017b; Gu 2016; Huang 2002;
Jiang 2001a/Jiang 2001b; Jiang 2014a/Jiang 2014b; Jin 2013; Kerr
2018; Kirkness 2017a/Kirkness 2017b; Kong 2007; Li 2008; Li 2013;
Li 2014; Lipsey 1984; Liu 2015; Lu 2016; Mitchell 2002; Ponzio
2001; Rampello 2005; Sun 2013; Thomas 2007; Towle 1989; Wang
2004a; Wang 2005a; Watkins 2007; Wiart 2000; Yang 2013; Yang
2014a/Yang 2014b; Zhang 2013; Zhao 2004; Zheng 2016). We rated
10 trials (11 comparisons) as unclear, as no information about
baseline demographics and depression scores between groups was
provided (Fang 2017; HoNmann 2015; Lai 2006a; Meng 2015; Murray
2002; Ohtomo 1991; Reding 1986; Robinson 2008a/Robinson 2008b;
Wang 2005; Yang 2002). We rated two trials (three comparisons)
as high risk, as baseline demographic or depression scores were
uneven between groups (Jiang 2001a/Jiang 2001b; Lincoln 2003).
E;ects of interventions
See: Summary of findings for the main comparison
Pharmacological intervention compared to placebo for treating
depression a(er stroke; Summary of findings 2 Non-invasive brain
stimulation compared to sham non-invasive brain stimulation
and/or usual care for treating depression a(er stroke; Summary
of findings 3 Psychological therapy compared to usual care
and/or attention control for treating depression a(er stroke;
Summary of findings 4 Pharmacological intervention and a form
of psychotherapy (combination) compared to pharmacological
intervention and usual care or attention control (single) for treating
depression a(er stroke; Summary of findings 5 Non-invasive
brain stimulation and pharmacological intervention (combination)
compared to pharmacological intervention and sham stimulation
or usual care (single) for treating depression a(er stroke
Overall, we included 3342 participants in this review. In view
of the large number and heterogeneous nature of the outcome
measures (multiple measures o(en used for the same endpoint
with no primary measure stated) and the reporting of results,
we considered it inappropriate to pool outcome data for many
endpoints. For details of all comparisons made for the trials with
outcome data, refer to the Data and analyses section.
See Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; Summary of findings 4; and
Summary of findings 5 for comparisons.
Primary outcomes
Depression (remission)
Meeting study criteria for depression at end of treatment
Eight trials (eight comparisons) on pharmacological interventions
reported on the outcome meeting study criteria for depression
at end of treatment (Andersen 1994; Fruehwald 2003; Lipsey
1984; Murray 2002; Ohtomo 1991; Ponzio 2001; Wang 2005; Yang
2002). We observed treatment eNects favouring pharmacological
interventions compared to placebo (risk ratio (RR) 0.70,
95% confidence interval (CI) 0.55 to 0.88, 1025 participants,
very low-certainty evidence; Analysis 1.1). However, substantial
heterogeneity (I2 = 68%) and wide confidence intervals were
evident across individual trials.
No trials of non-invasive brain stimulation alone assessed this
outcome (Analysis 2.1).
Five trials (six comparisons) of psychological therapy reported
on the outcome meeting study criteria for depression at end of
treatment and demonstrated an eNect favouring psychological
therapy over usual care and/or attention control (RR 0.77, 95% CI
0.62 to 0.95; 6 RCTs; 521 participants; very low-certainty evidence)
(Alexopoulos 2012; Fang 2017; Kirkness 2017a/Kirkness 2017b;
Mitchell 2002; Watkins 2007). We observed low heterogeneity (I2 =
36%) and wide confidence intervals (Analysis 3.1).
No trials of combination therapies assessed this outcome (Analysis
4.1; Analysis 5.1).
Less than 50% reduction in depression scale scores
Six trials (six comparisons) of pharmacological interventions
reported on this outcome (Andersen 1994; Lai 2006a; Li 2008;
Murray 2002; Wiart 2000; Yang 2002). We observed treatment eNects
favouring pharmacological therapy among those who received a
pharmacological intervention compared with placebo (RR 0.47,
95% CI 0.32 to 0.69; 6 RCTs; 511 participants; very low-certainty
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evidence). We observed substantial heterogeneity (I2 = 66%) and
wide confidence intervals (Analysis 1.2).
We did not perform a meta-analysis for the comparison
non-invasive brain stimulation versus sham non-invasive brain
stimulation or usual care (Analysis 2.2).
No trials of psychological interventions versus usual care and/
or attention control and pharmacological intervention and
psychological therapy (combination) versus pharmacological
intervention and usual care or attention control (single) assessed
this outcome (Analysis 3.2; Analysis 4.2).
We did not perform a meta-analysis for the comparison non-
invasive brain stimulation and pharmacological intervention
(combination) versus pharmacological intervention and sham
stimulation or usual care (single), as only one trial reported data on
this outcome for each comparison (Analysis 5.2).
Secondary outcomes
Depression scores
Average change in scores between baseline and end of treatment
We did not perform a meta-analysis on this outcome for
the comparison pharmacological interventions versus placebo
(Analysis 1.3), due to the heterogenous nature of the outcome
measures and single trials using multiple measures for this
outcome without specifying a primary outcome measure. Two
trials (three comparisons) found an eNect favouring psychological
therapy over usual care and/or attention control (mean diNerence
(MD) -6.20, 95% CI -8.24 to -4.16; 3 RCTs; 189 participants; very low-
certainty evidence; Analysis 3.3) (Kirkness 2017a/Kirkness 2017b;
Mitchell 2002).
Mean scores at end of treatment
We did not perform a meta-analysis on this outcome for the
comparison pharmacological interventions versus placebo due to
the heterogenous nature of the outcome measures (Analysis 1.4).
Seven trials (eight comparisons) demonstrated an eNect favouring
non-invasive brain stimulation over sham or usual care at end of
treatment (MD -6.63, 95% CI -9.71 to -3.55; 8 RCTs; 495 participants;
very low-certainty evidence) (Chen 2005a; Gu 2016; Jiang 2014a;
Meng 2015; Yang 2013; Yang 2014a/Yang 2014b; Zheng 2016).
However, considerable heterogeneity (I2 = 99%) and very wide
confidence intervals (Analysis 2.3 subgroup 2.3.1) are evident.
We did not perform a meta-analysis on the outcome for comparison
of psychological therapy versus usual care and/or attention control
(Analysis 3.4) due to the heterogenous nature of the outcome
measures.
We also observed a beneficial eNect for combination
therapy (pharmaceutical intervention and psychological therapy)
compared to pharmaceutical intervention alone at end of
treatment (MD -1.53, 95% CI -2.10 to -0.96; 2 RCTs; 198
participants; very low-certainty evidence; Analysis 4.3 subgroup
4.3.1). Heterogeneity was substantial (I2 = 87%) and confidence
intervals were very wide. We also observed this eNect among those
who received a combination of non-invasive brain stimulation
and pharmacological intervention in comparison to those who
received pharmacological intervention alone at end of treatment
(MD -4.09, 95% CI -5.61 to -2.57; 9 RCTs; 685 participants; very low-
certainty evidence; Analysis 5.3 subgroup 5.3.1). Heterogeneity was
substantial (I2 = 88%) and confidence intervals were very wide.
Mean scores at end of follow-up
Three trials (three comparisons) of non-invasive brain stimulation
addressed the outcome of mean depression scores at end of follow-
up and revealed an eNect favouring non-invasive brain stimulation
over sham or usual care (MD -2.60, 95% CI -3.3 to -1.87; 3 RCTs; 170
participants; very low-certainty evidence; Analysis 2.4 subgroup
2.4.1) (Gu 2016; Meng 2015; Yang 2013). However, confidence
intervals were very wide.
We did not perform a meta-analysis for the comparison non-
invasive brain stimulation and pharmacological intervention
versus pharmacological intervention alone, as only one trial
reported data on this outcome (Analysis 5.4 subgroup 5.4.1).
Meeting study criteria for depression at end of follow-up
Two trials (three comparisons) of psychological therapy assessed
this outcome and showed no statistically significant eNects for
those who received psychological therapy compared to usual care
and/or attention control (RR 0.85, 95% CI 0.59 to 1.21; 3 RCTs; 201
participants; very low-certainty evidence; I2 = 11%; Analysis 3.5,
subgroup 3.5.1) (Kirkness 2017a/Kirkness 2017b; Mitchell 2002).
Psychological distress scores
No significant eNect was observed in those who received
psychological therapy compared to usual care and/or attention
control on the outcome average change in scores between
baseline and end of treatment (MD -0.21, 95% CI -1.89 to 1.48; 2
RCTs; 377 participants; very low-certainty evidence) (Lincoln 2003;
Watkins 2007). Nor did we observe a significant eNect on mean
psychological distress scores at end of treatment (MD -0.43, 95% CI
-2.17 to 1.31; 2 RCTs; 377 participants; very low-certainty evidence).
See Analysis 3.8 subgroup 3.8.1 and Analysis 3.9 subgroup 3.9.1.
Anxiety scores
Mean scores at end of treatment
We did not perform a meta-analysis on this outcome for
comparison of psychological therapy versus usual care and/or
attention control due to the heterogenous nature of the outcome
measures and single trials using multiple measures for this
outcome without specifying a primary outcome measure (Analysis
3.11).
Mean scores at end of follow-up
We did not perform a meta-analysis on this outcome for
comparison: psychological therapy versus usual care and/or
attention control due to the heterogenous nature of the outcome
measures and single trials using multiple measures for this
outcome without specifying a primary outcome measure (Analysis
3.12).
Cognitive function scores
We did not perform a meta-analysis, as only one trial reported data
for this outcome (Analysis 1.6; Analysis 1.7; Analysis 5.5).
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Activities of daily living (ADL) scores
Average change in scores between baseline and end of treatment
Two trials (two comparisons) revealed that pharmacological
intervention compared to placebo had no significant eNect on
the average change in scores between baseline and end of
treatment (MD -8.00, 95% CI -24.18 to 8.18; 2 RCTs; 256 participants;
very low-certainty evidence) (Ponzio 2001; Reding 1986) (Analysis
1.8 subgroup 1.8.1). Similarly, two trials (two comparisons) also
showed that psychological therapy compared to usual care and/or
attention control had no significant eNect on the average change in
scores between baseline and end of treatment (SMD -0.03, 95% CI
-0.24 to 0.18; 2 RCTs; 377 participants; very low-certainty evidence;
Analysis 3.13) (Lincoln 2003; Watkins 2007).
Mean scores at end of treatment
Three trials of pharmacological interventions (three comparisons)
found no significant eNect on mean ADL scores at end of treatment
compared with placebo (MD 3.14, 95% CI -0.97 to 7.26; 3 RCTs; 316
participants; very low-certainty evidence; Analysis 1.9 subgroup
1.9.1) (Gao 2017a; Kong 2007; Li 2008). Two trials (two comparisons)
demonstrated no eNect among those who received non-invasive
brain stimulation compared to sham or usual care (SMD 1.84,
95% CI -1.40 to 5.08; 2 RCTs; 208 participants; very low-certainty
evidence; Analysis 2.5) (Jiang 2014a; Meng 2015). However, we
observed considerable heterogeneity (I2 = 99%) and very wide
confidence intervals.
We did not perform a meta-analysis on this outcome for
comparison: psychological therapy versus usual care and/or
attention control (Analysis 3.14), due to the heterogenous nature of
the outcome measures and single trials using multiple measures for
this outcome without specifying a primary outcome measure.
Two trials (two comparisons) found that a combination of
pharmacological intervention and psychological therapy had no
eNect on mean ADL scores compared to a single pharmacological
intervention at end of treatment (MD 11.83, 95% CI 0.27 to 23.40;
2 RCTs; 198 participants; very low-certainty evidence; Analysis 4.5
subgroup 4.5.1) (Cao 2009a; Wang 2005a). Similarly, five trials
(five comparisons) showed that combination therapy (non-invasive
brain stimulation and pharmacological intervention) had no eNect
compared to pharmacological intervention alone (single) (SMD
2.03, 95% CI 1.21 to 2.85; 5 RCTs; 403 participants; very low-
certainty evidence; Analysis 5.6) (Du 2005; Fan 2014; Jiang 2014b; Li
2013; Li 2014). However, the two comparisons showed considerable
heterogeneity (I2 = 94% and I2 = 91%) and very wide confidence
intervals.
Mean scores at end of follow-up
We did not perform a meta-analysis, as only one trial reported data
on this outcome (Analysis 3.15).
Disability scores
Two trials (two comparisons) found that psychological therapy had
no eNect on mean disability scores at end of treatment compared
to usual care and/or attention control (SMD -0.16, 95% CI -0.48 to
0.17; 2 RCTs; 162 participants; very low-certainty evidence; Analysis
3.16) (Alexopoulos 2012; Gao 2017b). Although two trials (two
comparisons) reported that non-invasive brain stimulation and
pharmacological intervention (combination) had an eNect on mean
disability scores at end of treatment compared to pharmacological
intervention alone (MD -10.02, 95% CI -20.14 to 0.11; 2 RCTs; 180
participants; very low-certainty evidence; Analysis 5.7 subgroup
5.7.1) (Lu 2016; Sun 2013).
Neurological function scores
Mean scores at end of treatment
Four trials (four comparisons) showed that pharmacological
interventions had an eNect on mean scores at end of treatment
compared to placebo (SMD -0.95, 95% CI -1.44 to -0.45; 4 RCTs;
304 participants; very low-certainty evidence; Analysis 1.13) (Huang
2002; Jiang 2001a; Kong 2007; Wang 2005). Heterogeneity was
substantial (I2 = 75%) and confidence intervals were very wide.
Similarly, we observed an eNect among those who received non-
invasive brain stimulation compared to sham or usual care (SMD
-2.21, 95% CI -3.32 to -1.09; 3 RCTs; 290 participants; very low-
certainty evidence; Analysis 2.7) (Meng 2015; Jiang 2014a; Zheng
2016). However, we noted considerable heterogeneity (I2 = 93%)
and wide confidence intervals.
We did not perform a meta-analysis for this comparison:
pharmacological intervention and psychological therapy versus
pharmacological intervention alone (Analysis 4.6 subgroup 4.6.1),
as only one trial reported data on this outcome.
In contrast, four trials (four comparisons) found that a combination
of non-invasive brain stimulation and pharmacological
intervention had an eNect on mean scores at end of treatment
compared to pharmacological intervention alone (MD -2.78, 95% CI
-4.13 to -1.44; 4 RCTs; 280 participants; very low-certainty evidence;
Analysis 5.8 subgroup 5.8.1) (Jiang 2014b; Jin 2013; Li 2013; Liu
2015). Heterogeneity was substantial (I2 = 82%) and confidence
intervals were very wide.
Adverse events: death
Nine trials (nine comparisons) found that pharmacological
intervention had no eNect on adverse events compared to placebo:
death (RR 0.64, 95% CI 0.20 to 2.07; 9 RCTs; 848 participants; very
low-certainty evidence; Analysis 1.14 subgroup 1.14.1) (Andersen
1994; Fruehwald 2003; Gao 2017a; Huang 2002; Li 2008; Lipsey 1984;
Murray 2002; Ponzio 2001; Wiart 2000). Although no heterogeneity
was observed (I2 = 0%), confidence intervals were very wide.
Two trials (two comparisons) reported that non-invasive brain
stimulation resulted in no deaths (Gu 2016; Jiang 2001a) (Analysis
2.8 subgroup 2.8.1).
Eight trials (eight comparisons) found that psychological therapy
had no eNect on adverse events compared to usual care or
attention control: death (RR 0.65, 95% CI 0.26 to 1.66; 8 RCTs; 831
participants; very low-certainty evidence; Analysis 3.17 subgroup
3.17.1) (Alexopoulos 2012; Fang 2017; Gao 2017b; Lincoln 2003;
Mitchell 2002; Thomas 2007; Towle 1989; Watkins 2007). We
observed no heterogeneity (I2 = 0%) but confidence intervals were
very wide.
Three trials (three comparisons) reported that a combination of
non-invasive brain stimulation and pharmacological intervention
resulted in no deaths compared to pharmacological intervention
and sham stimulation or usual care (Du 2005; Jiang 2014b; Liu
2015)) (Analysis 5.9 subgroup 5.9.1).
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Adverse events: all
Significant evidence of harm was demonstrated among adverse
events, in particular, CNS eNects (RR 1.55, 95% CI 1.12 to 2.15;
5 RCTs; 488 participants; very low-certainty evidence; I2 = 31%)
(Andersen 1994; Lipsey 1984; Murray 2002; Ponzio 2001; Wiart
2000), along with gastrointestinal eNects (RR 1.62, 95% CI 1.19
to 2.19; 4 RCTs; 473 participants; very low-certainty evidence) (Li
2008; Murray 2002; Ponzio 2001; Wiart 2000), among those who
received pharmacological interventions compared with placebo
(see Analysis 1.15 subgroup 1.15.1 and 1.15.5). We observed no
heterogeneity (I2 = 0%), but the confidence intervals were very
wide.
Two trials (two comparisons) reported that non-invasive brain
stimulation resulted in no other adverse events - not listed above
(e.g. dysuria, eye discomfort; Analysis 2.9) (Gu 2016; Jiang 2014a).
Four trials (four comparisons) found that psychological therapy
resulted in no significant adverse events (recurrent stroke - RR 5.0,
95% CI 0.24 to 103.12; 1 RCT; 254 participants; vascular events - RR
0.71, 95% CI 0.23 to 2.19; 1 RCT; 254 participants; very low-certainty
evidence), nor other events - not listed above (e.g. too ill) (RR 1.02,
95% CI 0.15 to 6.81; 2 RCTs; 206 participants; very low-certainty
evidence). See Analysis 3.18 (Mitchell 2002; Thomas 2007; Towle
1989; Watkins 2007).
Two trials (two comparisons) found that a combination of
non-invasive brain stimulation and pharmacological intervention
resulted in no significant adverse events (other events - not listed
above, e.g. insomnia, discomfort, headache) (RR 7.0, 95% CI 0.38 to
129.93; 2 RCTs; 120 participants; very low-certainty evidence). See
Analysis 5.10 (Du 2005; Jiang 2014b).
Adverse events: leaving the study early (including death)
Twelve trials (13 pharmacological comparisons) reported on this
outcome (Andersen 1994; Fruehwald 2003; Gao 2017a; Huang
2002; Kong 2007; Li 2008; Lipsey 1984; Murray 2002; Ponzio
2001; Robinson 2008a/Robinson 2008b; Wang 2005; Wiart 2000).
Pharmacological interventions had no eNect on the proportion of
participants leaving the study early (including death) compared to
placebo (RR 1.07, 95% CI 0.82 to 1.39; 13 RCTs; 1165 participants;
very low-certainty evidence; Analysis 1.16 subgroup 1.16.1).
Although we observed no heterogeneity (I2 = 0%), confidence
intervals were very wide.
Seven trials (eight comparisons) revealed that psychological
therapy had no eNect on the proportion of participants leaving
the study early (including death) compared to usual care and/
or attention control (RR 0.83, 95% CI 0.42 to 1.63; 8 RCTs; 784
participants; very low-certainty evidence; Analysis 3.19 subgroup
3.19.1) (Alexopoulos 2012; Gao 2017b; Kirkness 2017a/Kirkness
2017b; Lincoln 2003; Mitchell 2002; Towle 1989; Watkins 2007).
Although we observed no heterogeneity (I2 = 0%), confidence
intervals were very wide.
Four combination therapy trials (rTMS and pharmacological
interventions) (four comparisons) reported on this outcome. A
combination of rTMS and pharmacological interventions had no
eNect on the proportion of people leaving the study early (including
death) compared to pharmacological intervention alone (RR 1.33,
95% CI 0.32 to 5.58; 4 RCTs; 300 participants; very low-certainty
evidence) (Du 2005; Jiang 2014b; Liu 2015; Lu 2016). See Analysis
5.11 subgroup 5.11.1. We observed no heterogeneity (I2 = 0%), but
confidence intervals were very wide.
D I S C U S S I O N
Summary of main results
In this review update, we included 49 trials (56 comparisons)
involving 3342 participants that met our criteria. The large increase
in the number of included trials is partially explained by expansion
of the types of included interventions. This is the first time we
have included other (in addition to electroconvulsive therapy (ECT))
non-invasive brain stimulation interventions and combination
interventions.
Data were available for these comparisons: (1) pharmacological
interventions versus placebo; (2) one of various forms of
non-invasive brain stimulation versus sham stimulation or
usual care; (3) one of various forms of psychological therapy
versus usual care and/or attention control; (4) pharmacological
intervention and various forms of psychological therapy
versus pharmacological intervention and usual care and/or
attention control (with two comparisons); and (5) non-invasive
brain stimulation and pharmacological intervention versus
pharmacological intervention and sham stimulation or usual care
(with 10 comparisons).
Comparison 1. Comparing pharmacological intervention to
placebo, we found very low-certainty pooled evidence suggesting
benefit in treating depression to remission and reducing depressive
symptom scores on mood rating scales, along with evidence
of harm (more central nervous system and gastrointestinal
adverse events). These results are largely unchanged from
previous versions of this review. For pharmacological trials, a key
requirement is that a therapeutic dose of the medication must
be achieved for an adequate period of time. Guidelines from
the American College of Physicians suggest that antidepressants
should be continued for at least four months beyond initial
recovery, and that treatment should be changed if no response
has been shown by six weeks (Snow 2000). In this review, the
interventions in most pharmacological trials probably were not
given for an adequate length of time to show maximal or sustained
response. Therefore, we are unable to comment on the long-term
eNects of antidepressant therapy, or to provide information on
the most appropriate duration or dose of treatment; nor can we
say if one group of antidepressants is more eNicacious or provide
stopping rules for antidepressant therapy in this group.
Comparison 2. Comparing non-invasive brain stimulation to usual
care or sham stimulation, we found very low-certainty pooled
evidence that repetitive transcranial magnetic stimulation (rTMS)
reduces depressive symptom scores at end of treatment and
a(er follow-up, oN treatment. No reported data were related to
remission. No adverse events were reported. We did not include
this endpoint in previous versions of this review. The duration of
treatment in these trials was short, ranging from one to four weeks.
The impact of many diNerent facets of interventions such as rTMS
(including electrode placement, number of sessions, or particular
frequencies on outcomes) is not within the scope of this review.
Comparison 3. Comparing psychological therapy to usual care or
attention control, we found very low-certainty pooled evidence of
benefit in treating depression to remission at end of treatment,
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but this benefit was not sustained to the end of follow-up oN
treatment. We did not pool data related to changes in depression
symptom scores due to use of multiple measures across and
within studies with no a priori primary outcome measure identified.
Pooled evidence for adverse events included benefit and harm.
These results are diNerent from findings of previous versions
of this review, which demonstrated no treatment eNects. For
psychological therapy trials, good evidence shows that eNicacy is
linked to delivery of adequate exposure to the intervention. This
means that therapists should be trained and supervised in the
therapy they are delivering, and should use a standardised, pre-
specified framework for therapy. To achieve this in psychological
therapy trials, therapy is determined with use of a manual, and
research therapists are trained and supervised in use of the
manual. Success in brief therapy is linked to adherence to the
therapeutic model, as well as to the therapists' characteristics.
Future stroke psychological therapy trials should adhere to these
standard psychological therapy research guidelines if there is to be
any probability of demonstrating consistency and response.
Comparison 4. Comparing combined pharmacological intervention
and psychological therapy to pharmacological intervention plus
usual care or attention control, we found very low-certainty pooled
evidence of benefit in reducing depressive symptom scores on
mood rating scales. No reported data were related to remission. We
did not include this endpoint in previous versions of this review.
Comparison 5. Comparing non-invasive brain stimulation and
pharmacological intervention to usual care or sham stimulation
and pharmacological intervention, we found very low-certainty
pooled evidence of benefit in reducing depressive symptom scores
on mood rating scales. No reported data were related to remission.
Pooled evidence for adverse events included benefit and harm. We
did not include this endpoint in previous versions of this review.
We found no trials for these comparisons: (6) pharmacological
intervention and various forms of psychological therapy
interventions compared with placebo and psychological therapy;
(7) pharmacological intervention and non-invasive brain
stimulation versus placebo plus non-invasive brain stimulation;
(8) non-invasive brain stimulation and one of various forms of
psychological therapy versus non-invasive brain stimulation plus
usual care and/or attention control; and (9) non-invasive brain
stimulation and one of various forms of psychological therapy
versus sham brain stimulation or usual care plus psychological
therapy.
Evidence demonstrating benefit must continue to be considered
alongside several basic methodological limitations of many of
these trials, including the short duration of many interventions,
variation in the types of trial participants recruited and in
the methods used to diagnose depression, lack of an a priori
measurable endpoint, and high risk of bias in many trials. Of
particular concern is the evidence of harm (more adverse events)
given the small number of trials in which adverse events were
systematically recorded and reported, making reliable assessment
of the benefits and risks of treatments impossible.
The trials in this review included participants with depression
occurring several days to more than two years following stroke.
However, depression occurring in the early phase of stroke is likely
to be diNerent from that occurring several months or years a(er the
event. Survivors in the first weeks following stroke are coping with
the consequences of experiencing a potentially life-threatening
event, as well as recovering from the disabling eNects of the stroke
itself. In the medium to long term, survivors of stroke are more
likely to be adjusting to the prospects of permanent disability
and changes in social and financial circumstances. It is diNicult to
summarise the evidence from such mixed populations, and even
in doing so, whether it could be considered meaningful, especially
given the high risk of relapse of depression in the first few months
of recovery, which declines over time (Snow 2000).
In contrast to the wide range in the length of time between stroke
onset and entry into the trial, many trials included participants with
narrow demographic and clinical characteristics, in particular, they
excluded people with communication problems, cognitive loss, or
previous psychiatric illness. This reinforces a common criticism of
depression research - that trial participants are not representative
of those requiring treatment in the 'real world' (Zimmerman 2002).
It would appear that this criticism is also applicable to trials of
depression following stroke, where up to half of survivors may
be excluded on the basis of such criteria (Turner-Stokes 2003).
Given the older age of most people with stroke and the frequent
presence of neurological impairments, aphasia, and comorbid
medical conditions, the fact that up to half of all survivors of stroke
are excluded limits the external validity (generalisability) of the
results. Use of a large list of exclusions means that the results
are applicable to only a small proportion of stroke survivors who
have a narrow range of comorbidities and other characteristics.
Such exclusions may be justifiable for trials of psychological
therapy, in which participants are required to actively participate
in therapy by talking, but the exclusions seem inappropriate for
pharmacotherapy trials. Ideally, patients should be heterogeneous
with regard to stroke diagnosis, which requires the use of standard
diagnostic criteria and neuroimaging in a high proportion of
cases. Given diNerences in the natural history and management of
subarachnoid haemorrhage, it could be argued that this form of
stroke should be examined separately.
Lack of a consistent method to diagnose depression at trial entry
and outcomes in the included trials is a concern and a reflection
of the general lack of a standard definition for a 'healthy state'
among people with mood disorders (Keller 2003). Few trials have
stated whether the primary goal of therapy was remission (no
longer meeting the baseline criteria for depression), response (>
50% reduction in mood scores from baseline), or simply a greater
reduction in mood scores (or diNerence in scores) in one of the
randomised groups. Complete remission of symptoms is arguably
the most meaningful endpoint for the patient, whereas the
significance of a small reduction in mood scores on a continuous
scale is generally diNicult to interpret for the patient and for the
treating physician. These problems with outcome assessment were
further confounded by frequent use of multiple scales and selective
reporting of findings between and within trials. Any one scale was
used across only eight trials at most, and significantly diNerent
cut-points were used to determine depression at entry and at trial
end. Given the practical diNiculties and high costs of conducting
psychiatric interviews in clinical trials, it seems appropriate to
adopt a pragmatic approach to assess depression on the basis of a
validated mood questionnaire or structured interview. It is hoped
that the compulsory registration of trial protocols on publicly
available databases will reduce, if not eliminate, the opportunity
for selective reporting of results. It has been suggested that more
than one-third of eNicacy outcomes and half of harm outcomes are
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inadequately reported (Chan 2004). Several other methodological
deficiencies in trials further limit the conclusions that can be
drawn from this review. Many trials were small; less than half
reported adequate concealment of the randomisation sequence,
and dropout rates were high in several trials. Additionally, blinding
of investigators and outcome assessors was seldom stated.
Overall completeness and applicability of evidence
The present review included 49 trials (56 comparisons) with
3342 participants. Data were available for 20 pharmacological
comparisons, eight non-invasive brain stimulation comparisons, 16
psychological therapy comparisons, and 11 combination therapy
trials. Overall, consistent methods used to diagnose depression
were lacking, and we considered it inappropriate to pool outcome
data for many endpoints. The accuracy of the findings of this
systematic review and meta-analysis must be considered in light of
the basic methodological limitations described in the Risk of bias
in included studies table. Eighteen trials are considered dropouts,
21 trials are awaiting classification, and at least five ongoing trials
may contribute further evidence to future updates of this review.
Quality of the evidence
We rated the certainty of evidence for all comparisons by using the
five GRADE considerations (study limitations, consistency of eNect,
indirectness, imprecision, and publication bias; Schunemann
2011). We created a 'Summary of findings' table for each
comparison. Certainty assessment was very low.
Limitations in study design or execution
For the comparison of pharmacological interventions versus
placebo, we downgraded the certainty of evidence by two points
for the following outcomes: meeting study criteria for depression
at end of treatment, less than 50% reduction in depression scale
scores, mean neurological function scores at end of treatment,
and adverse events - death at end of treatment, all CNS events,
and gastrointestinal events - as we rated several studies as having
high or unclear risk for multiple risk of bias domains (Summary of
findings for the main comparison).
For the comparison of non-invasive brain stimulation versus sham,
we downgraded the certainty of evidence by two points for the
following outcomes: mean depression scores at end of treatment,
mean depression scores at end of follow-up, and mean neurological
function scores at end of treatment, as we rated several studies
as having high or unclear risk for multiple risk of bias domains
(Summary of findings 2).
For the comparison of psychological therapy versus usual care
and/or attention control, we downgraded the certainty of evidence
by two points for the following outcomes: meeting study criteria
for depression at end of treatment, average change in depression
scores between baseline and end of treatment, meeting study
criteria for depression at end of follow-up, and adverse events -
death at end of treatment and leaving the study early - as we rated
several studies as having high or unclear risk for multiple risk of bias
domains (Summary of findings 3).
For the comparison of pharmacological interventions and
psychological therapy (combination) versus pharmacological
intervention and usual care and/or attention control (single),
we downgraded the certainty of evidence by two points for the
following outcomes: mean depression scores at end of treatment
and mean activities of daily living scores at end of treatment,
as we rated two studies as having unclear risk for multiple risk
of bias domains, related to allocation concealment and blinding
of participants, personnel, and outcome assessors (Summary of
findings 4).
For the comparison of non-invasive brain stimulation
and pharmacological intervention (combination) versus
pharmacological intervention with sham or usual care (single), we
downgraded by two points the certainty of evidence for mean
depression scores, mean activities of daily living scores at end of
treatment, and leaving the study early, as we rated the study as
having high risk for multiple risk of bias domains, related to blinding
of participants, personnel, and outcome assessors (Summary of
findings 5).
Inconsistency of results
For the comparison of pharmacological interventions versus
placebo, we downgraded by two points the certainty of evidence
for the following outcomes: meeting study criteria for depression,
less than 50% reduction in depression scale scores, and mean
neurological function scores at end of treatment, as we observed
substantial heterogeneity (50% to 89%). We also downgraded the
certainty of evidence by one point for gastrointestinal events, as
we observed moderate heterogeneity (30% to 49%) (Summary of
findings for the main comparison).
For the comparison of non-invasive brain stimulation versus sham,
we downgraded the certainty of evidence by two points for mean
depression scores and neurological function scores at end of
treatment due to considerable heterogeneity observed (90% to
100%) (Summary of findings 2).
For the comparison of pharmacological interventions and
psychological therapy (combination) versus pharmacological
intervention and usual care and/or attention control (single),
we downgraded by two points the certainty of evidence for
mean depression scores at end of treatment due to substantial
heterogeneity (50% to 89%), and by two points for mean activities
of daily living scores at end of treatment for considerable
heterogeneity (90% to 100%) observed (Summary of findings 4).
For the comparison of non-invasive brain stimulation
and pharmacological intervention (combination) versus
pharmacological intervention with sham or usual care (single),
we downgraded by one point the certainty of evidence for
mean depression scores and mean neurological function scores
at end of treatment due to substantial heterogeneity (50% to
89%) observed. We also downgraded by two points the certainty
of evidence for mean activities of daily living scores at end
of treatment as considerable heterogeneity (90% to 100%) was
observed (Summary of findings 5).
Indirectness of evidence
All included trials addressed the main review questions (PICO).
Thus, we did not downgrade any outcomes for indirectness of
evidence (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5).
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Imprecision
For the comparison of pharmacological interventions versus
placebo, we downgraded the certainty of evidence by one point
for the following outcomes: meeting study criteria for depression
and less than 50% reduction in depression scale scores at end
of treatment, as the confidence intervals were wide. We also
downgraded by two points the certainty of evidence for mean
neurological scores and adverse events - death, CNS events, and
gastrointestinal events at end of treatment, as the confidence
intervals were very wide (Summary of findings for the main
comparison).
For the comparison of non-invasive brain stimulation versus sham,
we downgraded the certainty of evidence by two points for the
following outcomes: mean depression scores at end of treatment
and mean depression scores at end of follow-up, as the confidence
intervals were very wide. We also downgraded by one point the
certainty of evidence for mean neurological function scores at end
of treatment, as the confidence intervals were wide (Summary of
findings 2).
For the comparison of psychological therapy versus usual care and/
or attention control, we downgraded the certainty of evidence by
one point for meeting criteria for depression at end of treatment,
as the confidence intervals were wide. We also downgraded by
two points the certainty of evidence for the following outcomes:
average change in depression scores between baseline and end of
treatment, meeting study criteria for depression at end of follow-
up, and adverse events - death at end of treatment and leaving the
study early - as the confidence intervals were very wide (Summary
of findings 3).
For the comparison of pharmacological interventions and
psychological therapy (combination) versus pharmacological
intervention and usual care and/or attention control (single), we
downgraded the certainty of evidence by two points for mean
depression scores and activities of daily living scores at end of
treatment, as the confidence intervals were very wide (Summary of
findings 4).
For the comparison of non-invasive brain stimulation
and pharmacological intervention (combination) versus
pharmacological intervention with sham or usual care (single),
we downgraded the certainty of evidence by two points for the
following outcomes: mean depression scores, mean activities of
daily living scores, and mean neurological function scores at end of
treatment and leaving the study early, as the confidence intervals
were very wide (Summary of findings 5).
Publication bias
We assessed publication bias using funnel plots for the outcome
meeting study criteria for depression at end of treatment for
pharmaceutical interventions versus placebo; Figure 4 shows no
evidence of publication bias for this outcome. We did not assess
publication bias using funnel plots for the other outcomes in each
comparison due to the small number of studies (< 10 studies)
contributing to the analysis. Therefore, we did not downgrade
the certainty of evidence for publication bias for any outcomes
per comparison (Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
findings 4; Summary of findings 5).
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Figure 4.   Funnel plot of comparison: 1 Pharmacological interventions versus placebo, outcome: 1.1 Depression:
meeting study criteria for depression at end of treatment.
 
Potential biases in the review process
Strengths and weaknesses of this review
This review has rigorously adhered to Cochrane methods for
performing systematic reviews. During the review process, we tried
to avoid and minimise any biases. We undertook extensive searches
of databases and additional resources. We did not apply any
language restrictions during the search process. Thus, we believe
that we have identified and included in this review all potentially
relevant trials. We arranged for any relevant and non-relevant
non-English full-text trials to be translated into English, to finalise
the eligibility process. Furthermore, at least two review authors
independently extracted and managed the data.
The main weaknesses of this review are the heterogeneous nature
of the outcome measures and the frequent use of multiple scales
between and within trials. Inadequate reporting of some trials has
led us to rate some of these trials across categories as having
unclear risk of bias, with an overall rating of 'very low' certainty of
evidence.
Agreements and disagreements with other studies or
reviews
To date, no other systematic reviews have been as comprehensive
as this current review.
We found one other systematic review comparing eNects of
pharmacotherapy versus placebo in the stroke population (Chen
2006). Although this review appears similar, there are important
diNerences in the inclusion criteria. We included trials of
people with depression on recruitment and excluded trials with
participants who were not depressed at recruitment (included in
Hackett 2008a; update pending). Other reviews included trials of
people with and without diagnosed depression at recruitment. This
limits our ability to directly compare results. One network meta-
analysis comparing pharmacotherapy to placebo in people with a
diagnosis of major depressive disorder (but not stroke) also found
low-quality pooled evidence of benefit of pharmacotherapy in
treating depression to remission (Cipriani 2018). Many trials in that
review also provided inadequate information about randomisation
and allocation concealment, which restricts interpretation of
their results. This indicates that limitations in study design in
pharmacotherapy trials are not limited to stroke.
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One systematic review compared eNects of rTMS with sham rTMS
and a combination of rTMS and pharmacotherapy versus usual care
or sham rTMS and pharmacotherapy in treating depression a(er
stroke (Shen 2017). Those review authors included 22 trials (24
comparisons), of which 13 trials (15 comparisons) are also included
in our review (Chen 2005a; Fan 2014; Jiang 2014a; Jiang 2014b;
Jin 2013; Li 2013; Li 2014; Liu 2015; Lu 2016; Meng 2015; Yang
2013; Yang 2014a; Yang 2014b; Zhang 2013; Zheng 2016), and two
trials (three comparisons) are awaiting classification (Liu 2010; Yan
2010a/Yan 2010b). Seven of the trials included in Shen 2017 did not
meet our review criteria for the type of intervention. These trials
compared rTMS and pharmacotherapy versus pharmacotherapy
alone (with no sham rTMS or usual care). We did not include
any additional trials in our review. This review also found low-
quality pooled evidence that rTMS and a combination of rTMS and
pharmacotherapy reduced depressive symptom scores at end of
treatment and a(er follow-up. However, these findings must also
be considered in light of the same limitations in study design and
heterogeneity. Another systematic review compared eNects of non-
invasive brain stimulation (which includes rTMS and transcranial
direct current stimulation (tDCS)) versus sham stimulation or usual
care (Bucur 2018). Review authors included seven studies (case
studies and randomised controlled trials (RCTs)), of which one
trial is also included in our review (Gu 2016), and two trials are
considered 'dropouts', as outcome data were not reported grouped
by depressed/non-depressed participants at baseline (Jorge 2004;
Valiengo 2017). Review authors did not perform a meta-analysis
and only narratively described the included studies.
One systematic review reported on eNects of cognitive-behavioural
therapy (CBT) in treating depression a(er stroke. These review
authors included 23 trials, two of which are included in our review
(Gao 2017b; Lincoln 2003), and one is considered a 'dropout' as
the outcome data (reported median and interquartile ratio (IQR))
were not suitable for pooling (Kootker 2012). The 20 trials that
are not included in our review were conducted and published in
China, and none were identified by our search strategy, nor were
they accessible during this update. We will endeavour to locate,
translate, and assess these 20 trials in time for the next update of
this review.
Identification of ongoing studies and those awaiting classification
indicates that this is an area of stroke research for which further
evidence will evolve over the short and longer term.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Evidence from trials in people with stroke tentatively supports the
use of prescription antidepressants or psychological therapy to
treat depression, but this must be considered in light of evidence
of an associated increase in harm. Antidepressants may produce
a remission or a response in terms of lower scores on mood
rating scales but may also increase adverse events. Psychological
therapy does not appear to have the same associated risks. Any
use of pharmacological agents in people with persistent depressive
disorder a(er stroke would require caution, as little is known about
the risks, especially of seizures, falls, delirium, and interaction with
other medications.
Implications for research
We recommend that further research is needed in this area. Future
trials investigating eNects of pharmacological, psychological,
and non-invasive brain stimulation interventions, alone and in
combination, for treatment of depression in people a(er stroke
should:
• review and refine the methods for trials of psychological
endpoints in people with physical illness;
• recruit an adequate number of participants, so that variables
such as time passed between stroke and recruitment, inclusion
of patients with dysphasia, and subarachnoid haemorrhage
(SAH) can be controlled, and modest but clinically important
eNects can be detected;
• recruit a representative 'real-world' sample of patients to enable
results to be generalised to most stroke survivors;
• provide treatment for suNicient duration and follow-up, so that
rates of relapse or maintenance of remission can be assessed;
• carefully specify and monitor psychological interventions;
• describe interventions in suNicient detail to allow their
replication;
• include careful, prospective assessment and complete reporting
of adverse events;
• define a priori an unambiguous, measurable primary endpoint;
and
• limit the number of secondary outcomes to three or four and
report results for all outcomes.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Study design: parallel design
Number of arms: 2
Treatment arm:ecosystem focused therapy (EFT)
Control arm: attention control
Participants Geographical location: USA
Setting: inpatient
Stroke criteria: ischaemic and haemorrhagic stroke
Method of stroke diagnosis: not reported
Time since stroke: not reported
Inclusion criteria: (1) aged 60 years or older; (2) had an ischaemic, embolic, or haemorrhagic stroke;
(3) diagnosis of unipolar major depression by DSM-IV
Exclusion criteria: (1) moderately severe dementia (MMSE score < 20); (2) greater than moderate apha-
sia (NIHSS best language > 1); (3) expectation to be discharged to a nursing home; (4) psychotic depres-
sion (by DSM-IV); (5) suicidal intent or plan; (6) inability to speak English
Depression criteria: structured clinical interview for DSM-IV-TR and PHQ-9 cut-oN score ≥ 10
Total number randomised in this trial: 24
Number randomised to treatment group: 12 (50% men, mean age 72 years, SD 7)
Number randomised to control group: 12 (58% men, mean age 69 years, SD 10)
Alexopoulos 2012 
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Total number included in the final analysis: 24
Number included in treatment group for final analysis: 12 (50% men, mean age 72 years, SD 7)
Number included in control group for final analysis: 12 (58% men, mean age 69 years, SD 10)
Interventions Treatment: 12 weekly 45-minute personalised sessions of EFT were offered. Treatment was designed
to increase patient participation in rehabilitation and social activities, focusing on adherence, prob-
lem-solving, goal-setting, and co-ordination of care
Administered by: therapist trained in EFT using manuals; qualification of therapist not stated
Attention control: 12 weekly 45-minute sessions of Education on Stroke and Depression (ESD)
Administered by: therapist trained in ESD using manuals; qualification of therapist not stated
Supervision: 3 practice cases of EFT and ESD were supervised; qualifications of the supervisor not stat-
ed
Intervention fidelity: all EFT and ESD sessions were audio-taped and rated by reviewers who were not
members of the research team, using specially devised EFT and ESD fidelity scales (5 grades: 1 = poor, 5
= excellent). Mean EFT scores ranged from 4.0 to 4.4; mean ESD scores ranged from 4.6 to 4.9, indicating




• Depressive symptoms measured using the HDRS
Secondary outcomes
• Remission of depression (HDRS < 10)
• Disability measured using the WHODAS-II
Notes Author contact: emailed study authors to ask how missing data were handled and to ask for informa-
tion on sample size calculation 19 November 2018
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk Quote: "four therapists were trained and offered both EFT and ESD…" (p.
1056)
Comment: due to the nature of the trial, it was not possible to mask partici-
pants, therapists, or researchers to the treatment allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "…..the raters could not be blinded to the treatment condition, al-
though they were unaware of the study hypotheses" (p. 1058)
Alexopoulos 2012  (Continued)
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Unclear risk Comment: in the intervention arm, 2 died, 1 LTF was reported; in the control
arm, 1 discontinued treatment. Analysis includes all patients (ITT), but how
missing data were handled was not reported
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes were reported. No trial protocol or reg-
istry record available to compare with the publication
Other bias Low risk Comment: no statistically significant differences in demographic characteris-




Methods Study design: parallel design
Number of arms: 2
Treatment arm: citalopram (SSRI)
Control arm: matched placebo
Participants Geographical location: Denmark
Setting: mixed outpatient and inpatient
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage
Method of stroke diagnosis: diagnosis via clinical signs and CT (100%)
Time since stroke: 2 to 52 weeks (average time 12 weeks)
Inclusion criteria: (1) had stroke 2 to 52 weeks before randomisation
Exclusion criteria: (1) patients with subarachnoid haemorrhage or Binswanger's disease; (2) with pre-
vious degenerative or expansive neurological disease (such as multiple sclerosis, amyotrophic lateral
sclerosis, tumour, and hydrocephalus); (3) with history of psychiatric illness (except depression more
than 1 year earlier); (4) decreased consciousness; (5) dementia; (6) aphasia to such a degree that they
could not explain themselves or gave conflicting verbal and non-verbal signals
Depression criteria: HDRS score > 12 (score transformed to appropriate DSM-III-R criteria)
Total number randomised in this trial: 66
Number randomised to treatment group: 33 (36% men, mean age 68 years, SD 4)
Number randomised to control group: 33 (66% men, mean age 66 years, SD 9)
Total number included in the final analysis: 66
Number included in treatment group for final analysis: 33 (36% men, mean age 68 years, SD 4)
Number included in control group for final analysis: 33 (66% men, mean age 66 years, SD 9)
Interventions Treatment: citalopram (SSRI), 10 mg in participants > 66 years, 20 mg in participants < 67 years, daily;
dose doubled if no response to treatment within 3 weeks
Control: matched placebo
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• Depression measured using the HDRS
• Proportion no longer meeting entry criteria (HDRS score < 13)
• Depression measured using the Melancholia Scale
Secondary outcomes
• Disability measured using the BI
• Social functioning measured using the Social Activities Index
• Cognitive functioning measured using the MMSE
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "to ensure approximately equal numbers of patients in the treatment
groups, randomization was carried out in groups of 4, with 2 assigned to citalo-
pram"
Comment: method of sequence generation not reported
Allocation concealment
(selection bias)
High risk Comment: opaque envelopes with codes concealed until end of the study






Low risk Quote: "the trial was designed as a randomized, double-blind, placebo-con-
trolled study" (p. 1100)
Comment: who was blinded was not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "the trial was designed as a randomized, double-blind, placebo-con-
trolled study" (p. 1100)




Low risk Comment: ITT analysis (all participants including dropout were included). See
Table 2 (p. 1101) for last observation for dropout carried forward
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Treatment arm: fluoxetine (SSRI) + psychotherapy + usual care
Control arm: fluoxetine (SSRI) + usual care
Participants Geographical location: China
Setting: inpatient
Cao 2009a 
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Stroke criteria: cerebral haemorrhage and infarct
Method of stroke diagnosis: not reported
Time since stroke: not reported
Inclusion criteria: (1) 24-item HDRS score > 20; (2) can sign informed consent; (3) voluntary participa-
tion; (4) strong desire to change themselves; (5) willingness to communicate with others; (6) comple-
tion of 12 therapy sessions (treatment arm only)
Exclusion criteria: (1) history of psychiatric illness; (2) severe cognitive impairment; (3) verbal commu-
nication barrier; (4) severe illness (e.g. myocardial infarction)
Depression criteria: Chinese version of 24-item HDRS score > 20
Total number randomised in this trial: 144 (48% of total group men; mean age of total group 60
years, SD 9)
Number randomised to treatment group: 72 (as above)
Number randomised to control group: 72
Total number included in the final analysis: 144 (48% of total group men; mean age of total group 60
years, SD 9)
Number included in treatment group for final analysis: 72 (as above)
Number included in control group for final analysis: 72 (as above)
Interventions Treatment: fluoxetine (SSRI) 20 mg/d + group psychotherapy with 4 phases: an introductory session to
build group security and trust
Administered by: each group has 1 leader and 1 assistant. 2 neurologists qualified with group psy-
chotherapy (national counsellors, grade 2) serve as leaders, and 3 nurses with professional training
serve as assistants
Supervision: not reported
Intervention fidelity: not reported
Control: fluoxetine (SSRI) 20 mg/d
Duration of psychotherapy: 30 to 40 minutes, once/week for 12 weeks
Duration of fluoxetine: first depression 4 to 6 months, then taper and discontinue; recurrent depres-
sion: extended additional 3 to 6 months; depression episodes ≥ 3 times: more prolonged period
Follow-up: none
Outcomes Primary outcomes
• Depression measured using 24-item HDRS
Secondary outcomes
• Disability measured using BI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Cao 2009a  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: ITT; no missing data reported, but randomised participants who




Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record to compare with the publication
Other bias Low risk Comment: no differences in baseline 24-item HDRS and BI. Baseline demo-




Methods Study design: parallel design
Number of arms: 2
Treatment arm: psychotherapy + usual care
Control arm: usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: cerebral haemorrhage and infarct
Method of stroke diagnosis: not reported
Time since stroke: not reported
Inclusion criteria: (1) 24-item HDRS score > 20; (2) can sign informed consent; (3) voluntary participa-
tion; (4) strong desire to change themselves; (5) willingness to communicate with others; (6) comple-
tion of 12 therapy sessions (treatment arm only)
Exclusion criteria: (1) history of psychiatric illness; (2) severe cognitive impairment; (3) verbal commu-
nication barrier; (4) severe illness (e.g. myocardial infarction)
Depression criteria: Chinese version of 24-item HDRS > 20
Total number randomised in this trial: 144 (48% of total group men; mean age of total group 60
years, SD 9)
Number randomised to treatment group: 72 (as above)
Number randomised to control group: 72 (as above)
Cao 2009b 
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Total number included in the final analysis: 144 (48% of total group men; mean age of total group 60
years, SD 9)
Number included in treatment group for final analysis: 72 (as above)
Number included in control group for final analysis: 72 (as above)
Interventions Treatment: group psychotherapy with 4 phases: an introductory session to build group security and
trust
Administered by: each group has 1 leader and 1 assistant. 2 neurologists qualified with group psy-
chotherapy (national counsellors, grade 2) serve as leaders, and 3 nurses with professional training
serve as assistants
Supervision: not reported
Intervention fidelity: not reported
Control: usual care
Duration of psychotherapy: 30 to 40 minutes, once/week for 12 weeks
Follow-up: none
Outcomes Primary outcomes
• Depression measured using 24-item HDRS
Secondary outcomes
• Disability measured using BI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: ITT; no missing data reported but randomised participants who did




Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record to compare with the publication
Cao 2009b  (Continued)
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Other bias Low risk Comment: no differences in baseline 24-item HDRS and BI; baseline demo-




Methods Study design: parallel design
Number of arms: 2
Treatment arm: rTMS + cerebrovascular disease routine care
Control arm: cerebrovascular disease routine care
Participants Geographical location: China
Setting: mixed outpatient and inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by the
Fourth National Symposium on Cerebrovascular Disease in 1995; confirmation by brain CT or MRI
Time since stroke: 2 months
Inclusion criteria: (1) disease course of stroke on average > 2 months; (2) patients and family gave in-
formed consent
Exclusion criteria: (1) history of psychiatric illness; (2) obvious comprehension impairment; (3) obvi-
ous aphasia; (4) severe physical illness; (5) epilepsy
Depression criteria: depression was diagnosed by clinical interview according to the CCMD-2-R; 17-
item HDRS score > 17
Total number randomised in this trial: 32
Number randomised to treatment group: 16 (62% men, mean age 61 years, SD 4.9; modified SSS 18.3,
SD 4.8)
Number randomised to control group: 16 (56% men, mean age 61.2 years, SD 4.7; modified SSS 17.5,
SD 4.4)
Total number included in final analysis: 32
Number included in treatment group for final analysis: 16 (62% men, mean age 61 years, SD 4.9;
modified SSS 18.3, SD 4.8)
Number included in control group for final analysis: 16 (56% men, mean age 61.2 years, SD 4.7; mod-
ified SSS 17.5 SD, 4.4)
Interventions Treatment: low-frequency rTMS, fixed-dose 0.72 Tesla (60% of maximal stimulation intensity), fre-
quency 0.5 Hz, 1 sequence included 30 stimulations in each side of the pre-frontal lobe; plus cere-
brovascular disease routine care
Control: cerebrovascular disease routine care
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• Depression measured using 17-item HDRS





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Comment: randomisation performed by drawing lots, which is prone to bias
Allocation concealment
(selection bias)





High risk Comment: participants and personnel not blinded to group allocation. Study
used a prospective, randomised open-blinded endpoint (PROBE) design
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Treatment arm: brief positive psychotherapy + usual care
Control arm: usual care
Participants Geographical location: Scotland
Setting: outpatient
Stroke criteria: cerebrovascular infarct and haemorrhagic stroke
Method of stroke diagnosis: confirmed by local clinician based on clinical and/or radiological evi-
dence
Time since stroke: 3 to 36 months
Cullen 2018 
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Inclusion criteria: (1) adults aged 18 or over; (2) diagnosis of acquired, non-progressive brain injury; (3)
between 3 and 12 months post injury at time of recruitment; (4) presence of emotional distress (score
in moderate or above range on at least 1 subscale of the DASS-21; (5) medically stable; (6) able to con-
sent
Exclusion criteria: (1) significant communication impairment; (2) diagnosis of mild traumatic brain in-
jury; (3) comorbid developmental learning disability or degenerative neurological condition
Depression criteria: presence of emotional distress (score in moderate or above range on at least 1
subscale of the DASS-21)
Total number randomised in this trial (stroke participants only): 24
Number included in treatment group: 12 (67% men; mean age 55 years, SD 10)
Number included in control group: 12 (67% men; mean age 60 years, SD 9)
Total number included in final analysis (stroke participants only): 24
Number included in treatment group for final analysis: 12 (67% men; mean age 55 years, SD 10)
Number included in control group for final analysis: 12 (67% men; mean age 60 years, SD 9)
Interventions Treatment: participants in intervention arm received a brief positive psychotherapy intervention de-
livered over 8 weeks, in addition to accessing usual care within the clinical service. Study intervention
followed a manualised programme designed by the research team and based on aspects of Rashid
and Seligman’s (2013) programme, incorporating psychoeducation about ABI and positive psychol-
ogy (week 1), a range of therapeutic exercises, and homework focused on using signature character
strengths and reflecting on positive events (weeks 2 to 7 inclusive, with mid-point review at week 4),
and final review and plan for maintenance (week 8)
Administered by: not reported
Supervision: not reported
Intervention fidelity: not reported
Control: participants in control arm received usual care within the clinical service; the content of usu-
al care was not standardised: input varied between services and participants, but all participants could




• Depression measured using DASS-21 Depression
• Anxiety measured using DASS-21 Anxiety
• Stress measured using DASS-21 Stress
• Depression measured using AHI
Secondary outcomes
• Overall function measured using Mayo-Portland Adaptability Inventory-4 (MPAI-4) total (participant)
• Overall function measured using MPAI-4 total (informant)
• Caregiver Strain measured using Modified-Caregiver Strain Index
Notes Author contact: emailed study authors to request mean, SD for DASS-21 Depression and AHI post
treatment/end of follow-up. (Received reply from study author with mean SD for DASS-21 Depression,
AHI, and DASS-21 Anxiety for stroke patients only 09/11/2018)
Cullen 2018  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "stratified randomisation with blocking was used to allocate partici-
pants to two groups of equal size, stratified by service setting (stroke versus
CTCBI). Because service setting was a proxy for injury type (stroke versus non-
stroke) and for the nature of usual care that would be available to participants,
either of which could have influenced outcomes, including this as a stratifica-
tion factor ensured these aspects would be balanced across the intervention
and control groups" (p. 24)




Low risk Quote: "the allocation system was managed by the Robertson Centre for Bio-
statistics and was accessed via an automated telephone service after the base-





Unclear risk Quote: "screening, baseline assessments, allocation and interventions were
carried out by one RA (who was blinded to randomisation block length), and
the interim and follow-up measures were administered by a second RA, each
of whom was blind to the other’s findings. The second RA was blind to partic-
ipant allocation; a standard script was used to prevent unblinding during fol-
low-up telephone calls, and postal materials included clear instructions to par-
ticipants not to reveal treatment allocation information" (p. 24)
Comment: due to the nature of the intervention, it is unlikely that participants
were blinded to the group allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "a blinded assessor administered the DASS-21 and the AHI at 5, 9 and
20 weeks post-baseline. Of 27 participants randomised (median age 57; 63%
men; 82% ischaemic stroke survivors; median 5.7 months post-injury), 14 were




High risk Comment: per protocol analysis reported only; 11/27 participants not includ-
ed in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Treatment arm: rTMS + fluoxetine (SSRI)
Control arm: fluoxetine (SSRI)
Participants Geographical location: China
Setting: inpatient
Du 2005 
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Stroke criteria: stroke, types not stated
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by the
Fourth National Symposium on Cerebrovascular Disease in 1995; confirmation by brain CT or MRI
Time since stroke: not reported
Inclusion criteria: (1) 17-item HDRS score ≥ 8 points; (2) can sign informed consent
Exclusion criteria: (1) previous depression or psychiatric illness history; (2) aphasia; (3) severe cardiac,
pulmonary, hepatic, and renal impairment
Total number randomised in this trial: 60
Number randomised to treatment group: 30 (53% men; age range 59 to 82 years)
Number randomised to control group: 30 (53% men; age range 56 to 83 years)
Total number included in final analysis: 60
Number included in treatment group for final analysis: 30
Number included in control group for final analysis: 30
Interventions Treatment: low-frequency rTMS + 20 mg fluoxetine (SSRI) daily. Patients’ bilateral frontal lobes were
stimulated with 60% of maximal stimulus intensity, 30 times for each side. Frequency was 0.5 Hz, 1 se-
quence every day continuous for 5 days as a course, with an interval of 2 days between courses
Control: 20 mg fluoxetine (SSRI) daily
Treatment duration: 4 weeks
Follow-up: none
Outcomes Primary outcomes
• Depression measured using 17-item HDRS
• Cognitive functioning measured using MMSE
• Disability measured using BI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Comment: drawing lots used to generate randomisation sequence; this
method of sequence generation is prone to bias
Allocation concealment
(selection bias)





High risk Comment: participants and personnel not blinded to group allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Comment: outcome assessors not blinded to group allocation
Du 2005  (Continued)
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Low risk Comment: ITT; no missing data reported
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + duloxetine (SNRI) + stroke usual care
Control arm: duloxetine (SNRI) + stroke usual care
Participants Geographical location: China
Setting: unclear
Stroke criteria: not reported
Method of stroke diagnosis: not reported
Time since stroke: not reported
Inclusion criteria: (1) meeting diagnostic criteria of the CCMD-2-R for depression; (2) 17-item HDRS
score ≥ 8; (3) stable condition; (4) could tolerate rTMS; (5) patient or family member can sign informed
consent; (6) age 18 to 80 years
Exclusion criteria: (1) with previous depression, psychiatric illness history; (2) without 1-week washout
period of previous antidepressants; (3) consciousness disturbance or severe cognitive impairment; (4)
with epilepsy or severe cardiac, pulmonary, hepatic, or renal disease; (5) critical conditions or unstable
acute stage of stroke
Depression criteria: must meet diagnostic criteria of the CCMD-2-R for depression and the 17-item
HDRS score ≥ 8
Total number randomised in this trial: 90
Number randomised to treatment group: 45 (42% men, mean age 61.43, SD 8.74)
Number randomised to control group: 45 (51% men, mean age 64.78, SD 7.23)
Total number included in final analysis: 90
Number included in treatment group for final analysis: 45 (42% men, mean age 61.43, SD 8.74)
Number included in treatment group for final analysis: 45 (51% men, mean age 64.78, SD 7.23)
Interventions Treatment: rTMS (frequency: 1 Hz, intensity: 100% motor threshold, 30 times for a series, 10 series for
each treatment; location: bilateral dorsolateral pre-frontal) + duloxetine (SNRI) 60 mg/d + stroke usual
care (routine medication and rehabilitation)
Control: duloxetine (SNRI) + stroke usual care
Duration: 4 weeks
Fan 2014 
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Follow-up: none
Outcomes Primary outcomes
• Depression measured using 17-item HDRS
• Disability measured using MBI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: double-blind stated but who was blinded not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis; no missing data reported
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: constructive integrative psychosocial intervention (CIPI)
Control arm: standard care
Participants Geographical location: Singapore
Setting: inpatient
Stroke criteria: ischaemic and haemorrhagic stroke
Method of stroke diagnosis: clinically diagnosed new stroke
Time since stroke: 1 week
Fang 2017 
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Inclusion criteria: (1) had satisfactory mental status MMSE > 23; (2) had clinically diagnosed new
stroke within a week; (3) only patients who spoke English or Mandarin
Exclusion criteria: (1) other non-stroke-related neurological conditions such as brain tumour or trau-
matic brain injury; (2) patients discharged to a nursing home
Depression criteria: HADS score ≥ 8
Total number randomised in this trial: 42
Number randomised to treatment group: 23 (% men, age not recorded in the study)
Number randomised to control group: 19 (% men, age not recorded in the study)
Total number included in final analysis: 19
Number included in treatment group for final analysis: 13 (% men, age not recorded in the study)
Number included in control group for final analysis: 6 (% men, age not recorded in the study)
Interventions Treatment: CIPI result in a positive construction of experience of illness by patients and significant
others. This addresses their cognitions related to living with stroke and related behavioural response to
the stroke experience. Key qualities include evidence-supported components of psychosocial-behav-
ioural intervention life review and education
Administered by: not reported
Supervision: not reported





• Depression measured using HADS at 1, 3, and 6 months
Secondary outcome
• Cognitive functioning measured using MMSE at 1, 3, and 6 months
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "it used a randomized control group in an acute stroke unit with
pretest–posttest…."
Comment: based on study authors' responses; random number tables used
Allocation concealment
(selection bias)
High risk Comment: based on study authors' responses; sealed envelopes used to con-





High risk Comment: due to the nature of the trial, it was not possible to mask partici-
pants, clinicians, and researchers to treatment allocation
Fang 2017  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: per protocol analysis reported; 3/23 in treatment group not includ-
ed in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Treatment arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: Austria
Setting: inpatients
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage
Method of stroke diagnosis: diagnosis via clinical signs and CT (100%)
Time since stroke: 11 days
Inclusion criteria: (1) stroke on average 11 days before randomisation
Exclusion criteria: (1) MMSE < 20, more than mild communication deficit; (2) disease of the CNS and
previous degenerative or expansive neurological disorder
Depression criteria: psychiatric interview and HDRS score > 15
Total number randomised in this trial: 54
Number randomised to treatment group: 28 (46% men, mean age 65 years, SD 14)
Number randomised to control group: 26 (71% men, mean age 64 years, SD 14)
Total number included in final analysis: 40
Number included in treatment group for final analysis: 22 (% men and mean age not reported)
Number included in control group for final analysis: 18 (% men and mean age not reported)
Interventions Treatment: fluoxetine (SSRI) 20 mg daily; dose escalation at 4 weeks if HDRS score > 13
Control: matched placebo
Duration: 12 weeks. Open-label treatment was continued for a further 15 months for all (these data not
included in the review)
Follow-up: 18 months
Outcomes Primary outcomes
• Depression measured using HDRS, BDI, and CGI Scale-1
• Proportion of responders (HDRS < 13)
Fruehwald 2003 
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Secondary outcomes




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the randomization code list was generated by a computer program in
a random permuted block design for each centre" (p. 348)
Allocation concealment
(selection bias)
Low risk Quote: "all patients were randomly assigned to either fluoxetine or placebo
treatment by the drug company independently of the research teams and the





Low risk Quote: "… neither patients nor relatives, clinical examiners nor nursing staN
were aware of the drug treatment being given" (p. 348)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "… neither patients nor relatives, clinical examiners nor nursing staN








Unclear risk Comment: all pre-specified outcomes reported. No trial protocol or registry
record available to compare with the publication
Other bias Low risk Comment: non-significant trends towards more women and right-sided lesion




Methods Study design: parallel design
Number of arms: 2
Treatment arm: citalopram (SSRI) + 'attention control' psychological intervention (group B)
Control arm: placebo + 'attention control' psychological intervention (group A)
Participants Geographical location: China
Setting: outpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: occurrence of an ischaemic stroke that met the standards of WHO diag-
nostic criteria. Radiological MRI confirmation of an anatomical infarct observed on diffusion-weighted
acute MRI
Time since stroke: not reported
Gao 2017a 
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Inclusion criteria: (1) first-ever acute ischaemic stroke; (2) no history of depression; (3) no antidepres-
sant treatments received before our interventions; (4) over 18 years of age
Exclusion criteria: (1) presence of pre-stroke disease leading to pre-stroke disability; Barthel Index <
10
Depression criteria: 20-item BDI scores > 10
Total number randomised in this trial: 136
Number randomised to treatment group: 91 (50% men, mean age 66 years, SD 7)
Number randomised to control group: 45** (53% men, mean age 67 years, SD 10)
Total number included in final analysis: 128
Number included in treatment group for final analysis: 85 (% men and mean age were not reported)
Number included in control group for final analysis: 43** (% men and mean age were not reported)
Interventions Treatment: patients received active citalopram tablets (SSRI) and participated in similar placebo psy-
chological discussions as group A
Control: patients received placebo tablets and participated in a placebo psychological intervention,
1-hour discussions with non-psychological clinical doctors twice a week for 3 months; discussions fo-
cused on inquiries about stroke recovery and changes in daily life





• Depression measured using HDRS
• Depression measured using Melancholia Scale
Secondary outcomes
• Disability measured using BI
Notes Author contact: emailed study authors to request AE tables with numbers for all groups 23 Octoer
2018
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomization into one of three intervention groups was undertaken




High risk Quote: "... were prepared in advance and placed in consecutively numbered,
sealed, opaque envelopes" (p. 73)




High risk Quote: "when patients were enrolled, they were told to participate in drug
therapy, talk with doctors, and engage in rehabilitation at the same time. No
breaches in blinding were detected during the trial" (p. 74)
Gao 2017a  (Continued)
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All outcomes "the study therapists were asked not to divulge any treatment information to
their patients" (p. 75)
Comment: therapists delivering the intervention were not blinded to group al-
location
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: per protocol analysis reported only; 5/91 in control, 6/91 in treat-
ment not included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Treatment arm: 'active' psychological intervention + placebo (group C)
Control arm: 'attention control' psychological intervention + placebo (group A)
Participants Geographical location: China
Setting: outpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: occurrence of an ischaemic stroke that met the standards of WHO diag-
nostic criteria. Radiological MRI confirmation of an anatomical infarct observed on diffusion-weighted
acute MRI
Time since stroke: not reported
Inclusion criteria: (1) first-ever acute ischaemic stroke; (2) no history of depression; (3) no antidepres-
sant treatments received before our interventions; (4) over 18 years of age
Exclusion criteria: (1) presence of pre-stroke disease leading to pre-stroke disability; Barthel Index <
10
Depression criteria: 20-item BDI scores > 10
Total number randomised in this trial: 138
Number randomised to treatment group: 92 (52% men, mean age 65 years, SD 8)
Number randomised to control group: 46** (53% men, mean age years 67, SD 10)
Total number included in final analysis: 130
Number included in treatment group for final analysis: 87 (% men and mean age not reported)
Number included in control group for final analysis: 43** (% men and mean age not reported)
Gao 2017b 
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Interventions Treatment: patients received placebo tablets and had an ‘active’ psychological intervention: profes-
sional cognitive-behavioural therapy with psychologists who were trained by a professional cognitive
therapist for 1 week. The manual-based treatment included cognitive and behavioural courses that
consisted of education, activities, graded task assignments, and identifying and modifying useless be-
liefs and thoughts. Interventional measures were altered to meet individual demands
Administered by: psychologist trained in professional cognitive therapy
Supervision: not reported
Control: patients received placebo tablets and participated in a placebo psychological intervention,
1-hour discussions with non-psychological clinical doctors twice a week for 3 months; discussions fo-
cused on inquiries about stroke recovery and changes in daily life
Administered by: non-psychological clinical doctors
Supervision: not reported




• Depression measured using HDRS
• Depression measured using Melancholia Scale
Secondary outcomes
• Disability measured using BI
Notes Author contact: emailed study authors to request AE tables with numbers for all groups 23 October
2018
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomization into one of three intervention groups was undertaken




High risk Quote: "….were prepared in advance and placed in consecutively numbered,
sealed, opaque envelopes" (p. 73)





High risk Quote: "when patients were enrolled, they were told to participate in drug
therapy, talk with doctors, and engage in rehabilitation at the same time. No
breaches in blinding were detected during the trial" (p. 74)
"the study therapists were asked not to divulge any treatment information to
their patients" (p. 75)
Comment: therapists delivering the intervention not blinded to group alloca-
tion
Blinding of outcome as-
sessment (detection bias) 
High risk Quote: "the study therapists acted as clinical evaluators …" (p. 74)
Gao 2017b  (Continued)
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High risk Comment: per protocol analysis reported only; 5/91 in control, 6/91 in treat-
ment not included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Treatment arm: rTMS
Control arm: sham rTMS
Participants Geographical location: South Korea
Setting: unclear
Number of participants: 24
Stroke criteria: infarct and haemorrhage
Method of stroke diagnosis: not reported
Time since stroke: > 6 months
Inclusion criteria: (1) absence of depression or medication history of antidepressants before stroke
onset; (2) absence of severe cognitive dysfunction or aphasia; (3) absence of serious medical complica-
tions such as pneumonia or cardiac problems; (4) admitted > 6 months after stroke onset; (5) aged be-
tween 21 and 80 years only
Exclusion criteria: (1) history of depression before stroke onset; (2) medication history of antidepres-
sants before stroke onset; (3) serious medical complications such as pneumonia or cardiac problems
Depression criteria: BDI scores > 12 and 17-item HDRS scores > 6
Total number randomised in this trial: 24
Number randomised to treatment group: 12 (50% men, mean age 58 years, SD 9)
Number randomised to control group: 12 (42% men, mean age 58 years, SD 8)
Total number included in final analysis: 24
Number included in treatment group for final analysis: 12 (50% men, mean age 58 years, SD 9)
Number included in control group for final analysis: 12 (42% men, mean age 58 years, SD 8)
Interventions Treatment: Magstim Super Rapid Magnetic Stimulator (The Magstim Company, Wales, UK) with 70-
mm, air-cooled coil in the shape of a figure of 8. The coil was held with the handle posterior and ori-
ented sagittally. rTMS was performed over the le( F3 on the scalp according to the 10/20 electroen-
cephalography system (i.e. the DLPFC). For patients in the rTMS group, rTMS was delivered over the
DLPFC at 10 Hz, at an intensity of 110% of the motor threshold, duration of 5 seconds, and total of 20
Gu 2016 
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trains separated by 1-minute pauses (total of 1000 pulses). Each patient underwent 10 consecutive ses-
sions (Monday to Friday, 5 times per week for 2 weeks)
Control: sham stimulation was delivered using the same protocol, except that the angle of the coil was
at 90 perpendicular to the skull rather than tangential to it. Thus, the magnetic field could not pene-





• Depression measured using BDI and 17-item HDRS
Secondary outcomes
• Motor function measured using Upper limb Motoricity Index (MI-UE), lower limb MI-LE, Modified
Brunnstrom Classification (MBC), and Functional Ambulatory Category (FAC)
Notes Author contact: emailed study authors for method of randomisation, details of blinding of patients,
method of stroke diagnosis, number of patients screened/eligible, and sample size calculations 24 Oc-
tober 2018
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "all patients were randomly assigned to two groups, the rTMS and
sham groups…"(p. 271)
Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Quote: "a psychiatrist who was blinded to the study protocol performed rTMS
using a Magstim Super Rapid Magnetic Stimulator" (p. 271)
Comment: double-blind stated but not reported whether participants were
blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "the experimenters who applied the rTMS or sham stimulations were
different from the experimenters who assessed the degree of depression and
motor function. The experimenters who assessed depression and motor func-




Low risk Comment: ITT analysis reported; all participants included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol or registry
record available to compare with the publication
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: cognitive-behavioural therapy
Control arm: usual care
Participants Geographical location: Australia
Setting: inpatient
Stroke criteria: unclear
Method of stroke diagnosis: diagnosis of stroke confirmed by chart review
Time since stroke: not reported
Inclusion criteria: (1) > 18 years old; (2) adequate cognitive capacity to provide informed consent; (3)
adequate English and expressive and receptive communication skills
Exclusion criteria: (1) neurodegenerative disorder (e.g. dementia); (2) living > 50 km away from hospi-
tal
Depression criteria: depression score not an entry criteria. For unpublished analysis, HADS ≥ 8 used
for depression criteria
Total number randomised in this trial: 22
Number randomised to treatment group: 12 (75% men; mean age 60.8, SD 11.7)
Number randomised to control group: 10 (60% men; mean age 57.0, SD 14.2)
Total number included in final analysis: 17
Number included in treatment group for final analysis: 12 (75% men; mean age 60.8, SD 11.7)
Number included in control group for final analysis: 5 (60% men; mean age 57.0, SD 14.2)
Interventions Treatment: 8 × 1-hour cognitive-behavioural coping skills sessions delivered by clinical psychologist
with first 2 sessions in hospital, then 6 delivered at home
Administered by: clinical psychologist
Supervision: psychologist






• Depression measured using HADS and MADRS
• Anxiety measured using HADS
Secondary outcomes
• Disability measured using MBI
• Self-efficacy measured using Stroke Self Efficacy Questionnaire
Ho;mann 2015 
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews
• Functional capacity measured using Nottingham EADL
• Knowledge of stroke measured using Stroke Knowledge Questionnaire
• Quality of life measured using SAQoL
Notes This trial had 3 arms (self-management therapy, cognitive-behavioural therapy, and usual care), but
only data from cognitive-behavioural therapy compared with usual care (n = 17 participants) are pre-
sented here
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "... randomly allocated using a predetermined computer generated
randomisation sequence ..." (p. 118)
Allocation concealment
(selection bias)
High risk Comment: sealed opaque envelopes reported; this method of allocation con-





High risk Comment: due to the nature of the trial, it was not possible to mask partici-
pants, personnel delivering the intervention, and researchers to treatment al-
location
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "outcomes were assessed in a face-to-face interview conducted by a





Low risk Quote: "analysis was completed using ... and on an intention to treat basis and
missing data were addressed using the last observation carried forward proce-
dure" (p. 120)
Comment: ITT analysis reported. From whole data set, including depressed
and non-depressed, 1 intervention and 1 control withdrew post randomisation
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: China
Setting: inpatient
Stroke criteria: first-ever ischaemic or haemorrhagic stroke
Method of stroke diagnosis: diagnosis is consistent with the diagnostic criteria for acute stroke formu-
lated by the Chinese Medical Association with 1 single and unilateral lesion confirmed by brain CT or
MRI
Huang 2002 
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Time since stroke: unclear
Inclusion criteria: none reported
Exclusion criteria: (1) history of psychiatric illness; (2) severe heart disease; (3) previous organic brain
disease; (4) severe liver or kidney disease; (5) history of drug allergy
Depression criteria: psychiatric interview to confirm diagnosis meets depression diagnostic criteria of
the CCMD-2-R
Total number randomised in this trial: 80 (overall percentage of men 45%; 80 patients were a depres-
sive subgroup of 168 patients whose mean age was 62.2 years, SD 8.1)
Number randomised to treatment group: 40 (% men and mean age in treatment group not reported)
Number randomised to control group: 40 (% men and mean age in control group not reported; total
group as above)
Total number included in final analysis: 80 (overall percentage of men 45%; 80 patients were a de-
pressive subgroup of 168 patients whose mean age was 62.2 years, SD 8.1)
Number included in treatment group for final analysis: 40 (% men and mean age in treatment group
not reported)
Number included in control group for final analysis: 40 (% men and mean age in control group not
reported; total group as above)





• Depression measured using CCMD-2-R and 17-item HDRS
Secondary outcomes




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Comment: blinding of outcome assessors not reported
Huang 2002  (Continued)
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Low risk Comment: ITT analysis reported; no missing data reported
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: amitriptyline (TCA)
Control arm: placebo (not matched)
Participants Geographical location: China
Setting: inpatient
Stroke criteria: unclear
Method of stroke diagnosis: diagnosis via CT or MRI (100%)
Time since stroke: 0 to 7 days
Inclusion criteria: (1) Chinese Stroke Scale score > 8; (2) can independently complete HDRS, aged < 80
years; (3) no severe negative life events in past year; (4) first stroke; (5) no previous psychosis; (6) no an-
tidepressant medication
Exclusion criteria: (1) with history of psychosis; (2) on antidepressant medication
Depression criteria: HDRS > 8
Total number randomised in this trial: 45
Number randomised to treatment group: 30 (57% men, mean age 62 years, SD 14)
Number randomised to control group: 15** (60% men, mean age 63 years, SD 15)
Total number included in final analysis: 45
Number included in treatment group for final analysis: 30 (57% men, mean age 62 years, SD 14)
Number included in control group for final analysis: 15** (60% men, mean age 63 years, SD 15)
Interventions Treatment: amitriptyline (TCA) 50 mg increasing by 25 mg per day to 200 mg daily




• Depression measured using HDRS
Secondary outcomes
• Impairment measured using CSS
Jiang 2001a 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)
High risk Comment: 3-armed trial. Placebo frequency matched to Deanxit (intervention





High risk Comment: participants blinded but personnel not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: Deanxit
Control arm: placebo (not matched)
Participants Geographical location: China
Setting: inpatient
Stroke criteria: unclear
Method of stroke diagnosis: diagnosis via CT or MRI (100%)
Time since stroke: 0 to 7 days
Inclusion criteria: (1) CSS score > 8; (2) can independently complete HDRS, aged < 80 years; (3) no se-
vere negative life events in past year; (4) first stroke; (5) no previous psychosis; (6) no antidepressant
medication
Exclusion criteria: (1) with history of psychosis; (2) on antidepressant medication
Depression criteria: HDRS > 8
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Total number randomised in this trial: 45
Number randomised to treatment group: 30 (58% men, mean age 62 years, SD 14)
Number randomised to control group: 15** (60% men, mean age 63 years, SD 15)
Total number included in final analysis: 45
Number included in treatment group for final analysis: 30 (58% men, mean age 62 years, SD 14)
Number included in control group for final analysis: 15** (60% men, mean age 63 years, SD 15)
Interventions Treatment: Deanxit 2 tablets daily




• Depression measured using HDRS
Secondary outcomes




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)
High risk Comment: 3-armed trial. Placebo frequency matched to Deanxit (intervention





High risk Comment: participants blinded but personnel not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: TMS + acute stroke usual care
Control arm: acute stroke usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: Internal carotid artery territory infarct
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Time since stroke: 3 to 10 days
Inclusion criteria: (1) first-ever stroke; (2) age 30 to 70 years; (3) NIHSS at admission 8 to 20 points; (4)
GCS scale score > 8; (5) education level: at least high school, able to complete questionnaires; (6) no
communication barriers, able to communicate with medical staN; (7) can sign informed consent
Exclusion criteria: (1) comorbid severe organ failure; (2) history of epilepsy or consciousness distur-
bance; (3) contraindication for transcranial magnetic stimulation such as pacemaker implanted, severe
cardiac dysrhythmia; (4) worsened clinical condition, new infarct, or haemorrhagic transformation
Depression criteria: not reported
Total number randomised in this trial: 100
Number randomised to treatment group: 50 (% men and mean age not reported)
Number randomised to control group: 50 (% men and mean age not reported)
Total number included in final analysis: 100
Number included in treatment group for final analysis: 50 (% men and mean age not reported)
Number included in control group for final analysis: 50 (% men and mean age not reported)
Interventions Treatment: TMS + acute stroke usual care; frequency: start 3 to 10 days after stroke onset, 2 times a
day, 20 minutes each time, for successive 14 days; location: motor cortex on the healthy side




• Depression measured using HDRS
• Impairment measured using NIHSS
• Activities of daily living measured using ADL
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Jiang 2014a 
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Random sequence genera-
tion (selection bias)
Low risk Comment: random numbers table used for sequence generation
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: per protocol analysis reported only; 1 participant dropped out and
was not included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: TMS + sertraline (SSRI) + acute stroke usual care
Control arm: sertraline (SSRI) + acute stroke usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: internal carotid artery territory infarct
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Time since stroke: 3 to 10 days
Inclusion criteria: (1) first-ever stroke; (2) age 30 to 70 years; (3) NIHSS at admission 8 to 20 points; (4)
GCS scale score > 8; (5) education level: at least high school, able to complete questionnaires; (6) no
communication barriers, able to communicate with medical staN; (7) can sign informed consent
Exclusion criteria: (1) comorbid severe organ failure; (2) history of epilepsy or consciousness distur-
bance; (3) contraindication for transcranial magnetic stimulation such as pacemaker implanted, severe
cardiac dysrhythmia; (4) worsening clinical condition, new infarct, or haemorrhagic transformation
Depression criteria: not reported
Total number randomised in this trial: 100
Number randomised to treatment group: 50 (% men and mean age not reported)
Number randomised to control group: 50 (% men and mean age not reported)
Jiang 2014b 
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Total number included in final analysis: 99
Number included in treatment group for final analysis: 50
Number included in control group for final analysis: 49
Interventions Treatment: TMS + sertraline (SSRI) 50 mg/d + acute stroke usual care; frequency: start 3 to 10 days af-
ter stroke onset, 2 times a day, 20 minutes each time, for successive 14 days, location: motor cortex on
the healthy side




• Depression measured using HDRS
• Impairment measured using NIHSS
• Activities of daily living measured using ADL
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: random numbers table used for sequence generation
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: per protocol analysis reported only; 1 participant dropped out and
was not included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Jin 2013 
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Experimental arm: rTMS + sertraline (SSRI) + usual care
Control arm: sertraline (SSRI) + usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) without cerebral haemorrhage; (2) cerebral infarct history; (3) without epilepsy
history; (4) EEG showing no epileptiform discharge; (5) without head injury or intracranial infection his-
tory; (6) without intracranial metal or other foreign body
Exclusion criteria: not reported
Depression criteria: 17-item HDRS score ≥ 17
Total number randomised in this trial: 60
Number randomised to treatment group: 30 (63% men; mean age 56.0, SD 9.8)
Number randomised to control group: 30 (51% men; mean age 54.0, SD 10.2)
Total number included in final analysis: 60
Number included in treatment group for final analysis: 30
Number included in control group for final analysis: 30
Interventions Treatment: rTMS + sertraline (SSRI) 100 mg/d + usual care; frequency: 10 Hz, intensity: 80% resting
motor threshold, with each stimulation lasting 4 seconds with an interval of 56 seconds, total 20 min-
utes each treatment, 1 treatment per day, 5 treatments per week, location: le( DLPFC




• Depression measured using 17-item HDRS
• Impairment measured using NIHSS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)




Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Jin 2013  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: individual motivational interviewing
Control arm: usual care
Participants Geographical location: Australia
Setting: inpatient
Stroke criteria: cerebral infarction/intracerebral haemorrhage
Method of stroke diagnosis: medical diagnosis confirmed by neurologist in the medical notes
Time since stroke: not reported
Inclusion criteria: (1) acute presentation after acute stroke (cerebral infarction/intracerebral haemor-
rhage; (2) cognitively alert
Exclusion criteria: (1) subarachnoid haemorrhage; (2) mental health conditions, including depressive
symptoms requiring professional support within 1 month; (3) severe communication problems (e.g.
significant dysphasia or aphasia); (4) myocardial infarction; (5) concurrent neurological disease/trauma
Depression criteria: none
Total number randomised in this trial (stroke participants only): 10
Number randomised to treatment group: 4 (25% men, mean age 57 years, SD 20.8)
Number randomised to control group: 6 (50% men, mean age 65.8 years, SD 12.9)
Total number included in final analysis (stroke participants only): 9
Number randomised to treatment group: 4
Number included in control group: 5
Interventions Treatment: the over-arching principle of the intervention was to support the stroke survivor in adjust-
ing to life after stroke. The purpose of Session 1 was to set the agenda and encourage the patient to
talk about adjustment to stroke. In Session 2, the patient was encouraged to identify realistic goals for
recovery and barriers to achieving goals. In Session 3, the goals were to identify any ambivalence that
the patient had about achieving goals; to support the patient's optimism and self-efficacy, and to as-
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sist in identification of solutions to problems. Participants were encouraged to summarise their goals
and commitment and to clarify any information from the first 2 sessions. Sessions were scheduled for
30 minutes
Administered by: trained facilitators
Supervision: not stated
Intervention fidelity: not reported
Control: usual care
Duration: not reported
Follow-up: 1 month and 3 months
Outcomes Primary outcomes
• Feasibility (application, recruitment, and retention)
Primary clinical outcomes
• Depression measured using HADS and PHQ-9
• Anxiety measured using HADS
• Quality of life measured using quality of life Index
Secondary outcomes
• Disability measured using MBI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer-generated block randomisation list equally divided all
numbers between 1 and 60 into either treatment or control groups" (p. 3)
Allocation concealment
(selection bias)
Low risk Quote: "allocation to the intervention or control arms was concealed from
participants until after recruitment and baseline data collection. Envelopes
were prepared by the Principal Investigator and stored in a locked cupboard
in the ward. The envelopes were numbered sequentially, indicating the order
in which participants were enrolled into the study (e.g. the first participant re-
ceived the envelope labelled "Number 1", the second participant received the
envelope "Number 2", etc.). A note in the envelope indicated the allocation
(to intervention or control group), concealed by coloured paper to protect the
identity of the allocation group. The project manager opened the randomisa-





High risk Quote: "allocation to the intervention or control arms was concealed from
participants until after recruitment and baseline data collection" (p. 3) "Al-
though intentionally blinded, the research assistant may have become aware
of the allocation in conversation with the participant" (p. 5)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "the research assistant, a nurse with significant research experience,
was employed to collect data at the 2 follow-up time points. Although inten-
tionally blinded, the research assistant may have become aware of the alloca-
tion in conversation with the participant" (p. 5)
Incomplete outcome data
(attrition bias) 
Unclear risk Comment: per protocol analysis reported only; 10/48 participants not includ-
ed in the analysis
Kerr 2018  (Continued)
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: brief psychosocial-behavioural intervention (in-person)
Control arm: usual care
Participants Geographical location: USA
Setting: outpatient
Stroke criteria: ischaemic or haemorrhagic stroke
Method of stroke diagnosis: ischaemic or haemorrhagic stroke (verified by CT or MRI)
Time since stroke: 4 months
Inclusion criteria: (1) those with ischaemic or haemorrhagic stroke; (2) GDS score > 11; (3) within 4
months of stroke onset
Exclusion criteria: (1) GDS score < 11; (2) not within 4 months of stroke onset
Depression criteria: GDS score < 11
Total number randomised in this trial: 49
Number randomised to treatment group: 35 (48.6% men, mean age 58.5 years, SD not reported)
Number randomised to control group: 14** (50% men, mean age 60.7 years, SD not reported)
Total number included in final analysis: 44
Number included in treatment group for final analysis: 31
Number included in control group for final analysis: 13**
Interventions Treatment: brief in-person psychosocial-behavioural intervention (had 1 in-person orientation session
with the psychosocial nurse practitioner therapist, either at home or at our study offices. Participant re-
ceived participant manuals, discussed goals and expectations of each session, and learned how to fill
out homework sections
Administered by: psychosocial nurse practitioner therapist
Supervised by: not reported
Treatment fidelity: not reported
Control: usual care (participants reported on their progress at follow-up visits in their homes from re-
search nurses at 8 weeks, 21 weeks, and 12 months following entry to the study).
Duration: 8 weeks
Kirkness 2017a 
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Follow-up: 10 months
Outcomes Primary outcomes
• Response (per cent reduction in HDRS)
• Remission (HDRS score < 10) at 8 weeks and 12 months post treatment
Notes Emailed study authors to request mean and SD for HDRS, BI, and NIHSS score at 8 weeks and 12
months post treatment for all 3 groups 23 October 2018 (reply received - mean SD and remission for
HDRS and BI for all treatment groups sent by study author 06/11/2018)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the algorithm was based on an imbalance score which measured, for
a given set of random assignments, how far out of balance the study would be
within strata for each factor and then summed over factors. When a new sub-
ject was available for randomization, we computed what the imbalance score
would be if this subject were assigned to usual care, or to telephone interven-
tion, or to in-person intervention. Then randomization was done to allocate
two intervention participants to each control with each new assignment hav-
ing a higher probability of less imbalance. The schema did not require equal
numbers in each arm" (p. 4)
Allocation concealment
(selection bias)
Unclear risk Quote: "the study statistician generated the algorithm, which was secure-
ly stored and accessible only by the statistician and research nurse supervi-
sor" (p. 5)





High risk Quote: "participants were asked not to reveal their study arm to the outcome
assessors" (p. 5)
Comment: blinding of personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "... masking outcome assessors to the participant’s randomization sta-
tus. Participants were asked not to reveal their study arm to the outcome as-








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol to compare
with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: brief psychosocial-behavioural intervention (telephone)
Kirkness 2017b 
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Control arm: usual care
Participants Geographical location: USA
Setting: outpatient
Stroke criteria: ischaemic or haemorrhagic stroke
Method of stroke diagnosis: ischaemic or haemorrhagic stroke (verified by CT or MRI)
Time since stroke: 4 months
Inclusion criteria: (1) ischaemic or haemorrhagic stroke; (2) GDS score > 11; (3) within 4 months of
stroke onset
Exclusion criteria: (1) GDS score < 11; (2) not within 4 months of stroke onset
Depression criteria: GDS score < 11
Total number randomised in this trial: 51
Number randomised to treatment group: 37 (51.4% men, mean age 61.7 years, SD not reported)
Number randomised to control group: 14** (50% men, mean age 60.7 years, SD not reported)
Total number included in final analysis: 47
Number included in treatment group for final analysis: 34
Number included in control group for final analysis: 13**
Interventions Treatment: brief telephone psychosocial-behavioural intervention (had 1 in-person orientation ses-
sion with psychosocial nurse practitioner therapist, either at home or at our study offices. Participants
received participant manuals, discussed goals and expectations of each session, and learned how to fill
out homework sections
Administered by: psychosocial nurse practitioner therapist
Supervised by: not reported
Treatment fidelity: not reported
Control: usual care (participants reported on their progress at follow-up visits in their homes from re-




• Response (per cent reduction in HDRS)
• Remission (HDRS score < 10) at 8 weeks and 12 months post treatment
Notes Emailed study authors to request mean and SD for HDRS, BI, and NIHSS score at 8 weeks and 12
months post treatment for all 3 groups 23/10/2018 (reply received - mean SD and remission for HDRS
and BI for all treatment groups sent by trial author 06/11/2018)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the algorithm was based on an imbalance score which measured, for
a given set of random assignments, how far out of balance the study would be
Kirkness 2017b  (Continued)
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within strata for each factor and then summed over factors. When a new sub-
ject was available for randomization, we computed what the imbalance score
would be if this subject were assigned to usual care, or to telephone interven-
tion, or to in-person intervention. Then randomization was done to allocate
two intervention participants to each control with each new assignment hav-
ing a higher probability of less imbalance. The schema did not require equal
numbers in each arm" (p. 4)
Allocation concealment
(selection bias)
Unclear risk Quote: "the study statistician generated the algorithm, which was secure-
ly stored and accessible only by the statistician and research nurse supervi-
sor" (p. 5)





High risk Quote: "participants were asked not to reveal their study arm to the outcome
assessors" (p. 5)
Comment: blinding of personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "….masking outcome assessors to the participant’s randomization sta-
tus. Participants were asked not to reveal their study arm to the outcome as-








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol to compare
with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI) 20 mg/d
Control arm: placebo
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: diagnosis met the diagnostic criteria of various cerebrovascular diseases
formulated at the 4th National Cerebrovascular Disease Conference and confirmed as stroke by skull
CT or MRI
Time since stroke: < 7 days
Inclusion criteria: (1) all patients were < 7 days from their first-ever stroke; (2) able to understand and
carry out verbal instructions
Exclusion criteria: (1) diagnosis of major depression at evaluation or at any earlier period during the
index episode; (2) active suicidal ideation; (3) bipolar disorder, schizophrenia, or other psychotic disor-
Kong 2007 
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der; (4) currently taking antidepressants; (5) MMSE score ≤ 23; (6) medical contraindication to fluoxe-
tine; (7) history of allergy to fluoxetine; (8) history of substance abuse; (9) obvious liver and renal func-
tion deficit
Depression criteria: 24-item HDRS score ≥ 8 and ≤ 20
Total number randomised in this trial: 90
Number randomised to treatment group: 48 (60% men; mean age 64 years, SD 7; 62% ischaemic;
NIHSS 14.6, SD 5.8)
Number randomised to control group: 42 (58% men; mean age 62 years, SD 7; 58% ischaemic; NIHSS
14.3, SD 6.1)
Total number included in final analysis: 73
Number included in treatment group for final analysis: 37
Number included in control group for final analysis: 36
Interventions Treatment: fluoxetine (SSRI) 20 mg/d; no further details given





• Depression measured using 24-item HDRS
Secondary outcomes
• Functional capacity measured using BI
• Impairment measured using NIHSS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "treatment allocation was based on a computer-generated list of treat-
ment numbers" (p. 163)
Allocation concealment
(selection bias)






Low risk Quote: "the patient, relatives and the researchers were not aware of the drug
being given" (p. 163)
Comment: blinding of those who delivered the intervention not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Quote: "seventy-three of the 90 randomized patients accomplished the trial.
In the treatment group, 11 patients dropped out, including insufficient clinical
response (n = 4), somatic side effects (n = 2), intervening medical illness (n = 1),
hypomania (n = 3), and other reasons (n = 2). In the placebo group, 6 patients
Kong 2007  (Continued)
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews
existed, including insufficient clinical response (n = 2), somatic side effects (n =
1) and other reasons (n = 3)"
Comment: per protocol analysis reported only
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: paroxetine (SSRI)
Control arm: placebo
Participants Geographical location: China
Setting: inpatient
Stroke criteria: acute stroke
Method of stroke diagnosis: diagnosis via CT
Time since stroke: unclear
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: HDRS score > 6
Total number randomised in this trial: 80
Number included in treatment group: 40 (54% men in total, mean age 60 years, SD 14)
Number included in control group: 40 (54% men in total, mean age 60 years, SD 14)
Total number included in final analysis: 80
Number included in treatment group for final analysis: 40
Number included in control group for final analysis: 40





• Depression measured using HDRS and ZDS
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: China.
Setting: unclear
Stroke criteria: ischaemic or haemorrhagic stroke
Method of stroke diagnosis: each patient evaluated for inclusion by a neuro-psychiatrist. Presence of
recent < 6 weeks ischaemic or haemorrhagic stroke documented by CT or MRI before the study
Time since stroke: 4.78 days
Inclusion criteria: (1) lack of treatment with antidepressants during the 2 weeks before this study; (2)
only single ischaemic and haemorrhagic stroke
Exclusion criteria: (1) cognitive impairment (MMSE < 23); (2) severe aphasia; (3) history of alcoholism,
abnormal thyroid, or epilepsy
Depression criteria: HDRS score > 20
Li 2008 
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Total number randomised in this trial: 90
Number randomised to treatment group: 60 (47% men; mean age 68.5 years, SD 4.1; mean time since
stroke 4.83 weeks, SD 0.57)
Number randomised to control group: 30 (57% men; mean age 67.8 years, SD 3.9; mean time since
stroke 4.82, SD 0.67)
Total number included in final analysis: 86
Number included in treatment group for final analysis: 58
Number included in control group for final analysis: 28
Interventions Treatment: fluoxetine (SSRI) 20 to 40 mg depending on tolerability together with placebo to make up 6
tablets




• Depression measured using HDRS (mean HDRS score at end of trial)
• Percentage of responders (measure of clinical response defined as > 50% reduction in HDRS score
compared with baseline score)
Secondary outcomes
• Depression measured using HDRS (at 4 weeks)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer-generated randomisation was carried out…" (p. 843)
Allocation concealment
(selection bias)






High risk Quote: "neither the examiners involved nor the patients were aware of the
type of the administered medications" (p. 842)
Comment: physician initiated and moderated treatment dose based on pa-
tient’s tolerability and response. It is likely that the physician was not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "neither the examiners involved nor the patients were aware of the




High risk Comment: 2/60 patients in the fluoxetine group withdrew from the study due
to recurrent stroke; 2/30 withdrew due to increased depressive symptoms
within 4 weeks of the start of the trial. Per protocol analysis reported only
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
Li 2008  (Continued)
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + mirtazapine + stroke usual care
Control arm: mirtazapine + stroke usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) aged over 65 years; (2) patient or guardian can sign informed consent; (3) meet-
ing diagnostic criteria of the CCMD-3 for depression
Exclusion criteria: (1) comorbid with aphasia, comprehension, or expression impairment, or severe
mental retardation; (2) with severe cardiac, hepatic, or renal disease, or with epilepsy; (3) intracranial
metal implant, possible history of allergy to mirtazapine
Depression criteria: meeting diagnostic criteria of the CCMD-3 for depression and 17-item HDRS score
≥ 17
Total number randomised in this trial: 60
Number included in treatment group: 30 (56% men; mean age 64.8, SD 5.4)
Number included in control group: 30 (53% men; mean age 65.2, SD 4.8)
Total number included in final analysis: 60
Number included in treatment group for final analysis: 30
Number included in control group for final analysis: 30
Interventions Treatment: rTMS + mirtazapine (starting from 15 mg/d at night, if tolerable, increase to 30 mg/d in 2 to
3 days) + stroke usual care (medications + rehabilitation). Frequency: 1 Hz, intensity: 90% motor thresh-
old, each treatment lasting for 20 minutes, 5 treatments a week, location: right DLPFC




• Depression measured using HDRS
Secondary outcomes
• Impairment measured using NIHSS
Li 2013 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + fluoxetine (SSRI) + stroke usual care
Control arm: fluoxetine (SSRI) + stroke usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic and haemorrhagic stroke
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) meeting diagnostic criteria of the CCMD-3 for depression; (2) 17-item HDRS score
≥ 18
Exclusion criteria: not reported
Depression criteria: meeting diagnostic criteria of the CCMD-3 for depression and for 17-item HDRS
score ≥ 18
Total number randomised in this trial: 93
Li 2014 
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Number randomised to treatment group: 47 (49% men; mean age 57.6, SD 6.8)
Number randomised to control group: 46 (52% men; mean age 56.5, SD 6.7)
Total number included in final analysis: 93
Number included in treatment group for final analysis: 47
Number included in control group for final analysis: 46
Interventions Treatment: rTMS + fluoxetine (SSRI) 20 mg/d + stroke usual care (medications + rehabilitation)
Frequency: 10 Hz, intensity: 80% motor threshold, with each series lasting 4 seconds with an interval of
56 seconds, successive 20 series per day, 5 treatments a week, location: le( DLPFC




• Depression measured using HDRS
• Disability measured using MBI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: random number table used for sequence generation
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
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Methods Study design: parallel design
Number of arms: 3
Experimental arm: cognitive-behavioural therapy
Control arm 1: attention control
Control arm 2: usual care
Participants Geographical location: UK
Setting: outpatient
Stroke criteria: all subtypes
Method of stroke diagnosis: diagnosis via clinical signs and symptoms and CT
Time since stroke: 1 to 6 months
Inclusion criteria: not reported
Exclusion criteria: (1) blindness; (2) deafness; (3) participant did not speak English; (4) dementia docu-
mented in medical records; (5) treated for depression in previous 5 years; (6) lived outside specified lo-
cality; (7) participant could not complete questionnaire unaided
Depression criteria: psychiatric interview (SCAN), BDI score > 10, WDI score > 18
Total number randomised in this trial: 123
Number randomised to treatment group: 39 (51% men, mean age 67 years, SD 13)
Number randomised to attention control and usual care group^: 84 (51% men, mean age 66 years,
SD 14)
Total number included in final analysis: 111
Number included in treatment group for final analysis: 34
Number included in control group for final analysis: 77
Interventions Treatment: cognitive-behavioural therapy (techniques included education, graded task assignment,
activity scheduling, and identification and modification of unhelpful thoughts and beliefs. Interven-
tions were tailored to meet the individual’s needs. Frequency and duration of sessions were 10 × 1 hour
sessions over 13 weeks
Administered by: trained therapist
Supervision: therapist received training and clinical supervision by experienced cognitive therapist
Intervention fidelity: not reported
Attention control: no formal therapeutic intervention; conversation focused on day-to-day occur-
rences and discussion regarding physical effects of stroke and life changes (10 × 1 hour visits over 13
weeks)




• Depression measured using BDI, WDI, GHQ 28
• Activities of daily living measured using EADL scale
• Leaving the study early
Lincoln 2003 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer generated random number sequence was prepared in ad-
vance and sealed in opaque, consecutively numbered envelopes by an inde-
pendent researcher" (p. 112)
Allocation concealment
(selection bias)
High risk Quote: "….prepared in advance and sealed in opaque, consecutively num-
bered envelopes by an independent researcher" (p. 112)





High risk Comment: due to the nature of the intervention, it was not possible to mask
participants, CBT therapists, or researchers to treatment allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "outcome assessments were administered by an assistant psycholo-
gist, who was blind to the group allocation, 3 and 6 months after randomiza-
tion. The primary outcome measures were the BDI and WDI, which were sent








Unclear risk Comment: all pre-specified outcomes were reported; no trial protocol avail-
able to compare with the publication
Other bias High risk Comment: significantly more participants in the treatment group with an




Methods Study design: parallel design
Number of arms: 2
Experimental arm: nortriptyline (TCA)
Control arm: matched placebo
Participants Geographical location: USA
Setting: mixed
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage
Method of stroke diagnosis: diagnosis via clinical signs and CT (100%)
Time since stroke: 262 ± 437 days
Inclusion criteria: (1) included outpatients who requested treatment for poststroke depressive disor-
der
Lipsey 1984 
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Exclusion criteria: (1) current treatment for depression; (2) severe comprehension deficit; (3) medical
contraindication to nortriptyline
Depression criteria: psychiatric interview (PSE, DSM-III)
Total number randomised in this trial: 39
Number randomised to treatment group: 17
Number randomised to control group: 22
Total number included in final analysis: 34
Number included in treatment group for final analysis: 14 (64% men, mean age 62 years, SD 9)
Number included in control group for final analysis: 20 (65% men, mean age 60 years, SD 12)
Interventions Treatment: nortriptyline (TCA) 20 to 100 mg daily; 2 treatment regimens combined; dose escalation
over treatment period to 100 mg
Control: matched placebo
Duration: 4 to 6 weeks
Follow-up: not reported
Outcomes Primary outcomes






Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "all patients were randomly assigned to nortriptyline or placebo treat-
ment by means of a random number table" (p. 297)
Allocation concealment
(selection bias)





Low risk Quote: "patients and their families, clinical examiners and nursing staN were
unaware of the drug treatment being given" (p. 297)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "patients and their families, clinical examiners and nursing staN were




High risk Comment: per protocol analysis reported; 5/39 (13%) not included in analyses
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
Lipsey 1984  (Continued)
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + citalopram (SSRI) + short-term benzodiazepines (BZDs) if needed for insom-
nia
Control arm: citalopram (SSRI) + short-term BZDs if needed for insomnia
Participants Geographical location: China
Setting: mixed
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) can sign informed consent; (2) 17-item HDRS score ≥ 17
Exclusion criteria: (1) drug dependence history in recent 6 months; (2) bleeding tendency, severe he-
patic or renal impairment, or other physical illness; (3) epilepsy history, head injury with consciousness
loss history, history of cranial operation, metal implant or electronic devices in the body
Depression criteria: 17-item HDRS score ≥ 17
Total number randomised in this trial: 60
Number included in treatment group: 30 (56% men; mean age 64.2, SD 3.1)
Number included in control group: 30 (53% men; mean age 65.1, SD 3.5)
Total number included in final analysis: 60
Number included in treatment group for final analysis: 30
Number included in control group for final analysis: 30
Interventions Treatment: rTMS + citalopram (SSRI), starting from 10 mg/d in the morning, may titrate up to 20 mg/
d according to the patient’s condition + short-term BZDs (only for difficulty in falling asleep; combined
duration: less than 1 week). Frequency: 10 Hz, intensity: 80% resting motor threshold, 1 stimulation
lasts 5 seconds and stops for 20 seconds, total treatment time: 20 minutes, 1 treatment per day, 5 treat-
ments a week, total 4 weeks, location: le( DLPFC




• Depression measured using 17-item HDRS
Secondary outcome
Liu 2015 
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• Impairment measured using NIHSS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + duloxetine (SNRI) + ischaemic stroke routine care
Control arm: duloxetine (SNRI) + ischaemic stroke routine care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) clear consciousness; (2) 24-item HDRS score ≥ 20; (3) meeting diagnostic criteria
of ICD-10 for depression
Exclusion criteria: (1) cognitive impairment; (2) no language impairment; (3) severe cardiac or pul-
monary disease, hepatic or renal impairment; (4) bleeding tendency
Depression criteria: meeting diagnostic criteria of ICD-10 for depression and 24-item HDRS score ≥ 20
Lu 2016 
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Total number randomised in this trial: 80
Number randomised to treatment group: 40 (57.5% men; mean age 65.3, SD 8.8)
Number randomised to control group: 40 (52.5% men; mean age 63.8, SD 8.4)
Total number included in final analysis: 73
Number included in treatment group for final analysis: 36
Number included in control group for final analysis: 37
Interventions Treatment: rTMS + duloxetine (SNRI) 60 mg/d + ischaemic stroke routine care. Frequency: 3.0 Hz, in-
tensity: 110% resting motor threshold, 1 treatment lasts 5 minutes, 5 treatments a week, location: le(
temporoparietal area




• Depression measured using MADRS
• Depression measured using 24-item HDRS
• Dependence measured using SDS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: random numbers table used for sequence generation
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS
Control arm: sham rTMS
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: brain CT or MRI confirmed cerebral infarct
Inclusion criteria: (1) normal expression ability; (2) first stroke; (3) clear consciousness, can sign in-
formed consent, right-handedness; (4) HDRS score ≥ 8
Exclusion criteria: (1) history of psychiatric illness; (2) cerebral haemorrhage, history of epilepsy, con-
traindication for TMS, not finishing treatment course
Depression criteria: HDRS score ≥ 8
Total number randomised in this trial: 108
Number randomised to treatment group: 54 (62.9% men; mean age 64.2, SD 4.2)
Number randomised to control group: 54 (64.8% men; mean age 65.8, SD 4.0)
Total number included in final analysis: 108
Number included in treatment group for final analysis: 54
Number included in control group for final analysis: 54
Interventions Treatment: rTMS + usual care (which includes antidepressants if already on them, no change of antide-
pressant dosage or medication during treatment). Frequency: 10 Hz, intensity: 80% motor threshold, 1
stimulation lasts 4.9 seconds and stops for 20 seconds, 86 cycles a day, total 1960 impulses a day, loca-
tion: le( DLPFC
Control: sham rTMS, keeping coils at 90-degree angles with the scalp + usual care (which includes anti-




• Depression measured using HDRS
• Disability measured using BI
• Impairment measured using CSS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: random numbers table used for sequence generation
Meng 2015 
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Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: cognitive-behavioural therapy plus problem-solving
Control arm: written information from the Stroke Association including information about depression
Participants Geographical location: USA
Setting: outpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: verified by CT or MRI
Time since stroke: within 4 months
Inclusion criteria: (1) stroke within 4 months; (2) 21 years of age and older
Exclusion criteria: (1) subarachnoid or intracranial haemorrhagic stroke; (2) global aphasia; (3) re-
duced level of consciousness (GCS < 15)
Depression criteria: diagnosis of depression validated by the Diagnostic Interview and Structured
Hamilton among those who scored > 10 on the GDS
Total number randomised in this trial: 101
Number randomised to treatment group: 48 (60% men, mean age 57 years, age range 25 to 88 years)
Number randomised to control group: 53 (60% men, mean age 57 years, age range 29 to 88 years)
Total number included in final analysis: 92
Number included in treatment group for final analysis: 44
Number included in control group for final analysis: 48
Mitchell 2002 
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Interventions Treatment: cognitive-behavioural therapy plus problem-solving. Sessions were focused on the indi-
vidual; however, a participant could opt to have a family member or an informal caregiver join these
sessions. The brief psychosocial–behavioural intervention was adapted from the "Seattle Protocols"
shown to reduce disability associated with depression in Alzheimer disease. All participants received
written information from the Stroke Association including information about depression. Participants
could receive antidepressant medication at the discretion of their usual care provider. Frequency and
duration: 9 sessions over 8 weeks
Administered by: therapists
Supervision: all therapists met monthly with the clinical psychologist who developed the intervention
Intervention fidelity: sessions were audio-taped, and session content was compared to the content
specified for each visit
Control: all participants received written information from the Stroke Association including informa-





• Depression measured using HDRS




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomization status was generated by a computerized adaptive ran-
domisation procedure…" (p. 3075)
Allocation concealment
(selection bias)





High risk Comment: due to the nature of the trial, it was not possible to mask partici-
pants, clinicians, and researchers to treatment allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "all outcome assessors were masked to the participant’s randomiza-









High risk Comment: caregiving burden and benefit (Sense of Competence Scale) out-
come in the protocol not reported in the publication
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: sertraline (SSRI)
Control arm: matched placebo
Participants Geographical location: Sweden
Setting: mixed
Stroke criteria: all subtypes
Method of stroke diagnosis: diagnosis via clinical signs and CT (100%)
Time since stroke: 12 months
Inclusion criteria: (1) > 17 years of age; (2) stroke within previous 12 months
Exclusion criteria: (1) under 18 years of age; (2) severely impaired communication; (3) apparent diffi-
culties in adhering to study protocol; (4) acute myocardial infarction; (5) psychiatric illness other than
depression; (6) significant risk of suicide; (7) antidepressants during the month before randomisation;
(8) current use of psychotropic medication or opiate analgesic drugs; (9) < 20% reduction in MADRS
score at 6 weeks
Depression criteria: psychiatric interview (DSM-IV, major and minor) and MADRS > 9
Total number randomised in this trial: 123
Number randomised to treatment group: 62 (52% men, mean age 71 years, SD 10)
Number randomised to control group: 61 (44% men, mean age 71 years, SD 10)
Total number included in final analysis: 123
Number included in treatment group for final analysis: 62
Number included in control group for final analysis: 61











Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a centralised randomization procedure was applied. The Central
Pharmacy in Stockholm kept the randomization list" (p. 709)
Murray 2002 
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Allocation concealment
(selection bias)
Low risk Quote: "each centre pharmacy received a consecutive series of presealed





Low risk Quote: "patients received double-blind identical capsules of either sertraline
50 mg or placebo, once a day as a starting dose" (p. 709)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: double-blind placebo-controlled trial, which suggests that out-




High risk Quote: "efficacy analyses were based on the intention to treat (ITT), last obser-
vation carried forward population…" (p. 710)
"… response and remission rates were calculated for those patients who com-
pleted the study" (p. 710)
Comment: continuous outcomes analysed by ITT; dichotomous outcomes
analysed per protocol (data reported for 38/62, 61% intervention participants;
31/61, 51% control participants)
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: Aniracetam (nootropic agent)
Control arm: matched placebo
Participants Geographical location: Japan
Setting: unclear
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: not reported
Time since stroke: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: based on physician's impression, no scale used for evaluation
Total number randomised in this trial: 285
Number randomised to treatment group: 150 (details unclear)
Number randomised to control group: 135 (details unclear)
Total number included in final analysis: 206
Ohtomo 1991 
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Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear





• Depression measured by physician assessment of change in depression from baseline to end of treat-
ment
• Anxiety measured by physician assessment of change
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Comment: generation sequence controlled by Professor Furukawa
Allocation concealment
(selection bias)





Low risk Comment: double-blind reported and matched placebo used
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Unclear risk Comment: all pre-specified outcomes reported. No trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: paroxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: Italy
Ponzio 2001 
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Setting: outpatient
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Time since stroke: not reported
Inclusion criteria: (1) 18 to 85 years of age; (2) MMSE score > 23
Exclusion criteria: (1) concurrent predominant psychiatric disorders; (2) receiving psychotropic phar-
macotherapy; (3) with substance abuse/dependence; (4) participation in other clinical trials; (5) suicide
risk; (6) concomitant medication intolerance to paroxetine
Depression criteria: MADRS > 18
Total number randomised in this trial: 229
Number randomised to treatment group: 112 (54% men, mean age 64 years, SD 11)
Number randomised to control group: 117 (55% men, mean age 66 years, SD 11)
Total number included in final analysis: 229
Number included in treatment group for final analysis: 112
Number included in control group for final analysis: 117





• Depression (change in scores from baseline to end of treatment) measured using MADRS and CGI
Secondary outcomes
• Proportion scoring < 7 on MADRS and responders on CGI
• Disability (change in scores from baseline to end of treatment) measured using BI




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "subjects randomised to paroxetine…" (p. 1)
Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Quote: "blinding of study medication was maintained by referring to
dosage…" (p. 1)
Comment: in study design, it states that this study is a 'double-blind, place-
bo-controlled' trial, but in treatment, this is a 'single-blind placebo' trial
Ponzio 2001  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: in study design, it states that this is a 'double-blind, placebo con-




Low risk Quote: "the primary analysis (post stroke depression) population was the in-
tention-to-treat (ITT) population…." (p. 1)
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: reboxetine (NRI)
Control arm: matched placebo
Participants Geographical location: Italy
Setting: outpatient
Stroke criteria: single ischaemic or haemorrhagic stroke
Method of stroke diagnosis: diagnosis via CT and MRI
Time since stroke: 2 weeks
Inclusion criteria: (1) presence of major or minor depression; (2) presence of retarded depression; (3)
lack of treatment with antidepressants 2 weeks before randomisation; (4) absence of treatment with
neuroleptic drugs during 3 months before enrolment; (5) can sign informed consent
Exclusion criteria: (1) previous degenerative or expansive neurological disease; (2) tumour, multiple
sclerosis, amyotrophic sclerosis, hydrocephalus, SAH, Binswanger's disease; (3) history of psychiatric
illness (other than depression); (4) severe aphasia; (5) severe cognitive deficit; (6) chronic alcoholism
Depression criteria: psychiatric interview, HDRS > 20, BDI > 15
Total number randomised in this trial: 31
Number randomised to treatment group: 16 (44% men, mean age 78 years, SD 4)
Number randomised to control group: 15 (46% men, mean age 77 years, SD 4)
Total number included in final analysis: 31
Number included in treatment group for final analysis: 16
Number included in control group for final analysis: 15
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer-generated randomization was carried out by a physician
who was not involved in the evaluation of patients…" (p. 277)
Allocation concealment
(selection bias)
Low risk Quote: "the generator of randomization assigned a code number (0) to pa-
tients who were treated with reboxetine, and a different code (1) was given to
patients treated with placebo. Code 0 was stuck on totally white boxes, with-





High risk Quote: "the generator of randomization handed over, for each patient, the box
marked with the code and containing the tablets that should be taken" (p. 279)
Comment: participants were blinded but the personnel who delivered the in-
tervention knew the treatment allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "the other physician was in charge of the follow-up visits and of the




Low risk Comment: follow-up of all participants was complete; ITT analysis reported
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol to compare
with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: trazodone-HCl (TCA)
Control arm: matched placebo
Participants Geographical location: USA
Setting: inpatients
Stroke criteria: all subtypes
Method of stroke diagnosis: diagnosis via clinical signs and CT (% not reported)
Time since stroke: 45 to 48 days
Inclusion criteria: not reported
Reding 1986 
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Exclusion criteria: (1) myocardial infarction within previous month; (2) on antiarrhythmic medication
Depression criteria: psychiatric interview (DSM-III, major and minor)
Total number randomised in this trial: 17
Number randomised to treatment group: 11 (66% men, mean age 68 years, SE 2)
Number randomised to control group: 6 (73% men, mean age 68 years, SE 3)
Total number included in final analysis: 17
Number included in treatment group for final analysis: 11
Number included in control group for final analysis: 6
Interventions Treatment: trazodone-HCl (TCA) 50 mg daily; dose escalation every 3 days to target dose of 200 mg
Control: matched placebo
Duration: 32 ± 6 days (treatment group) and 24 ± 4 days (control group)
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using clinical diagnosis of depression and ZDS
Secondary outcomes
• Disability measured using BI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "patients were assigned to either treatment or placebo groups accord-
ing to a table of random numbers" (p. 763)
Allocation concealment
(selection bias)






Low risk Quote: "…or placebo in an identical capsule was administered orally…" (p.
763)
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Unclear risk Comment: all pre-specified outcomes reported; no trial protocol to compare
with the publication
Other bias Unclear risk Comment: baseline demographic information not reported
Reding 1986  (Continued)
 
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews
 
Methods Study design: parallel design
Number of arms: 2
Experimental arm: nefiracetam (nootropic agent)
Control arm: matched placebo
Participants Geographical location: USA
Setting: unclear
Stroke criteria: ischaemic and primary intracerebral haemorrhage
Method of stroke diagnosis: unclear
Time since stroke: 10 days to 3 months
Inclusion criteria: not reported
Exclusion criteria: (1) other psychiatric or neurological disease (e.g. Alzheimer’s disease, Parkinson’s
disease); (2) depression or suicidal plans requiring psychiatric hospitalisation; (3) on psychotropic med-
ication (excluding benzodiazepines or insomnia medication); (4) comprehension deficit precluding ver-
bal interview; (5) life-threatening illness; (6) previous subarachnoid haemorrhage
Depression criteria: psychiatric interview to confirm DSM-IV diagnosis of "depression due to stroke
with major depressive-like episode" plus HDRS score ≥ 18
Total number randomised in this trial: 76
Number randomised to treatment group: 48 (40% men; mean age 68.1, SD 11.9)
Number randomised to control group: 28** (54% men; mean age 66.8, SD 13.0)
Total number included in final analysis: 66
Number included in treatment group for final analysis: 41
Number included in control group for final analysis: 25**
Interventions Treatment: nefiracetam (nootropic agent) 900 mg, 3 × 150 mg capsule twice/d




• Depression measured using HDRS
• Depression measured using BDI
Secondary outcomes
• Apathy measured using Apathy Scale
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: based on the study author's responses, sequence generation was
attained with computer-generated numbers
Allocation concealment
(selection bias)
Low risk Quote: "nefiracetam or placebo was administered double-blind in three iden-





Low risk Comment: study author states that this study was double-blinded but does
not state who was blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: study author states that this study was double-blinded but does




High risk Quote: "...missing data points were estimated using LOCF..." (p. 146)
"attrition related bias cannot be ruled out" (p. 149)
Comment: the number of dropouts reported and the number analysed are in-
consistent within and between publications
Selective reporting (re-
porting bias)
High risk Comment: study author reports that a number of measures were assessed but
does not provide details of these measures in the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: nefiracetam (nootropic agent)
Control arm: matched placebo
Participants Geographical location: USA
Setting: unclear
Stroke criteria: ischaemic and primary intracerebral haemorrhage
Method of stroke diagnosis: unclear
Time since stroke: 10 days to 3 months
Inclusion criteria: not reported
Exclusion criteria: (1) other psychiatric or neurological disease (e.g. Alzheimer’s disease, Parkinson’s
disease); (2) depression or suicidal plans requiring psychiatric hospitalisation; (3) on psychotropic med-
ication (excluding benzodiazepines or insomnia medication); (4) comprehension deficit precluding ver-
bal interview; (5) life-threatening illness; (6) previous subarachnoid haemorrhage
Depression criteria: psychiatric interview to confirm DSM-IV diagnosis of "depression due to stroke
with major depressive-like episode" plus HDRS score ≥ 18
Total number randomised in this trial: 83
Robinson 2008b 
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Number included in treatment group: 55 (40% men; mean age 64.7, SD 11.9)
Number included in control group: 28** (54% men; mean age 66.8, SD 13.0)
Total number included in final analysis: 72
Number included in treatment group for final analysis: 47
Number included in control group for final analysis: 25**
Interventions Treatment: nefiracetam 600 mg, 3 × 150 mg capsule twice/d




• Depression measured using HDRS
• Depression measured using BDI
Secondary outcomes
• Apathy measured using Apathy Scale




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: based on the study author's responses, sequence generation was
attained with computer-generated numbers
Allocation concealment
(selection bias)
Low risk Quote: "nefiracetam or placebo was administered double-blind in three iden-





Low risk Comment: study author states that this study was double-blinded but does
not state who was blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: study author states that this study was double-blinded but does




High risk Quote: "...missing data points were estimated using LOCF..." (p. 146)
"attrition related bias cannot be ruled out" (p. 149)
Comment: the number of dropouts reported and the number analysed are in-
consistent within and between publications
Selective reporting (re-
porting bias)
High risk Comment: study author reports that a number of measures were assessed but
does not provide details of these measures in the publication
Other bias Unclear risk Comment: baseline demographic information was not reported
Robinson 2008b  (Continued)
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + Deanxit (flupentixol and melitracen)
Control arm: Deanxit (flupentixol and melitracen)
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Time since stroke: 8 days
Inclusion criteria: (1) meeting diagnostic criteria of the CCMD-3 for depression; (2) clear conscious-
ness, no obvious aphasia or comprehension impairment; (3) no severe cardiac disease history; (4) first
stroke or previous stroke without sequelae; (5) internal carotid system cerebral infarct, no epilepsy or
head injury history, can sign informed consent
Exclusion criteria: (1) cerebral haemorrhage, progressive stroke, intracranial infection, intracranial tu-
mour, seizure attack or consciousness disturbance, severe cardiac event (heart function class ≥ 3), pul-
monary (respiratory failure) and renal (uremia) impairment, mental implant in the body (e.g. pacemak-
er, metal stent), pregnancy or children
Depression criteria: meeting diagnostic criteria of the CCMD-3 for depression
Total number randomised in this trial: 100
Number randomised to treatment group: 50 (78% men, mean age 64.6, SD 11.4)
Number randomised to control group: 50 (68% men, mean age 66.5, SD 11.1)
Total number included in final analysis: 100
Number included in treatment group for final analysis: 50
Number included in control group for final analysis: 50
Interventions Treatment: rTMS + Deanxit (flupentixol and melitracen), 10.5 mg/d in the morning, starting on day 8
after stroke onset. Frequency: 1 Hz, intensity: 90% motor threshold, 30 stimulations for 1 series, 1 series
a day, location: bilateral pre-frontal area, starting on day 8 after stroke onset




• Depression measured using HDRS
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: behavioural psychotherapy
Control arm: usual care
Participants Geographical location: UK
Setting: mixed
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Time since stroke: 8.85 days
Inclusion criteria: (1) presence of aphasia confirmed by a speech and language therapist (hospital or
community participants) or using the Sheffield Screening Test for Acquired Language Disorders (volun-
tary sector participants)
Exclusion criteria: (1) receiving treatment for depression pre-stroke (at the time of stroke), (2) with de-
mentia, (3) blind or deaf; (4) unable to speak English before stroke
Depression criteria: using the 'sad' item of the VAMS and the 10-item hospital version of the SAD-Q,
completed by a nurse, relative, or carer. Those identified as having low mood on the 'sad' item of the
VAMS (cut-oN > 50) or the SAD-Q (cut-oN > 6)
Total number randomised in this trial: 105
Number randomised to treatment group: 51 (57% men, mean age 68.5 years, SD 13.1)
Thomas 2007 
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Number randomised to control group: 54 (69% men, mean age 65.5 years, SD 13.9)
Total number included in final analysis: 89
Number included in treatment group for final analysis: 43
Number included in control group for final analysis: 46
Interventions Treatment 1: behavioural psychotherapy up to 20 sessions of treatment over 3 months, with each ses-
sion lasting approximately 1 hour. The manual had been developed from studies of cognitive-behav-
ioural therapy for depression after stroke and with older adults, and from guidelines on conducting
cognitive-behavioural therapy with people with aphasia. The intensity of therapy was le( to the discre-
tion of the assistant psychologist. The intervention was tailored to the individual's needs, and commu-
nication resources such as pictures, photographs, and letter charts were used
Administered by: assistant psychologist
Supervision: therapy was delivered by an assistant psychologist supervised weekly by a clinical psy-
chologist. All assistant psychologists attended a joint monthly supervision meeting with a consultant
clinical neuropsychologist. Assistant psychologists received training in supported communication from
speech and language therapists and were provided with a therapy manual
Intervention fidelity: delivery of therapy was monitored by observation of therapy sessions by the
chief investigator. The content of therapy was documented using record forms completed by the assis-





• Depression measured using the 21-item hospital version of the SAD-Q – an observational measure of
mood completed by a relative or primary carer
• Depression measured using the 'sad' item of VAMS
Secondary outcomes
• Self-esteem measured using Visual Analogue Self-Esteem Scale
• Activities of daily measured using Nottingham Leisure Questionnaire
• Caregiver strain measured using CSI
• Patient and carer satisfaction with care measured using 100-mm VAS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "participants were randomly allocated to one of two groups…..using a
computer generated pseudo-random list…" (p. 400)
Allocation concealment
(selection bias)
Low risk Quote: "the assistant psychologist providing treatment accessed the alloca-






High risk Comment: due to the nature of the trial, not possible to mask participants,
personnel, and researchers to treatment allocation
Thomas 2007  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: primary endpoint self-assessed by relative or carer who was aware





High risk Quote: "outcomes were analysed by intention to treat" (p. 401)
"...missing data using the last observation carried forward on the assumption
of no change…" (p. 402)
Comment: only per protocol analysis reported
Selective reporting (re-
porting bias)
High risk Comment: one secondary outcome measure (Extended Activities of Daily Liv-
ing Scale) not reported in the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: pragmatic approach (counselling)
Control arm: custom-designed information booklet
Participants Geographical location: UK
Setting: outpatients
Stroke criteria: all subtypes
Method of stroke diagnosis: diagnosis via clinical signs
Time since stroke: 6 to 7 months
Inclusion criteria: (1) able to complete questionnaires unaided
Exclusion criteria: (1) stroke < 1 year before randomisation; (2) residence in hospital or residential care
Depression criteria: WDI score > 17 or GHQ-28 score > 9
Total number randomised in this trial: 44
Number randomised to treatment group: 21 (43% men, mean age 70 years, SD 9)
Number randomised to control group: 23 (30% men, mean age 69 years, SD 7)
Total number included in final analysis: 43
Number included in treatment group for final analysis: 21
Number included in control group for final analysis: 22
Interventions Treatment: pragmatic approach dealing with problems identified by social worker and patients; in-
cluded counselling the patient and caregiver, giving opportunity to reflect upon their situation and ex-
press their feelings (duration: 2 to 11 visits over 16 weeks, mean visits 6.8 ± 2.8; however, length and
content of visits varied)
Administered by: not reported
Supervision: not reported
Towle 1989 
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Intervention fidelity: unclear; no report of formal evaluation of the quality or content of therapy pro-
vided
Control: custom-designed information booklet (covered areas believed to be of use and interest to
stroke survivors and their families, such as details on housing and financial benefits; aids to daily living;
addresses of stroke clubs and self-help groups; telephone number of local social services department),
1 visit, no ongoing visits




• Depression (change in scores from baseline to end of treatment) measured using WDI and GHQ-28
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the order of the envelopes had been decided before the study using
random number tables" (p. 520)
Allocation concealment
(selection bias)
High risk Quote: "the patients were then allocated randomly to one of two groups using
sealed envelopes each containing a slip of paper stating either "treatment" or





High risk Quote: "the patients were then allocated randomly to one of two groups using
sealed envelopes each containing a slip of paper stating either "treatment" or
"no treatment"" (p. 520)
Comment: due to the nature of the trial, it was not possible to mask partici-
pants or social worker to treatment allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "each patient was visited 8 weeks and 16 weeks later by the indepen-
dent assessor who repeated the pre-intervention questionnaires"









Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: psychological therapy
Wang 2004a 
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Control arm: usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by the
Fourth National Symposium on Cerebrovascular Disease in 1995 and confirmation by brain CT
Time since stroke: not reported
Inclusion criteria: (1) first-ever stroke
Exclusion criteria: (1) history of psychiatric illness; (2) previous neurological disease or uncooperative
with examination
Depression criteria: psychiatric interview to confirm diagnosis meets depression diagnostic criteria of
the CCMD-2-R
Total number randomised in this trial: 70
Number randomised to treatment group: 35 (57% men; mean age 56, SD 8)
Number randomised to control group: 35 (54% men; mean age 56, SD 7)
Total number included in final analysis: 70
Number included in treatment group for final analysis: 35
Number included in control group for final analysis: 35
Interventions Treatment: psychological therapy 1 hour twice/week administered by a psychiatrist. Psychological
therapy entailed psychological support and explanation, relaxing training, and music therapy
Administered by: not reported
Supervision: not reported





• Depression measured using ZDS
• Cognition measured by P300
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Comment: method of allocation concealment not reported
Wang 2004a  (Continued)
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Unclear risk Comment: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: China
Setting: inpatient
Stroke criteria: all stroke
Method of stroke diagnosis: diagnosis consistent with Diagnostic Criteria for Cerebrovascular Disease
formulated by the Fourth National Conference of Chinese Medical Association in 1995
Inclusion criteria: not reported
Exclusion criteria: (1) history of psychiatric illness; (2) dementia; (3) aphasia; (4) disturbance of con-
sciousness
Depression criteria: HDRS scores > 17
Total number randomised in this trial: 108
Number randomised to treatment group: 54 (57% men, mean age 58.9 years for total sample)
Number randomised to control group: 54 (57% men, mean age 58.9 years for total sample)
Total number included in final analysis: 108
Number included in treatment group for final analysis: 54
Number included in control group for final analysis: 54
Interventions Treatment: fluoxetine (SSRI) 20 to 40 mg/d. If reduction in HDRS scores ≤ 5 points after 2 weeks of
treatment, increase dosage to 40 mg/d
Wang 2005 
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• Depression measured using HDRS (remission: no depression symptoms and HDRS < 7; improved de-
pression symptoms: reduction of HDRS scores by ≥ 5; ineffective: severely depressed mood and re-
duction in HDRS scores < 4)
Secondry outcomes
• Neurological Impairment measured using CSS
• Leaving the trial early
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: single-blind reported but who was blinded not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: ITT (last observation carried forward) for dichotomous endpoints;
unclear for continuous endpoints
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: combined psychotherapy + paroxetine (SSRI)
Control arm: paroxetine (SSRI)
Participants Geographical location: China
Wang 2005a 
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Setting: inpatient
Stroke criteria: ischaemic and haemorrhagic stroke; haemorrhagic subtypes not specified
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for cerebrovascular disease
formulated by the National Symposium on Cerebrovascular Disease of Chinese Medical Association in
1995 and confirmation by brain CT or MRI
Time since stroke: 21.85 days
Inclusion criteria: (1) first-ever stroke
Exclusion criteria: (1) history of psychiatric illness, depressive phase of bipolar disorders; (2) antide-
pressants and antipsychotics in the previous 3 months; (3) severe cognitive impairment, aphasia; (4)
severe cardiac impairment, hepatic or renal impairment; (5) coma; (6) too severe clinical condition to
receive interview; (7) allergy to paroxetine
Depression criteria: meeting both organic depression and organic anxiety diagnostic criteria of the
CCMD-3
Total number randomised in this trial: 54
Number included in treatment group: 27 (52% men; mean age 64.0, SD 5.3)
Number included in control group: 27 (52% men; mean age 62.4, SD 6.1)
Total number included in final analysis: 54
Number included in treatment group for final analysis: 27
Number included in control group for final analysis: 27
Interventions Treatment: combined psychotherapy, 1 session/week variable length 30 to 60 minutes administered
by a psychotherapist + SSRI (paroxetine) 20 mg/d in the morning. Psychotherapy was described as hav-
ing a supportive focus
Administered by: not reported
Supervision: not reported
Intervention fidelity: not reported




• Depression measured using HDRS
Secondary outcomes
• Anxiety measured using HARS
• Disability measured using BI
• Impairment measure using SSS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Wang 2005a  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: 2/54 treatment and 0/54 control dropped out. ITT for categorical
outcome variable: clinical efficacy of participants with missing data regarded




Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: motivational interviewing
Control arm: usual care
Participants Geographical location: UK
Setting: inpatient
Stroke criteria: all subtypes
Method of stroke diagnosis: diagnosis via clinical signs and CT (100%)
Time since stroke: 5 to 28 days
Inclusion criteria: (1) over 18 years of age
Exclusion criteria: (1) severe cognitive and communication problems; (2) moving out of the area after
discharge; (3) already receiving psychiatric or clinical psychology intervention
Depression criteria: GHQ score > 4
Total number randomised in this trial: 254
Number randomised to treatment group: 127 (52% men, mean age 68 years, SD 12)
Number randomised to control group: 127 (53% men, mean age 68 years, SD 12)
Total number included in final analysis: 254
Number included in treatment group for final analysis: 127
Watkins 2007 
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Number included in control group for final analysis: 127
Interventions Treatment: motivational interviewing, up to 4 sessions, 1 per week, with same therapist
Administered by: therapists
Supervision: therapists received 4 days of training in motivational interviewing by a specialist followed
by up to 10 practice sessions until competent and confident of the technique. Therapists were super-
vised by a clinical psychologist through team meetings and 1-to-1 clinical supervision sessions on a
monthly basis with additional informal support throughout the study
Intervention fidelity: therapy sessions were audio recorded. The quality of the application of moti-
vational interviewing was assessed by analysing a purposive sample of 60 sessions from different pa-
tients. A clinical psychologist reviewed the content of 20 therapist utterances around the midpoint of
each session using a structured evaluation tool, "Motivational Interviewing Skill Code (version 2)". Ut-
terances rated motivational interviewing-consistent included open questions, reflections, advise with
permission, affirm, emphasise control, reflect, re-frame, and support. Utterances rated motivational
interviewing-inconsistent included advise without permission, confront, direct, raise concern without
permission, and warn. The percentage of motivational interviewing-consistent utterances was deter-
mined (total MI-consistent/(total MI-consistent plus MI-inconsistent)). Unclear if or how this informa-
tion was fed back to therapists
Control: usual care




• Depression (proportion no longer meeting study criteria for depression, change in scores from base-
line to end of treatment) measured using GHQ-28
• Disability measured using BI
• Stroke Impairment measured using Stroke Expectations Questionnaire
Notes Additional unpublished data provided by study authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a research nurse randomized patients (1:1 ratio) to either usual care
(control) or MI (intervention) using minimization over sex, age (65 and 65
years), baseline function in activities of daily living (ADL; Barthel: 18 to 20; 11 to
17; 0 to 10), and location (acute stroke unit)"
Allocation concealment
(selection bias)
High risk Quote: "the same nurse then assigned intervention group patients to 1 of 4






High risk Quote: "the same nurse then assigned intervention group patients to 1 of 4
therapists using an opaque sealed envelope in a pseudorandomized blocked
design" (p. 1957)
Comment: due to the nature of the intervention, it was not possible to mask
participants, nurses, and researchers to treatment allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "surviving patients were sent a questionnaire. Patients not returning
questionnaires within 2 weeks were telephoned by a second research nurse,
blind to group allocation, and given the option of declining, having a further
Watkins 2007  (Continued)
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews
questionnaire posted, completing the questionnaire over the telephone, or re-




Low risk Quote: "where data were missing, imputations were performed as described
previously" (p. 1958)
Comment: ITT analysis reported
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported. No trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: France
Setting: not reported
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage
Method of stroke diagnosis: diagnosis via clinical signs and CT (100%)
Time since stroke: 48 days
Inclusion criteria: (1) all antidepressant or neuroleptic drugs stopped 10 days before enrolment
Exclusion criteria: (1) severe psychiatric problems that required hospitalisation; (2) severe cognitive
impairment; (3) chronic alcoholism; (4) chronic associated handicapping pathology; (5) contraindica-
tion to fluoxetine
Depression criteria: psychiatric interview (ICD-10 criteria) and MADRS score > 19
Total number randomised in this trial: 31
Number randomised to treatment group: 16 (56% men, mean age 66 years, SD 7)
Number randomised to control group: 15 (40% men, mean age 69 years, SD 12)
Total number included in final analysis: 31
Number included in treatment group for final analysis: 16
Number included in control group for final analysis: 15
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• Depression (change in scores from baseline to end of treatment, 50% reduction in score) measured
using MADRS
Secondary outcomes
• Functional capacity measured using FIM
• Cognitive function measured using MMSE
• Motor function measured using Motoricity Index





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)
Low risk Quote: "treatment lasted up to 45 days (end point) and was given in the form
of identical white capsules containing 20 mg of either fluoxetine or placebo,
delivered in boxes coded by the central pharmacy of the University Hospital





Low risk Quote: "treatment lasted up to 45 days (end point) and was given in the form
of identical white capsules containing 20 mg of either fluoxetine or placebo,
delivered in boxes coded by the central pharmacy of the University Hospital
complex of Bordeaux" (p. 1829)
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Quote: "an intent-to-treat statistical analysis was conducted in which the last
visit recorded was used as an end point" (p. 1830)




Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: paroxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: China
Yang 2002 
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Setting: outpatient
Stroke criteria: ischaemic and haemorrhagic stroke
Method of stroke diagnosis: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: HDRS score > 7
Total number randomised in this trial: 121
Number included in treatment group: 64 (63% men, mean age 64 years, SD 3)
Number included in control group: 57 (56% men, mean age 63 years, SD 5)
Total number included in final analysis: 110
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear





• Depression (50% reduction in scores from baseline to end of treatment) measured using HDRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
Yang 2002  (Continued)
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: high-frequency rTMS + antidepressants
Control arm: sham rTMS + antidepressants
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: confirmed brain CT or MRI
Inclusion criteria: (1) 24-item HDRS score ≥ 8; (2) first stroke; (3) right-handedness; (4) clear conscious-
ness; (5) able to express personal will
Exclusion criteria: (1) history of epilepsy, metal implant in the body; (2) history or family history of psy-
chiatric illness
Depression criteria: 24-item HDRS score ≥ 8
Total number randomised in this trial: 38
Number randomised to treatment group: 19 (63% men; mean age 61, SD 8)
Number randomised to control group: 19 (52.6% men; mean age 60, SD 9)
Total number included in final analysis: 38
Number included in treatment group for final analysis: 19
Number included in control group for final analysis: 19
Interventions Treatment: high-frequency rTMS + antidepressants. Frequency: 10 Hz, intensity: 80% motor threshold,
1 stimulation lasts 4.9 seconds and stops for 20 seconds, total impulse number: 1960/d, 16 minutes per
day, for 10 working days, location: le( DLPFC




• Depression measured using HDRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Comment: method of allocation concealment not reported
Yang 2013 
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)














Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: high-frequency rTMS
Control arm: sham rTMS
Participants Geographical location: China
Setting: mixed
Stroke criteria: not reported
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) meeting diagnostic criteria of the CCMD-3 for depression; (2) 24-item HDRS score
≥ 8; (3) first stroke; (4) clear consciousness; (5) able to express personal will and to sign informed con-
sent
Exclusion criteria: (1) history or family history of psychiatric illness; (2) unable to co-operate with the
examination due to obvious aphasia or severe cognitive dysfunction; (3) history of epilepsy, metal im-
plant in the body
Depression criteria: meeting diagnostic criteria of the CCMD-3 for depression and 24-item HDRS score
≥ 8
Total number randomised in this trial: 56
Number randomised to treatment group: 37 (75.6% men; mean age 56.6, SD 13.6)
Number randomised to control group: 19** (73% men; mean age 53.3, SD 14.6)
Total number included in final analysis: 55
Number included in treatment group for final analysis: 37
Number included in control group for final analysis: 19**
Yang 2014a 
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Interventions Treatment: high-frequency rTMS. Frequency: 10 Hz, intensity: 90% motor threshold, 1 stimulation lasts
5 seconds and stops for 35 seconds, total impulse number: 1500, location: le( DLPFC
Control: sham rTMS. With coils kept at 90-degree angles with the scalp and with coils contacting the




• Depression measured using HDRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: low-frequency rTMS
Control arm: sham rTMS
Participants Geographical location: China
Setting: mixed
Yang 2014b 
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Stroke criteria: not reported
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) meeting diagnostic criteria of the CCMD-3 for depression; (2) 24-item HDRS score
≥ 8; (3) first stroke; (4) clear consciousness; (5) able to express personal will and to sign informed con-
sent
Exclusion criteria: (1) history or family history of psychiatric illness; (2) unable to co-operate with the
examination due to obvious aphasia or severe cognitive dysfunction; (3) history of epilepsy, metal im-
plant in the body
Depression criteria: meeting diagnostic criteria of the CCMD-3 for depression and 24-item HDRS score
≥ 8
Total number randomised in this trial: 55
Number randomised to treatment group: 37 (81% men; mean age 52.3, SD 11)
Number randomised to control group: 18** (73% men; mean age 53.3, SD 14.6)
Total number included in final analysis: 55
Number included in treatment group for final analysis: 37
Number included in control group for final analysis: 18**
Interventions Treatment: low-frequency rTMS. Frequency: 1 Hz, intensity: 90% motor threshold, 1 stimulation lasts
10 seconds and stops for 2 seconds, total impulse number: 1000, location: le( DLPFC
Control: sham rTMS. With coils kept at 90-degree angles with the scalp and with coils contacting the




• Depression measured using HDRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: information about blinding of outcome assessors not reported
Yang 2014b  (Continued)
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Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + fluoxetine + stroke medications
Control arm: fluoxetine + stroke medications
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic and haemorrhagic stroke
Method of stroke diagnosis: complying with diagnostic criteria for cerebral infarction and cerebral
haemorrhage formulated by the Fourth National Conference on Cerebrovascular Diseases
Inclusion criteria: (1) meeting diagnostic criteria of the CCMD-3 for depression; (2) 17-item HDRS score
≥ 17; (3) no history of psychiatric illness and history of drug abuse or alcohol; (4) not taking any an-
tipsychotic drugs 2 weeks before enrolment; (5) relatively stable clinical condition, able to clearly ex-
press feelings, no communication obstacle; (6) age 40 to 70 years, Han ethnic group, co-operative dur-
ing treatment, able to complete all exams and to sign informed consent, educational level: junior high
school or above
Exclusion criteria: not reported
Depression criteria: meeting diagnostic criteria of the CCMD-3 for depression and 17-item HDRS score
≥ 17
Total number randomised in this trial: 82
Number randomised to treatment group: 41 (56% men; mean age 56.9, SD 5.8)
Number randomised to control group: 41 (53.6% men; mean age 57.7, SD 6.6)
Total number included in final analysis: 82
Number included in treatment group for final analysis: 41
Number included in control group for final analysis: 41
Interventions Treatment: rTMS + fluoxetine (20 mg/d) + stroke medications. Frequency: 10 Hz, intensity: 90% motor
threshold, 1 stimulation lasts 4 seconds in 1 series, 20 series a day, 3 times a week, location: le( DLPFC
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Outcomes Primary outcome
• Depression measured using HDRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: random number table used for sequence generation
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication




Methods Study design: parallel design
Number of arms: 2
Experimental arm: psychoeducation
Control arm: usual care
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: diagnosis via CT or MRI (100%)
Time since stroke: not reported
Inclusion criteria: (1) cognitively competent; (2) no acute medical problems
Exclusion criteria: (1) serious mental problems; (2) low intelligence; (3) other serious neurological con-
dition; (4) heart failure; (5) other acute disease
Zhao 2004 
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Depression criteria: HDRS score > 17
Total number randomised in this trial: 70
Number randomised to treatment group: 35 (57% men, mean age 65 years, SD 13)
Number randomised to control group: 35 (51% men, mean age 61 years, SD 14)
Total number included in final analysis: 70
Number included in treatment group for final analysis: 35
Number included in control group for final analysis: 35
Interventions Treatment: psychoeducation, daily, less than 30 minutes
Administered by: special personnel who received 2 weeks training before the trial started
Supervision: not reported





• Depression (reduction in scores from baseline to end of treatment) measured using HDRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





High risk Comment: single-blind reported; participants not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
Other bias Low risk Comment: no differences in baseline demographic characteristics between
groups
Zhao 2004  (Continued)
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: intra-low frequency (ILF)-TMS + cerebrovascular disease routine care + early reha-
bilitation
Control arm: cerebrovascular disease routine care + early rehabilitation
Participants Geographical location: China
Setting: inpatient
Number of participants: 82
Stroke criteria: ischaemic and haemorrhagic stroke
Method of stroke diagnosis: complying with diagnostic criteria for cerebral infarction and cerebral
haemorrhage formulated by the Fourth National Conference on Cerebrovascular Diseases
Inclusion criteria: (1) meeting diagnostic criteria of the CCMD-3 for depression; (2) stable vital signs,
ability to understand and perform rehabilitation
Exclusion criteria: (1) history of psychiatric illness; (2) dementia; (3) severe physical illness; (4) history
of epilepsy
Depression criteria: meeting diagnostic criteria of the CCMD-3 for depression
Total number randomised in this trial: 82
Number randomised to treatment group: 41 (56% men; mean age 63.8, SD 8.5)
Number randomised to control group: 41 (60% men; mean age 64.3, SD 6.9)
Total number included in final analysis: 82
Number included in treatment group for final analysis: 41
Number included in control group for final analysis: 42
Interventions Treatment: intra-low frequency (ILF)-TMS + cerebrovascular disease routine care + early rehabilitation.
Frequency: < 0.2 Hz, 20 minutes per treatment, and 1 treatment per day, at least 5 times a week, lasting
for 2 successive courses




• Depression measured using HDRS
• Impairment measured using SSS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Zheng 2016 
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Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comment: information about blinding of participants and personnel not re-
ported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: ITT analysis reported; no missing data
Selective reporting (re-
porting bias)
Unclear risk Comment: all pre-specified outcomes reported; no trial protocol available to
compare with the publication
Other bias Low risk Comment: no differences in baseline demographics between groups
Zheng 2016  (Continued)
** Results for control group halved.
^ Results for attention control and control group pooled.
ABI: acquired brain injury.
ADL: activities of daily living.
AE: adverse event.
AHI: Authentic Happiness Inventory.




CCMD-2-R: Chinese Classification of Mental Disorders, Second Edition, Revised.
CCMD-3: Chinese Classification of Mental Disorders, Third Edition.
CGI: Clinical Global Impression Scale.
CIPI: constructive integrative psychosocial intervention.
CNS: central nervous system.
CSI: Caregiver Strain Index.
CSS: Chinese Stroke Scale.
CT: computed tomography.
DASS-21: Depression Anxiety Stress Scales - 21 items.
DLPFC: dorsolateral pre-frontal cortex.
DSM: Diagnostic and Statistical Manual.
EADL: extended activities of daily living.
EFT: ecosystem focused therapy.
ESD: Education on Stroke and Depression.
FAC: Functional Ambulatory Category.
FIM: Functional Independence Measure.
GCS: Glasgow Coma Scale.
GDS: Geriatric Depression Scale.
GHQ-28: 28-item General Health Questionnaire.
HADS: Hospital Anxiety Depression Scale.
HARS: Hamilton Anxiety Rating Scale.
HDRS-24: 24-item Hamilton Depression Rating Scale.
HDRS-17: 17-item Hamilton Depression Rating Scale.
HRQoL: health-related quality of life.
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Hz: Hertz.
ICD: International Classification of Diseases.
ILF: intra-low frequency.
ITT: intention to treat.
LTF: loss to follow-up.
LOCF: last observation carried forward.
MADRS: Montgomery Asberg Depression Rating Scale.
MBC: Modified Brunnstrom Classification.
MBI: Modified Barthel Index.
MI: motivational interviewing.
MMSE: Mini Mental State Examination.
MPAI-4: Mayo-Portland Adaptability Inventory-4.
MRI: magnetic resonance imaging.
NIHSS: National Institute of Health Stroke Scale.
NRI: norepinephrine reuptake inhibitor.
P300: the P300 is a wave that represents a positive deflection in the human event-related potential. It is most commonly elicited when a
patient detects an occasional "target" stimulus in a regular train of standard stimuli.
PHQ-9: 9-item Patient Health Questionnaire.
PSE: Present State Examination.
QoL: quality of life.
rTMS: repetitive transcranial magnetic stimulation.
SAD-Q: Stroke Aphasia Depression Questionnaire.
SAH: subarachnoid haemorrhage.
SAQoL: Stroke Aphasia Quality of Life Scale.
SCAN: Schedules for Clinical Assessment in Neuropsychiatry.
SD: standard deviation.
SDS: Severity of Dependence Scale.
SE: standard error.
SNRI: selective norepinephrine reuptake inhibitor.
SSRI: selective serotonin reuptake inhibitor.
SSS: Scandinavian Stroke Scale.
TCA: tricyclic antidepressant.
TMS: transcranial magnetic stimulation.
VAMS: Visual Analogue Mood Scale.
VAS: visual analogue scale (100 mm).
WDI: Wakefield Depression Inventory.
WHO: World Health Organization.
WHODAS- II: World Health Organization Disability Assessment Schedule.
ZDS: Zung Depression Scale.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aben 2014 Depression not the primary outcome of this study
Agnoli 1985 Inability to isolate stroke patients
Bai 2017 Depression not the primary outcome of this study
Bramanti 1989 Data not available for depressed participants only
Casella 1960 Depression not the primary outcome of this study
Chang 2011 Data not available for depressed participants only
Cheng 2016 Depression not the primary outcome of this study
Choi-Kwon 2006 Data not available for depressed participants only
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Study Reason for exclusion
Chollet 2011 Depression not the primary outcome of this study
Clark 2003 Data not available for depressed participants only
Delbari 2011 Data not available for depressed participants only
Downes 1995 Data not available for depressed participants only
Evans 1997 Participants were acute geriatric medical inpatients with depression. We were unable to isolate any
chronic stroke patients. No acute stroke patients were included in the sample
Finkenzeller 2006 Depression assessments not available at a consistent time point
Hadidi 2014 Data not available for depressed participants only
Hu 2003 Depression not the primary outcome of this study
ISRCTN88489864 Depression not the primary outcome of this study
Jiang 2004 Depression not the primary outcome of this study
Jorge 2004 Data not available for depressed participants only
Jorge 2008 Data not available for depressed participants only
Kim 2010a Data not available for depressed participants only
Kim 2010b Data not available for depressed participants only
Kim 2017 Data not available for depressed participants only
Kim 2017a Data not available for depressed participants only
Kootker 2012 Data not available in the format suitable for this review
Laska 2005 Depression not an outcome of this study
Leijon 1989 Depression not an outcome of this study
Lobjanidze 2010 Depression not the primary outcome of this study
Mauri 1988 Data not available in a format suitable for this review
Meara 1998 Data not available for depressed participants only
Narushima 2007 Depression not the primary outcome of this study
Ohtomo 1985 Data not available for depressed participants only
Ostwald 2014 Data not available for depressed participants only
Otomo 1986 Participants not depressed at entry into the study
Raffaele 1996 Data not available for depressed participants only
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Study Reason for exclusion
Rich 2016 Depression not the primary outcome of this study
Robinson 2000 Data not available for depressed participants only
Robinson 2017 Depression not the primary outcome of this study
Rudberg 2017 Depression not the primary outcome of this study
Sieger 2018 Depression not the primary outcome of this study
Sivenius 2001 Depression not the primary outcome of this study
Su 2004a Depression not the primary outcome of this study
Sun 2000 Data not available for depressed participants only
Szepfalusi 2017 Depression not the primary outcome of this study
Valiengo 2017 Data not available for depressed participants only
Visser 2015 Depression not the primary outcome of this study
Walker-Batson 1995 Depression not the primary outcome of this study
Wang 2009 Depression not the primary outcome of this study
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Study design: parallel design
Number of arms: 2
Experimental arm: paroxetine (SSRI)
Control arm: placebo
Participants Geographical location: China
Setting: unclear
Number of participants: 36
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Inclusion criteria: not reported
Exclusion criteria: (1) cognitive impairment (MMSE < 24); (2) depression deterioration (HDRS > 24);
(3) suicidal mood; (4) drug intolerability
Depression criteria: unclear
Total number randomised in this trial: 36
Number randomised to treatment group: 24
Number randomised to control group: 12**
Chen 2002a 
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Total number included in final analysis: 34
Number included in treatment group for final analysis: 24
Number included in control group for final analysis: 10**
Interventions Treatment: paroxetine (SSRI) 200 mg once daily




• Depression measured using HDRS
Secondary outcomes
• Disability measured using BI
• Impairment measured using CSS




Methods Study design: parallel design
Number of arms: 2
Experimental arm: doxepin
Control arm: placebo
Participants Geographical location: China
Setting: unclear
Number of participants: 36
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Inclusion criteria: not reported
Exclusion criteria: (1) cognitive impairment (MMSE < 24); (2) depression deterioration (HDRS > 24);
(3) suicidal mood; (4) drug intolerability
Depression criteria: unclear
Total numbers randomised in this trial: 36
Numbers randomised to treatment group: 24
Numbers randomised to control group: 12**
Total numbers included in final analysis: 26
Numbers included in treatment group for final analysis: 16
Numbers included in control group for final analysis: 10**
Interventions Treatment: doxepin 25 mg 3 × daily
Chen 2002b 
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• Depression measured using HDRS
Secondary outcomes
• Disability measured using BI
• Impairment measured using CSS




Methods Study design: parallel design
Number of arms: 2
Treatment arm: paroxetine (SSRI) + psychotherapy + education
Control arm: paroxetine (SSRI)
Participants Geographical location: China
Setting: outpatient
Stroke criteria: ischaemic and haemorrhagic stroke
Method of stroke diagnosis: clinical diagnosis with imaging consistent with stroke using Oxford
Community Stroke Project classification and structural brain CT classification (by anatomical loca-
tion)
Time since stroke: 2 to 6 months
Inclusion criteria: (1) meeting depression diagnostic criteria of the CCMD-3 and 17-item HDRS
score > 17)
Exclusion criteria: (1) bipolar disorders; (2) drug dependence or abuse
Depression criteria: psychiatric interview; meeting depression diagnostic criteria of the CCMD-3;
17-item HDRS score > 17; HARS score > 7; clinical impression
Total number randomised in this trial: 68
Number randomised to treatment group: 34 (56% men; mean age 61.3 years, SD 9.3)
Number randomised to control group: 34 (47% men; mean age 60.5 years, SD 10.4)
Total number included in final analysis: 68
Number included in treatment group for final analysis: 34 (56% men; mean age 61.3 years, SD
9.3)
Number included in control group for final analysis: 34 (47% men; mean age 60.5 years, SD 10.4)
Interventions Treatment: combination of paroxetine (SSRI, variable dose, started from 10 mg/d, titrated up to 20
to 30 mg/d) + psychotherapy: combination of cognitive therapy targeted at beliefs about stroke de-
Ding 2005 
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pression; behavioural therapy targeted at attitudes in practice and education. Psychotherapy was
delivered in 40 to 60-minute sessions, 2 to 3 sessions a week
Administered by: a professional physician; training in psychotherapy unclear
Supervision of therapists: not reported
Intervention fidelity: not reported




• Depression measured using HDRS
Secondary outcomes
• Anxiety measured using HARS
• Activities of daily living measured using BI
• Symptoms measured using Treatment Emergent Symptom Scale
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: telephone counselling
Control arm: usual care
Participants Geographical location: USA
Setting: outpatient
Stroke criteria: unclear (also includes people with spinal cord injury, CNS disease, and 'other')
Method of stroke diagnosis: not reported
Inclusion criteria: (1) patients discharged from rehabilitation centre; (2) housebound; (3) able to
hear; (4) ordinary speech; (5) sufficient cognitive ability to engage in meaningful conversation
Exclusion criteria: not reported
Depression criteria: score taken from the Life Satisfaction Index (LSI); unclear how scored
Total number randomised in this trial: 38
Number randomised to treatment group: 19 (95% men, mean age 54.8 years, SD 11.9 years); 4
with stroke
Number randomised to control group: 19 (95% men, mean age 54.8 years, SD 10.2 years); 5 with
stroke
Total number included in final analysis: unclear
Evans 1985 
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Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: 8-weekly hour-long counselling sessions by phone with groups of 4 patients. Formula-
tion of behaviorally specific goals encouraged and developed with each patient, and discussion di-
rected at finding ways to meet those goals
Administered by: an experienced counsellor
Supervision: not reported




• Depression - unclear what measure was used





Methods Study design: parallel design
Number of arms: 2
Experimental arm: sertraline (SSRI) + psychological therapy
Control arm: sertraline (SSRI)
Participants Geographical location: Germany
Setting: inpatient
Stroke criteria: all subtypes
Method of stroke diagnosis: unclear
Time since stroke: < 3 months
Inclusion criteria: (1) onset of stroke no longer than 3 months
Exclusion criteria: (1) previous or current psychiatric disorder like substance abuse, borderline
or antisocial personality disorder, or other prominent Axis I disorder; (2) with previous depressive
disorder, only if participants were still treated with antidepressive medication for this matter; (3)
stronger cognitive impairment (e.g. dementia, aphasia, delirium) (no defined criteria or cut-oN)
Depression criteria: HADS > 7 on the subscale Depression, HDRS score > 13
Total number randomised in this trial: 21
Number randomised to treatment group: 9 (39% men, mean age 64.7, SD 11.1)
Number randomised to control group: 12 (50% men, mean age 71.7, SD 7.1)
Total number included in final analysis: 21
Finkenzeller 2009 
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Number included in treatment group for final analysis: 9 (39% men, mean age 64.7, SD 11.1)
Number included in control group for final analysis: 12 (50% men, mean age 71.7, SD 7.1)
Interventions Treatment: sertraline (SSRI) 50 mg/d + psychological therapy (twice a week)
Administered by: not reported
Supervision: not reported
Intervention fidelity: not reported
Control: sertraline (SSRI)
Duration: 4 to 8 weeks
Follow-up: none
Outcomes Primary outcomes
• Depression (response > 50% reduction in initial score) measured using HDRS
• Depression (remission) measured using HDRS (< 8)
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: sertraline (SSRI)
Control arm: placebo
Participants Geographical location: UK
Setting: unclear
Stroke criteria: unclear (also includes people with non-vascular events such as trauma, hypoxia,
or encephalitis)
Method of stroke diagnosis: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: unclear
Total number randomised in this trial: unclear
Number randomised to treatment group: unclear
Number randomised to control group: unclear
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Hanspal 2007 
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• Depression: unclear what measure was used




Methods Study design: parallel design
Number of arms: 2
Treatment arm: amitriptyline (TCA) + psychological intervention + routine drugs for cerebrovascu-
lar disease
Control arm: amitriptyline (TCA) + routine drugs for cerebrovascular disease
Participants Geographical location: China
Setting: unclear
Stroke criteria: cerebral infarction and haemorrhage
Method of stroke diagnosis: stroke diagnosed according to the standards of National Fourth Cere-
bral Vascular Disease Meeting of Chinese Medical Association in 1995
Inclusion criteria: (1) score > 8 in the CCMD-2-R
Exclusion criteria: (1) history of mental disorder; (2) patients with coma, anepia, intelligence dis-
order; (3) patients with severe disease of heart, liver, and lung
Depression criteria: score > 8 in the CCMD-2-R
Total number randomised in this trial: 67
Number randomised to treatment group: 35 (54.3% men, mean 64 years, SD 9)
Number randomised to control group: 32 (percentage of men and mean age not reported for this
group)
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: amitriptyline (TCA + psychological intervention + routine drugs for cerebrovascular
disease). Psychological intervention included (1) treatment of cognitive behaviour; (2) supportive
psychological treatment; (3) education about hypertension, coronary heart disease, and diabetes;
(4) education about psychological hygiene
Administered by: not reported
Supervision: not reported
He 2003 
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Intervention fidelity: not reported




• Depression measured using HDRS
• Activities of daily living (unclear what measure was used)




Methods Study design: parallel design
Number of arms: 2
Experimental arm: paroxetine (SSRI)
Control arm: psychotherapy + paroxetine (SSRI)
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke and cerebral haemorrhage
Method of stroke diagnosis: first-ever stroke with a diagnosis consistent with diagnostic criteria
for cerebral infarct formulated by the Fourth National Conference on Cerebrovascular Disease and
confirmation by brain CT or MRI
Time since stroke: not reported
Inclusion criteria: (1) first-ever stroke; (2) meeting organic depressive disorder/organic anxiety dis-
order diagnostic criteria of ICD-10; (3) 17-item HDRS score ≥ 17; HARS score ≥ 14
Exclusion criteria: (1) history of psychiatric illness; (2) taking antidepressants and neuroleptics in
the previous 3 months; (3) aphasia; (4) severe cognitive impairment; (5) allergy to paroxetine; (6)
suicidal behaviour; (7) in a coma
Depression criteria: meeting organic depressive disorder/organic anxiety disorder diagnostic cri-
teria of ICD-10 and 17-item HDRS score ≥ 17; HARS score ≥ 14
Total number randomised in this trial: 54
Number randomised to treatment group: 27 (52% men; mean age 64, SD 5.3)
Number randomised to control group: 27 (52% men; mean age 62.4, SD 6.1)
Total number included in final analysis: 54
Number included in treatment group for final analysis: 27
Number included in control group for final analysis: 27
Interventions Treatment: combined psychotherapy (early supportive psychotherapy (1 × 30 minutes ses-
sion/week) + paroxetine (SSRI) 20 mg/d
Administered by: not reported
Supervision: not reported
He 2005 
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Intervention fidelity: not reported




• Depression measured using HDRS
• Anxiety measured by HARS
Secondary outcomes
• Symptoms measured using Treatment Emergent Symptom Scale
• Disability measured using BI
• Impairment measured using SSS
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: venlafaxine (SNRI) + cognitive therapy
Control arm: venlafaxine (SNRI)
Participants Geographical location: China
Setting: mixed
Stroke criteria: ischaemic stroke only
Method of stroke diagnosis: first-ever stroke with diagnosis consistent with diagnostic criteria
for cerebral infarct formulated by the Fourth National Conference on Cerebrovascular Disease and
confirmation by brain CT or MRI
Time since stroke: not reported
Inclusion criteria: (1) first-ever stroke; (2) depression developed in the acute stage of cerebral in-
farct; (3) HDRS score ≥ 18
Exclusion criteria: (1) history of psychiatric illness; (2) dementia; (3) aphasia; (4) consciousness
disturbance; (5) apraxia; (6) other organic disease; (7) systematic disease; (8) depression developed
in the acute stage of cerebral infarct
Depression criteria: HDRS score ≥ 18; depression developed in the acute stage of cerebral infarct
Total number randomised in this trial: 82
Number randomised to treatment group: 41 (% men not reported, mean age 62.2 years, SD 8.3)
Number randomised to control group: 41 (% men not reported, mean age 61.8 years, SD 8.7)
Total number included in final analysis: 80
Number included in treatment group for final analysis: 40 (63% men, mean age not reported)
Number included in control group for final analysis: 40 (61% men, mean age not reported)
Huang 2005 
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Interventions Treatment: venlafaxine (SNRI) 121.56 mg/d + combined cognitive therapy (more than 1 hour every
session, 1 session/week initially, 1 session fortnightly 1 month later, and 1 to 2 sessions/month 2
months later)
Administered by: not reported
Supervision: not reported
Intervention fidelity: not reported




• Depression measured using HDRS
Secondary outcomes
• Symptoms measured using Treatment Emergent Symptom Scale
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: unclear
Number of arms: 4
Experimental arm 1: group psychotherapy
Experimental arm 2: behavioral therapy
Experimental arm 3: combined antidepressant and individual psychotherapy plus group psy-
chotherapy
Control arm: unclear
Participants Geographical location: unclear
Setting: unclear
Stroke criteria: unclear
Method of stroke diagnosis: unclear
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: unclear
Total number randomised in this trial: unclear
Number randomised to treatment group: unclear
Number randomised to control group: unclear
Katz 1998 
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Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment 1: group psychotherapy
Treatment 2: behavioural therapy





• Depression - unclear what measure was used





Methods Study design: unclear
Number of arms: unclear
Experimental arm: psychotherapy
Control arm: unclear
Participants Geographical location: unclear
Setting: unclear
Number of participants: unclear
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: unclear
Total number randomised in this trial: unclear
Number randomised to treatment group: unclear
Number randomised to control group: unclear
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Latow 1983 
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• Depression - unclear what measure was used




Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS
Control arm: sham stimulation
Participants Geographical location: Republic of Korea
Setting: not reported
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: radiological diagnosis of location of infarct is given, but it is unclear
whether this was used to make the diagnosis
Inclusion criteria: (1) patients who did not respond to conventional antidepressant medication
(paroxetine 20 mg/d); (2) Rancho Los Amogos cognitive function scale more than VIIa
Exclusion criteria: (1) history of psychiatric illness; (2) aphasia; (3) arrhythmia; (4) le( pre-frontal
cortical lesion; (5) seizure or internal metallic device
Depression criteria: BDI > 17
Total number randomised in this trial: 20
Number randomised to treatment group: 10 (70% men, mean age 67.8, SD 2.3)
Number randomised to control group: 10 (60% men, mean age 66.3, SD 3.0)
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: rTMS 10 Hz at an intensity of 110% for 1 second
Administered by: not reported
Control: sham stimulation
Frequency: 10 trains separated by 60 seconds
Duration: for 10 days during a 2-week period
Lee 2005 
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Follow-up: none
Outcomes Primary outcomes
• Depression measured using HDRS
• Depression measured using BDI
Secondary outcomes
• Cognitive function measured using MMSE




Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + routine care + physical factors treatment + acupuncture + psychothera-
py
Control arm: sham rTMS + routine care + physical factors treatment + acupuncture + psychothera-
py
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: clinical diagnosis plus confirmation by imaging that a relevant lesion
needed to be visible
Inclusion criteria: (1) no dementia; (2) no aphasia; (3) clear consciousness; (4) age < 75 years
Exclusion criteria: (1) cerebral haemorrhage; (2) history of epilepsy; (3) metal implant in the body;
(4) other serious physical illness; (5) history of psychiatric illness or family history
Depression criteria: meeting diagnostic criteria of ICD-10 for depression and 24-item HDRS score >
20
Total number randomised in this trial: 60
Number randomised to treatment group: 30 (36% men; mean age 59, SD 9)
Number randomised to control group: 30 (30% men; mean age 58, SD 11)
Total number included in final analysis: 60
Number included in treatment group for final analysis: 30
Number included in control group for final analysis: 30
Interventions Treatment: rTMS + routine care (medications (sertraline or citalopram), physical factors treatment
(musical therapy, high-voltage static current therapy), Chinese medicine (acupuncture), and psy-
chotherapy (patient-centred therapy, cognitive therapy, behaviour therapy)). Frequency: 10 to 15
Hz, intensity: 90% motor threshold, 1 stimulation lasting 1 second and stop for 10 seconds, total
1200 stimulations per day, for 10 days, location: le( DLPFC
Control: sham rTMS + routine care (medications (sertraline or citalopram), physical factors treat-
ment (musical therapy, high-voltage static current therapy), Chinese medicine (acupuncture), and
Liu 2010 
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psychotherapy (patient-centred therapy, cognitive therapy, behaviour therapy)). Keeping the coils




• Depression measured using HDRS
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: nurse-led education intervention
Control arm: unclear
Participants Geographical location: unclear
Setting: outpatient
Number of participants: 41
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: unclear
Total number randomised in this trial: 41
Number randomised to treatment group: 20
Number randomised to control group: 21
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
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• Depression measured using BDI




Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI)
Control arm: placebo
Participants Geographical location: Iran
Setting: inpatient
Stroke criteria: acute ischaemic stroke
Method of stroke diagnosis: documented with CT scan
Time since stroke: not reported
Inclusion criteria: (1) acute ischaemic stroke (documented with CT scan) that leads monoparesis,
hemiparesis, or hemiplegia; (2) not in a comatose state and stable
Exclusion criteria: (1) death due to any cause during assessment; (2) pregnancy; (3) poor compli-
ance of drugs and physiotherapy; (4) miscarriage returning of patient for further exams and assess-
ments; (5) any drug complication during assessment (prospected or not); (6) any metabolic disease
(liver, renal, cardiac impairment, and hyperthyroidism); (7) ischaemic stroke in the territory of an-
terior cerebral artery (ACA) or posterior cerebral artery (PCA), using any interfering drugs with flu-
oxetine (such as cyproheptadine, selegiline)
Depression criteria: none
Total number randomised in this trial: 172
Number randomised to treatment group: 86 (50.6% men; mean age 63.2, SD 11.4)
Number randomised to control group: 86 (41.3% men; mean age 64.6, SD 11.9)
Total number included in final analysis: 150
Number included in treatment group for final analysis: 75
Number included in control group for final analysis: 75






• Depression measured using ZDS
• Disability measured using BI
Razazian 2016 
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: paroxetine (SSRI) + cognitive therapy (frequency unknown)
Control arm: paroxetine (SSRI)
Participants Geographical location: China
Setting: inpatient
Stroke criteria: unclear
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by
the Second National Symposium on Cerebrovascular Disease and confirmation by brain CT or MRI
Time since stroke: 2 weeks ago
Inclusion criteria: (1) no history of aphasia or agnosia; (2) clear consciousness; (3) stroke onset at
least 2 weeks ago
Exclusion criteria: (1) history of psychiatric illness; (2) organic or reactive depression; (3) comorbid
with other severe psychiatric symptoms, or family history
Depression criteria: psychiatric interview to confirm diagnosis meets diagnostic criteria of
CCMD-2-R; ZDS score ≥ 50
Total number randomised in this trial: 41
Number randomised to treatment group: 20 (60% men; mean age 57.5, SD 5.2)
Number randomised to control group: 21 (57% men; mean age 56.3, SD 5.7)
Total number included in final analysis: 41
Number included in treatment group for final analysis: 20
Number included in control group for final analysis: 21
Interventions Treatment: combined paroxetine (SSRI) 20 mg/d in the morning and cognitive therapy (frequency
unknown). Cognitive therapy entailed guiding patients to apply cognitive remediation for negative
thoughts; recognise situations causing depression; re-establish healthy ideas and attitudes; estab-
lish family co-operation
Administered by: not reported
Supervision: not reported
Intervention fidelity: not reported




• Depression measured using ZDS
Tang 2002 
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Secondary outcomes
• Cognitive functioning measured using MMSE
• Evaluation of clinical status, stratifying clinical status as recovered (disappearance of symptoms,
insight recovery, social function recovery), obviously improved (most symptoms disappear, in-
sight partial recovery), improved (only slightly improved), not efficacious (no any improvement
and even worse)
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS + conventional drugs, rehabilitation training, and psychological coun-
selling therapy
Control arm: conventional drugs, rehabilitation training, and psychological counselling therapy
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: clinical criteria only
Inclusion criteria: (1) meeting diagnostic criteria of ICD for organic depression; (2) 17-item HDRS
score ≥ 8; (3) over 65 years of age
Exclusion criteria: not reported
Depression criteria: meeting diagnostic criteria of ICD for organic depression and 17-item HDRS
score ≥ 8
Total number randomised in this trial: 150
Number randomised to treatment group: 75 (56% men; mean age 56.7, SD 7.2)
Number randomised to control group: 75 (53% men; mean age 57.9, SD 6.8)
Total number included in final analysis: 150
Number included in treatment group for final analysis: 75
Number included in control group for final analysis: 75
Interventions Treatment: rTMS + conventional drugs, rehabilitation training, and psychological counselling ther-
apy. Frequency: 10 Hz, intensity: 60% motor threshold, 1 stimulation lasts 4 seconds and stops for
56 seconds, 30 stimulations for 1 series, 5 series a week, for successive 12 weeks, location: le( DLF-
PC
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• Depression measured using HDRS
• Disability measured using BI
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: high-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/
tablet, 1 tablet twice a day + psychotherapy
Control arm: sham rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1 tablet twice
a day + psychotherapy
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by
the Fourth National Symposium on Cerebrovascular Disease in 1995 and confirmation by brain CT
or MRI stated
Time since stroke: < 6 months
Inclusion criteria: (1) right-handedness; (2) disease course < 6 months; (3) can sign informed con-
sent
Exclusion criteria: (1) history of psychiatric illness or family history; (2) aphasia; (3) severe demen-
tia; (4) severe physical illness, consciousness disturbance, or deafness, which influences the ex-
pression of depressed mood; (4) psychoactive or non-addiction-producing substance-induced de-
pression; (5) various reasons to refuse trial or difficulty in finishing trial
Depression criteria: depression diagnosed according to CCMD-3
Total number randomised in this trial: 20
Number randomised to treatment group: 10 (50% men; mean age 68.65, SD 7.62)
Number randomised to control group: 10** (55% men; mean age 68.70, SD 8.94)
Total number included in final analysis: 20
Number included in treatment group for final analysis: 10
Number included in control group for final analysis: 10**
Interventions Treatment: high-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1
tablet twice a day + psychotherapy. High rTMS frequency: 10 Hz; intensity: 110% motor threshold;
location: le( DLPFC; 1 sequence included continuous stimulations for 30 minutes, frequency of
treatment: 1 sequence a day during 09:00 to 10:00
Control: sham rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1 twice a day + psy-
chotherapy. Sham rTMS 0 Hz; intensity: 0; location: le( or right DLPFC; 1 sequence included contin-
uous stimulations for 30 minutes, frequency of treatment: 1 sequence a day during 09:00 to 10:00
Duration: 7 days
Yan 2010a 
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Follow-up: none
Outcomes Primary outcomes
• Depression measured using HDRS
• Impairment measured using NIHSS
Secondary outcomes
• Adverse events
• Leaving the trial early
• Death
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: low-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/
tablet, 1 tablet twice a day + psychotherapy
Control arm: sham rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1 tablet twice
a day + psychotherapy
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by
the Fourth National Symposium on Cerebrovascular Disease in 1995 and confirmation by brain CT
or MRI stated
Time since stroke: < 6 months
Inclusion criteria: (1) right-handedness; (2) disease course < 6 months; (3) can sign informed con-
sent
Exclusion criteria: (1) history of psychiatric illness or family history; (2) aphasia; (3) severe demen-
tia; (4) severe physical illness, consciousness disturbance, or deafness, which influences the ex-
pression of depressed mood; (4) psychoactive or non-addiction-producing substance-induced de-
pression; (5) various reasons to refuse trial or difficulty in finishing trial
Depression criteria: depression diagnosed according to the CCMD-3
Total number randomised in this trial: 20
Number randomised to treatment group: 10 (55% men; mean age 69.65 ± 5.81)
Number randomised to control group: 10** (55% men; mean age 68.70 ± 8.94)
Total number included in final analysis: 20
Number included in treatment group for final analysis: 10
Number included in control group for final analysis: 10**
Yan 2010b 
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Interventions Treatment: low-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1
tablet twice a day + psychotherapy. Low rTMS frequency: 1 Hz; intensity: 110% motor threshold; lo-
cation: le( DLPFC; 1 sequence included continuous stimulations for 30 minutes; frequency of treat-
ment: 1 sequence a day during 09:00 to 10:00
Control: sham rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1 tablet twice a day
+ psychotherapy. Sham rTMS 0 Hz; intensity: 0; location: le( or right DLPFC; 1 sequence included





• Depression measured using HDRS
• Impairment measured using NIHSS
Secondary outcomes
• Adverse events
• Leaving the trial early
• Death
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: high-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/
tablet, 1 tablet twice a day + psychotherapy
Control arm: routine care + flupentixol and melitracen 10.5 mg/tablet, 1 tablet twice a day + psy-
chotherapy
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by
the Fourth National Symposium on Cerebrovascular Disease in 1995 and confirmation by brain CT
or MRI stated
Time since stroke: < 6 months
Inclusion criteria: (1) right-handedness; (2) disease course < 6 months; (3) can sign informed con-
sent
Exclusion criteria: (1) history of psychiatric illness or family history; (2) aphasia; (3) severe demen-
tia; (4) severe physical illnesses, consciousness disturbance, or deafness, which influences the ex-
pression of depressed mood; (4) psychoactive or non-addiction-producing substance-induced de-
pression; (5) various reasons to refuse trial or difficulty in finishing trial
Depression criteria: depression diagnosed according to the CCMD-3
Yan 2010c 
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Total number randomised in this trial: 20
Number randomised to treatment group: 10 (50% men; mean age 68.65, SD 7.62)
Number randomised to control group: 10** (60% men; mean age 67.25, SD 9.15)
Total number included in final analysis: 20
Number included in treatment group for final analysis: 10
Number included in control group for final analysis: 10**
Interventions Treatment: high-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1
tablet twice a day + psychotherapy. High rTMS frequency: 10 Hz; intensity: 110% motor threshold;
location: le( DLPFC; 1 sequence included continuous stimulations for 30 minutes; frequency of
treatment: 1 sequence a day during 09:00 to 10:00





• Depression measured using HDRS
• Impairment measured using NIHSS
Secondary outcomes
• Adverse events
• Leaving the trial early
• Death
Notes Unable to obtain information to determine if the psychotherapy component of the intervention




Methods Study design: parallel design
Number of arms: 2
Experimental arm: low-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/
tablet, 1 tablet twice a day + psychotherapy
Control arm: routine care + flupentixol and melitracen 10.5 mg/tablet, 1 tablet twice a day + psy-
chotherapy
Participants Geographical location: China
Setting: inpatient
Stroke criteria: not reported
Method of stroke diagnosis: diagnosis consistent with diagnostic criteria for stroke formulated by
the Fourth National Symposium on Cerebrovascular Disease in 1995 and confirmation by brain CT
or MRI stated
Time since stroke: < 6 months
Inclusion criteria: (1) right-handedness; (2) disease course < 6 months; (3) can sign informed con-
sent
Yan 2010d 
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Exclusion criteria: (1) history of psychiatric illness or family history; (2) aphasia; (3) severe demen-
tia; (4) severe physical illness, consciousness disturbance, or deafness, which influences the ex-
pression of depressed mood; (4) psychoactive or non-addiction-producing substance-induced de-
pression; (5) various reasons to refuse trial or difficulty in finishing trial
Depression criteria: depression diagnosed according to the CCMD-3
Total numbers randomised in this trial: 20
Numbers randomised to treatment group: 10 (55% men; mean age 69.65, SD 5.81)
Numbers randomised to control group: 10** (60% men; mean age 67.25, SD 9.15)
Total numbers included in final analysis: 20
Numbers included in treatment group for final analysis: 10
Numbers included in control group for final analysis: 10**
Interventions Treatment: low-frequency rTMS + routine care + flupentixol and melitracen 10.5 mg/tablet, 1
tablet twice a day + psychotherapy. Low rTMS frequency: 1 Hz; intensity: 110% motor threshold; lo-
cation: le( DLPFC; 1 sequence included continuous stimulations for 30 minutes; frequency of treat-
ment: 1 sequence a day during 09:00 to 10:00





• Depression measured using HDRS
• Impairment measured using NIHSS
Secondary outcomes
• Adverse events
• Leaving the trial early
• Death
Notes Unable to obtain information to determine if the psychotherapy component of the intervention
meets the review criteria for psychotherapy
Yan 2010d  (Continued)
** Results for control group halved.
ACA: anterior cerebral artery.
BDI: Beck Depression Inventory.
BI: Barthel Index.
CCMD-2-R: Chinese Classification of Mental Disorders, Second Edition, Revised.
CCMD-3: Chinese Classification of Mental Disorders, Third Edition.
CNS: central nervous system.
CSS: Chinese Stroke Scale.
CT: computed tomography.
DLPFC: dorsolateral pre-frontal cortex.
HADS: Hospital Anxiety Depression Scale.
HARS: Hamilton Anxiety Rating Scale.
HDRS-17: 17-item Hamilton Depression Rating Scale.
HDRS-24: 24-item Hamilton Depression Rating Scale.
Hz: hertz.
ICD: International Classification of Diseases.
LSI: Life Satisfaction Index.
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MMSE: Mini Mental State Examination.
MRI: magnetic resonance imaging.
NIHSS: National Institute of Health Stroke Scale.
PCA: posterior cerebral artery.
rTMS: repetitive transcranial magnetic stimulation.
SD: standard deviation.
SNRI: selective norepinephrine reuptake inhibitor.
SSRI: selective serotonin reuptake inhibitor.
SSS: Scandinavian Stroke Scale.
TCA: tricyclic antidepressant.
ZDS: Zung Depression Scale.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Promoting psychosocial well-being following stroke: study protocol for a randomised, controlled
trial
Methods Study design: parallel design
Number of arms: 2
Experimental arm: dialogue-based intervention
Control arm: usual care
Participants Geographical location: Norway
Setting: mixed
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Inclusion criteria: (1) adults over 18 years of age; (2) acute stroke within the last month before in-
clusion; (3) medically stable; (4) sufficient cognitive functioning to participate (assessed by physi-
cian/stroke team); (5) interested in participating; (6) able to understand and speak Norwegian; (7)
able to give informed consent
Exclusion criteria: (1) serious somatic or psychiatric disease, as these are assumed to impact abil-
ity to participate in the intervention; (2) severe dementia; (3) significant impressive aphasia or se-
vere expressive aphasia
Depression criteria: no criteria for depression at entry
Interventions Treatment: dialogue-based intervention to promote psychosocial well-being. Intervention con-
sists of 8 one to one and a half hour dialogue-based sessions between the stroke survivor and a
specially trained health professional (RN or OT). Each meeting has a guiding topical outline, which
addresses significant issues described in the research literature (e.g. bodily changes, emotional
challenges, personal relations, daily life issues, meaningful activities, existential issues, important
values)
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• Depression measured using GHQ-28
Secondary outcomes
• Coherence measured using SOC-13
• Health-related quality of life measured using SAQoL-39
Starting date December 2014
Contact information Dr. Marit Kirkevold, Institute of Health and Society and Research Center for Rehabilitation and Re-







Trial name or title Exercise and brain stimulation for post-stroke
Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS
Control arm: Sham rTMS
Participants Geographical location: USA
Setting: unclear
Stroke criteria: unclear
Method of stroke diagnosis: not reported
Inclusion criteria: (1) major depressive disorder (PHQ-9 > 10); (2) no antidepressant medications
or clinically able to discontinue medications
Exclusion criteria: (1) unable to ambulate at least 150 feet before stroke, or experienced intermit-
tent claudication while walking; (2) history of congestive heart failure, unstable cardiac arrhyth-
mias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnoea at rest or during
ADLs; (3) history of oxygen dependence; (4) pre-existing neurological disorders, dementia, or pre-
vious stroke; (5) history of major head trauma; (6) legal blindness or severe visual impairment; (7)
history of psychosis or other Axis I disorder that is primary; (8) life expectancy < 1 year; (9) severe
arthritis or other problem that limits passive range of motion; (10) history of DVT or pulmonary
embolism within 6 months; (11) uncontrolled diabetes with recent weight loss, diabetic coma, or
frequent insulin reactions; (12) severe hypertension with systolic > 200 mmHg and diastolic > 110
mmHg at rest; (13) suicide attempt in the last 2 years or at suicidal risk as assessed by SCID inter-
view; (14) previous or current enrolment in a clinical trial to enhance motor recovery; (15) currently
exercising ≥ 2 times per week (≥ 20 minutes); (16) presence of non-MRI compatible implants, preg-
nancy, or severe claustrophobia
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• Depression measured using HDRS
Secondary outcome
• Walking speed
Starting date 1 January 2016







Trial name or title Repetitive transcranial magnetic stimulation for depression after basal ganglia ischaemic stroke:
protocol for a multicentre randomised double-blind placebo-controlled trial
Methods Study design: parallel design
Number of arms: 2
Experimental arm: active rTMS
Control arm: sham rTMS
Participants Geographical location: China
Setting: inpatient
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: clinical and MRI or CT findings of basal ganglia ischaemic stroke
Inclusion criteria: (1) first-time ischaemic stroke; (2) recent stroke (within 3 weeks to 3 months)
Exclusion criteria: (1) prior history of depressive disorders or major trauma within 1 year, severe
depression, or any other severe mental disorder; (2) current or prior antidepressant use for any rea-
son; (3) aphasia or severe cognitive impairment, severe hearing impairment, or severe language
comprehension deficit due to other causes; (4) other cerebral disease such as Parkinson's disease,
encephalitis, dementia, multiple sclerosis, head injury, severe systemic disease, or ongoing neopla-
sia; (5) ongoing postoperative recovery
Depression criteria: DSM-IV diagnosis of depression due to stroke (ICD-10-CM code 293.83
(F06.32))
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Follow-up: not reported
Outcomes Primary outcome
• Depression measured using 24-item HDRS
Secondary outcomes
• Impairment measured using NIHSS
• Activities of Daily Living measured using ADLS
• Cognitive functioning measured using MoCA
• Aphasia measured using Aphasia Battery in Chinese, Social Support Revalued Scale
Starting date 20 November 2017






Trial name or title BEhavioural Activation therapy for Depression after Stroke (BEADS): a study protocol for a feasibili-
ty randomised controlled pilot trial of a psychological intervention for post-stroke depression
Methods Study design: parallel design
Number of arms: 2
Experimental arm: behavioural activation therapy
Control arm: usual care
Participants Geographical location: UK
Setting: mixed
Number of participants: unclear
Stroke criteria: ischaemic or haemorrhagic stroke
Method of stroke diagnosis: not reported
Inclusion criteria: (1) minimum of 3 months and maximum of 5 years post stroke; (2) 18 years of
age or older; (3) living in community settings (including nursing homes)
Exclusion criteria: (1) receiving medical or psychological treatment for depression at the time at
which they had their stroke (based on self-report by patient/carer) and/or currently receiving psy-
chological intervention; (2) diagnosis of dementia before the stroke (based on self-report by pa-
tient/carer); (3) communication difficulties that would impact their capacity to take part in the in-
tervention; (4) visual or hearing impairment that would impact capacity to take part in the inter-
vention (based on the therapist’s discretion at baseline assessment); (5) unable to communicate in
English before the stroke or without mental capacity to consent to take part in the trial
Depression criteria: PHQ-9 score ≥ 10. For participants with communication difficulties or severe
cognitive difficulties who are unable to complete the PHQ-9, a score of at least 50/100 on VAMS Sad
item
Thomas 2016 
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Interventions Treatment: behavioural activation (BA) therapy is a structured and individualised treatment that
aims to increase people's level of activity, particularly the frequency of pleasant or enjoyable
events, to improve mood. Maximum of 15 sessions of BA over 4 months, with an expected aver-
age of 10 sessions. Therapy sessions were face-to-face on an individual basis, at participants' resi-
dences, and lasted about 1 hour. A BA treatment manual was developed
Administered by: assistant psychologist
Supervision: not reported





• Depression measured using PHQ-9, SAD-Q Hospital version (observer-rated depression)
Secondary outcomes
• Activities of daily living measured using Nottingham Leisure Questionnaire
• Functional outcome measured using Nottingham EADL
• Health-related quality of life measured using EQ5D
Starting date 12 December 2014
Contact information Dr. Shirley Thomas; Division of Rehabilitation and Ageing, School of Medicine, B Floor Medical
School, Queens Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
Email: shirley.thomas@nottingham.ac.uk
Notes Author contact:emailed study authors to check if they can share findings (reply received: the fun-




Trial name or title Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression
Methods Study design: parallel design
Number of arms: 2
Experimental arm: rTMS
Control arm: sham rTMS
Participants Geographical location: China
Setting: unclear
Number of participants: unclear
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: ischaemic brain region or infarction confirmed by CT or MRI
Xu 2016 
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews
Inclusion criteria: (1) 2 weeks to 3 months after acute ischaemic stroke
Exclusion criteria: (1) all kinds of serious mental disorders other than depressive disorder; con-
firmed cases of various types of depression, or history of major mental trauma within 1 year; (2)
verbal communication failure (aphasia, severe cognitive impairment, severe hearing loss, etc.); (3)
other systemic diseases that have a serious impact on abilities of daily living; (4) brain disease oth-
er than stroke (such as Parkinson's disease, encephalitis, multiple sclerosis, brain trauma, etc.); (5)
nuclear magnetic resonance or transcranial magnetic stimulation contraindications
Depression criteria: diagnostic criteria of depression disorder caused by other somatic disease







• Depression measured using HDRS
Secondary outcomes
• Dependence measured using Social Support Revalued Scale
• Disability and impairments measured using Medical Coping Modes Questionnaire
Starting date 1 January 2016
Contact information Dr. Suiyi Xu
Email: suiyixu@sina.com
Notes Author contact: emailed study authors to check if there are any published results for the trial 3 De-
cember 2018; no reply received
Xu 2016  (Continued)
ADLs: activities of daily living.
ADLS: Activities of Daily Living Scale.
BA: behavioural activation.
CT: computed tomography.
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
DSM-v: Diagnostic and Statistical Manual of Mental Disorders, Fi(h Edition.
DVT: deep vein thrombosis.
EADL: Extended Activities of Daily Living.
EQ5D: EuroQoL 5-dimensions.
GHQ-28: 28-item General Health Questionnaire.
HDRS-24: 24-item Hamilton Depression Rating Scale.
ICD: International Classification for Diseases.
MoCA: Montreal Cognitive Assessment.
MRI: magnetic resonance imaging.
NIHSS: National Institutes of Health Stroke Scale.
OT: occupational therapist.
PHQ-9: 9-item Patient Health Questionnaire.
RN: registered nurse.
rTMS: repetitive transcranial magnetic stimulation.
SAD-Q: Stroke Aphasia Depression Questionnaire - hospital version.
SAQoL-39: Stroke Aphasia Quality of Life Scale.
SCID: severe combined immunodeficiency.
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SOC-13: Sense of Coherence.
VAMS: Visual Analog Mood Scale.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Pharmacological interventions versus placebo





Statistical method Effect size
1 Depression: meeting study criteria
for depression at end of treatment
8 1025 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.55, 0.88]
1.1 Clinician interview/impression
(number not improved)
1 285 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.54, 0.95]
1.2 DSM-III 1 39 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.32, 2.03]
1.3 MADRS 2 352 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.59, 1.60]
1.4 HDRS 4 349 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.46, 0.68]
2 Depression: < 50% reduction in
scale scores at end of treatment
6 511 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.32, 0.70]
2.1 HDRS 4 357 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.25, 0.61]
2.2 MADRS 2 154 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.59, 1.01]
3 Depression: average change in
scores between baseline and end of
treatment
5   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
3.1 BDI (high score = more depressed) 1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 CGI (low score = improve-
ment/high score = deterioration)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 HDRS (high score = more de-
pressed)
2   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 MADRS (high score = more de-
pressed)
3   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Depression: mean scores at end of
treatment
15   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
4.1 BDI (high score = more depressed) 4   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 CGI (low score = improve-
ment/high score = deterioration)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 HDRS (high score = more de-
pressed)
13   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
4.4 MADRS (high score = more de-
pressed)
2   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Melancholia scale (high score =
more depressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Zung Depression Scale (high score
= more depressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Anxiety: meeting study criteria for
anxiety at end of treatment
1   Odds Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
5.1 Clinician interview/impression 1   Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Cognitive function: average change
in scores between baseline and end
of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
6.1 MMSE (low score = cognitive im-
pairment)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Cognitive function: mean scores at
end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
7.1 MMSE (low score = cognitive im-
pairment)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Activities of daily living: average
change in scores between baseline
and end of treatment
2 256 Mean Difference (IV, Random, 95% CI) -8.0 [-24.18, 8.18]
8.1 Barthel Index (high score = more
dependent)
2 256 Mean Difference (IV, Random, 95% CI) -8.0 [-24.18, 8.18]
9 Activities of daily living: mean
scores at end of treatment
3 316 Mean Difference (IV, Random, 95% CI) 3.14 [-0.97, 7.26]
9.1 Barthel Index (high score = more
dependent)
3 316 Mean Difference (IV, Random, 95% CI) 3.14 [-0.97, 7.26]
10 Disability: average change in
scores between baseline and end of
treatment
3   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
10.1 Functional Independence Mea-
sure (low score = dependence)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Motoricity Index (low score =
more motor impairment)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Scandinavian Stroke Scale (low
score = more neurological deficit)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
10.4 Rankin Scale (high score = more
disability)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Disability: mean scores at end of
treatment
3   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
11.1 Functional Independence Mea-
sure (low score = dependence)
2   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 Motoricity Index (low score =
more motor impairment)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 Scandinavian Stroke Scale (low
score = more neurological deficit)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Neurological function: average
change in scores between baseline
and end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
12.1 Chinese Stroke Scale (high score
= more impairment)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Neurological function: mean
scores at end of treatment
4 304 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.44, -0.45]
13.1 Chinese Stroke Scale (high score
= more impairment)
3 231 Std. Mean Difference (IV, Random, 95% CI) -1.15 [-1.59, -0.72]
13.2 National Institutes of Health
Stroke Scale (high score = more im-
pairment
1 73 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.87, 0.06]
14 Adverse events: death 9 848 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.20, 2.07]
14.1 At end of treatment 9 848 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.20, 2.07]
15 Adverse events: all 10   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Central nervous system events
(e.g. confusion, sedation, tremor)
5 488 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [1.12, 2.15]
15.2 Psychiatric events (e.g. anxiety,
increased depression)
3 183 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.05, 1.70]
15.3 Recurrent stroke 3 195 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.29, 7.76]
15.4 Vascular events - not stroke (e.g.
dizziness, palpitation)
7 587 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.94, 2.22]
15.5 Gastrointestinal effects (e.g. con-
stipation, diarrhoea)
4 473 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [1.19, 2.19]
15.6 Other events - not listed above
(e.g. dysuria, eye discomfort)
7 638 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.00, 1.75]
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Statistical method Effect size
15.7 Protocol violation (e.g. refused
treatment, withdrew consent)
5 334 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.45, 2.68]
16 Adverse events: leaving the study
early (including death)
13   Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 All dropouts and withdrawals 13 1165 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.82, 1.39]
 
 
Analysis 1.1.   Comparison 1 Pharmacological interventions versus placebo,
Outcome 1 Depression: meeting study criteria for depression at end of treatment.
Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Clinician interview/impression (number not improved)  
Ohtomo 1991 52/150 65/135 17.87% 0.72[0.54,0.95]
Subtotal (95% CI) 150 135 17.87% 0.72[0.54,0.95]
Total events: 52 (Pharmacotherapy), 65 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.29(P=0.02)  
   
1.1.2 DSM-III  
Lipsey 1984 5/17 8/22 5.12% 0.81[0.32,2.03]
Subtotal (95% CI) 17 22 5.12% 0.81[0.32,2.03]
Total events: 5 (Pharmacotherapy), 8 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.45(P=0.65)  
   
1.1.3 MADRS  
Murray 2002 7/62 4/61 3.42% 1.72[0.53,5.58]
Ponzio 2001 82/112 97/117 22.15% 0.88[0.77,1.01]
Subtotal (95% CI) 174 178 25.57% 0.98[0.59,1.6]
Total events: 89 (Pharmacotherapy), 101 (Placebo)  
Heterogeneity: Tau2=0.07; Chi2=1.39, df=1(P=0.24); I2=27.92%  
Test for overall effect: Z=0.1(P=0.92)  
   
1.1.4 HDRS  
Andersen 1994 11/33 23/33 10.75% 0.48[0.28,0.81]
Fruehwald 2003 8/28 6/26 5.18% 1.24[0.5,3.09]
Wang 2005 24/54 45/54 16.57% 0.53[0.39,0.74]
Yang 2002 33/64 53/57 18.94% 0.55[0.43,0.71]
Subtotal (95% CI) 179 170 51.44% 0.56[0.46,0.68]
Total events: 76 (Pharmacotherapy), 127 (Placebo)  
Heterogeneity: Tau2=0.01; Chi2=3.36, df=3(P=0.34); I2=10.78%  
Test for overall effect: Z=5.72(P<0.0001)  
   
Total (95% CI) 520 505 100% 0.7[0.55,0.88]
Total events: 222 (Pharmacotherapy), 301 (Placebo)  
Favours Pharmacotherapy 500.02 100.1 1 Favours Placebo
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Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.06; Chi2=21.68, df=7(P=0); I2=67.71%  
Test for overall effect: Z=3.03(P=0)  
Test for subgroup differences: Chi2=5.51, df=1 (P=0.14), I2=45.56%  
Favours Pharmacotherapy 500.02 100.1 1 Favours Placebo
 
 
Analysis 1.2.   Comparison 1 Pharmacological interventions versus placebo,
Outcome 2 Depression: < 50% reduction in scale scores at end of treatment.
Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 HDRS  
Andersen 1994 11/33 23/33 16.06% 0.48[0.28,0.81]
Lai 2006a 18/40 34/40 19.06% 0.53[0.37,0.76]
Li 2008 20/60 22/30 18.14% 0.45[0.3,0.69]
Yang 2002 8/64 42/57 13.73% 0.17[0.09,0.33]
Subtotal (95% CI) 197 160 66.99% 0.4[0.25,0.61]
Total events: 57 (Pharmacotherapy), 121 (Placebo)  
Heterogeneity: Tau2=0.14; Chi2=10.12, df=3(P=0.02); I2=70.37%  
Test for overall effect: Z=4.13(P<0.0001)  
   
1.2.2 MADRS  
Murray 2002 33/62 40/61 20.24% 0.81[0.6,1.09]
Wiart 2000 6/16 10/15 12.77% 0.56[0.27,1.16]
Subtotal (95% CI) 78 76 33.01% 0.77[0.59,1.01]
Total events: 39 (Pharmacotherapy), 50 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.85, df=1(P=0.36); I2=0%  
Test for overall effect: Z=1.87(P=0.06)  
   
Total (95% CI) 275 236 100% 0.48[0.32,0.7]
Total events: 96 (Pharmacotherapy), 171 (Placebo)  
Heterogeneity: Tau2=0.17; Chi2=21.51, df=5(P=0); I2=76.76%  
Test for overall effect: Z=3.73(P=0)  
Test for subgroup differences: Chi2=6.35, df=1 (P=0.01), I2=84.26%  
Favours Pharmacotherapy 1000.01 100.1 1 Favours Placebo
 
 
Analysis 1.3.   Comparison 1 Pharmacological interventions versus placebo, Outcome
3 Depression: average change in scores between baseline and end of treatment.
Study or subgroup Pharmacotherapy Placebo Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.3.1 BDI (high score = more depressed)  
Fruehwald 2003 28 -6.1 (5.6) 26 -4.1 (6.5) -0.33[-0.86,0.21]
   
1.3.2 CGI (low score = improvement/high score = deterioration)  
Fruehwald 2003 28 -2.7 (1.6) 26 -2.1 (1.7) -0.36[-0.9,0.18]
Favours Pharmacotherapy 52.5-5 -2.5 0 Favours Placebo
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Study or subgroup Pharmacotherapy Placebo Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
   
1.3.3 HDRS (high score = more depressed)  
Fruehwald 2003 28 -23.3 (12) 26 -19.1 (15.1) -0.3[-0.84,0.23]
Jiang 2001a 30 -20.1 (6.8) 15 -11.8 (7.5) -1.15[-1.82,-0.49]
   
1.3.4 MADRS (high score = more depressed)  
Murray 2002 62 -8.5 (8.9) 61 -7.6 (9.3) -0.1[-0.45,0.26]
Ponzio 2001 112 -12 (9.5) 117 -9.9 (7.5) -0.25[-0.51,0.01]
Wiart 2000 16 -16.6 (8.1) 15 -8.4 (7.8) -1[-1.76,-0.25]
Favours Pharmacotherapy 52.5-5 -2.5 0 Favours Placebo
 
 
Analysis 1.4.   Comparison 1 Pharmacological interventions versus
placebo, Outcome 4 Depression: mean scores at end of treatment.
Study or subgroup Pharmacotherapy Placebo Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.4.1 BDI (high score = more depressed)  
Fruehwald 2003 28 6.1 (5.6) 26 6.8 (7.4) -0.11[-0.64,0.43]
Rampello 2005 16 8.1 (3.4) 15 18.4 (3.3) -2.98[-4.04,-1.92]
Robinson 2008a 48 9.1 (7.1) 28 8.9 (7.3) 0.03[-0.44,0.49]
Robinson 2008b 55 9.6 (7.5) 28 8.9 (7.3) 0.09[-0.36,0.55]
   
1.4.2 CGI (low score = improvement/high score = deterioration)  
Fruehwald 2003 28 3.1 (1.3) 26 3.4 (1.7) -0.2[-0.73,0.34]
   
1.4.3 HDRS (high score = more depressed)  
Andersen 1994 33 11.4 (5.1) 33 14.1 (4.7) -0.54[-1.04,-0.05]
Fruehwald 2003 28 9.5 (7.9) 26 11.2 (12.4) -0.16[-0.7,0.37]
Gao 2017a 91 8.1 (2.4) 45 8.5 (3.4) -0.14[-0.5,0.21]
Huang 2002 40 4.8 (0.6) 40 16.3 (1.3) -11.33[-13.18,-9.47]
Jiang 2001a 30 5.1 (3.1) 15 13.2 (5.6) -1.95[-2.7,-1.2]
Kong 2007 48 12.6 (5.3) 42 16.3 (3.7) -0.79[-1.22,-0.36]
Lai 2006a 40 12.5 (8.4) 40 21.5 (4.3) -1.34[-1.82,-0.85]
Li 2008 60 14.5 (2.4) 30 18.7 (3.9) -1.4[-1.88,-0.91]
Lipsey 1984 17 2.8 (2.7) 22 10 (8.1) -1.11[-1.79,-0.42]
Rampello 2005 16 9.3 (2.2) 15 22.7 (2.4) -5.77[-7.46,-4.08]
Robinson 2008a 48 10.2 (7.5) 28 9.5 (6.6) 0.1[-0.37,0.56]
Robinson 2008b 55 9.5 (6.6) 28 9.5 (6.6) 0[-0.46,0.46]
Wang 2005 54 11.2 (4.3) 54 15.3 (4.6) -0.93[-1.33,-0.53]
   
1.4.4 MADRS (high score = more depressed)  
Murray 2002 62 10.5 (9.6) 61 12 (8.5) -0.16[-0.52,0.19]
Wiart 2000 16 11.8 (6.7) 15 18.7 (10) -0.79[-1.53,-0.06]
   
1.4.5 Melancholia scale (high score = more depressed)  
Andersen 1994 33 10.5 (5.1) 33 12.9 (4.5) -0.49[-0.98,-0]
   
1.4.6 Zung Depression Scale (high score = more depressed)  
Lipsey 1984 17 31 (10) 22 42 (15.5) -0.81[-1.47,-0.15]
Favours Pharmacotherapy 105-10 -5 0 Favours Placebo
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Analysis 1.5.   Comparison 1 Pharmacological interventions versus placebo,
Outcome 5 Anxiety: meeting study criteria for anxiety at end of treatment.
Study or subgroup Pharmacotherapy Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.5.1 Clinician interview/impression  
Ohtomo 1991 46/150 57/135 0.61[0.37,0.98]
Favours Pharmacotherapy 1000.01 100.1 1 Favours Placebo
 
 
Analysis 1.6.   Comparison 1 Pharmacological interventions versus placebo, Outcome 6
Cognitive function: average change in scores between baseline and end of treatment.
Study or subgroup Pharmacotherapy Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.6.1 MMSE (low score = cognitive impairment)  
Wiart 2000 16 1.3 (3.7) 15 2.1 (3) -0.8[-3.15,1.55]
Favours Pharmacotherapy 105-10 -5 0 Favours Placebo
 
 
Analysis 1.7.   Comparison 1 Pharmacological interventions versus
placebo, Outcome 7 Cognitive function: mean scores at end of treatment.
Study or subgroup Pharmacotherapy Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.7.1 MMSE (low score = cognitive impairment)  
Wiart 2000 16 24.8 (3.9) 15 26.2 (3) -1.4[-3.84,1.04]
Favours Pharmacotherapy 105-10 -5 0 Favours Placebo
 
 
Analysis 1.8.   Comparison 1 Pharmacological interventions versus placebo, Outcome 8
Activities of daily living: average change in scores between baseline and end of treatment.
Study or subgroup Pharmacotherapy Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.8.1 Barthel Index (high score = more dependent)  
Ponzio 2001 112 1.7 (0) 117 1.8 (0)   Not estimable
Reding 1986 11 -28 (23.2) 16 -20 (17.5) 100% -8[-24.18,8.18]
Subtotal *** 123   133   100% -8[-24.18,8.18]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
   
Total *** 123   133   100% -8[-24.18,8.18]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
Favours Pharmacotherapy 10050-100 -50 0 Favours Placebo
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Analysis 1.9.   Comparison 1 Pharmacological interventions versus placebo,
Outcome 9 Activities of daily living: mean scores at end of treatment.
Study or subgroup Pharmacotherapy Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.9.1 Barthel Index (high score = more dependent)  
Gao 2017a 91 71.5 (16.2) 45 72.3 (15.9) 26.31% -0.8[-6.51,4.91]
Kong 2007 48 60.4 (12.5) 42 52.3 (13.5) 27.81% 8.1[2.7,13.5]
Li 2008 60 40.8 (3.7) 30 38.4 (5.8) 45.88% 2.4[0.12,4.68]
Subtotal *** 199   117   100% 3.14[-0.97,7.26]
Heterogeneity: Tau2=8.26; Chi2=5.34, df=2(P=0.07); I2=62.55%  
Test for overall effect: Z=1.5(P=0.13)  
   
Total *** 199   117   100% 3.14[-0.97,7.26]
Heterogeneity: Tau2=8.26; Chi2=5.34, df=2(P=0.07); I2=62.55%  
Test for overall effect: Z=1.5(P=0.13)  
Favours Pharmacotherapy 10050-100 -50 0 Favours Placebo
 
 
Analysis 1.10.   Comparison 1 Pharmacological interventions versus placebo, Outcome
10 Disability: average change in scores between baseline and end of treatment.
Study or subgroup Pharmacotherapy Placebo Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.10.1 Functional Independence Measure (low score = dependence)  
Wiart 2000 16 24.7 (20.4) 15 16.4 (23.2) 0.37[-0.34,1.08]
   
1.10.2 Motoricity Index (low score = more motor impairment)  
Wiart 2000 16 18.9 (23.8) 15 11.9 (26) 0.27[-0.43,0.98]
   
1.10.3 Scandinavian Stroke Scale (low score = more neurological deficit)  
Fruehwald 2003 28 13.5 (7.4) 26 15.4 (9.2) -0.22[-0.76,0.31]
   
1.10.4 Rankin Scale (high score = more disability)  
Ponzio 2001 112 -0.4 (0) 117 -0.4 (0) Not estimable
Favours Pharmacotherapy 42-4 -2 0 Favours Placebo
 
 
Analysis 1.11.   Comparison 1 Pharmacological interventions versus
placebo, Outcome 11 Disability: mean scores at end of treatment.
Study or subgroup Pharmacotherapy Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.11.1 Functional Independence Measure (low score = dependence)  
Gao 2017a 91 71.1 (17) 45 71.5 (17.6) -0.4[-6.62,5.82]
Wiart 2000 16 87.4 (22.8) 15 88.7 (25.3) -1.3[-18.29,15.69]
   
1.11.2 Motoricity Index (low score = more motor impairment)  
Wiart 2000 16 48.5 (24.6) 15 55.3 (26.5) -6.8[-24.83,11.23]
   
1.11.3 Scandinavian Stroke Scale (low score = more neurological deficit)  
Favours Pharmacotherapy 105-10 -5 0 Favours Placebo
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Study or subgroup Pharmacotherapy Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Fruehwald 2003 28 53.5 (4.8) 26 52.8 (5.4) 0.7[-2.03,3.43]
Favours Pharmacotherapy 105-10 -5 0 Favours Placebo
 
 
Analysis 1.12.   Comparison 1 Pharmacological interventions versus placebo, Outcome 12
Neurological function: average change in scores between baseline and end of treatment.
Study or subgroup Pharmacotherapy Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.12.1 Chinese Stroke Scale (high score = more impairment)  
Jiang 2001a 30 -14.8 (6.4) 15 -13.1 (6.8) -1.75[-5.87,2.37]
Favours Pharmacotherapy 105-10 -5 0 Favours Placebo
 
 
Analysis 1.13.   Comparison 1 Pharmacological interventions versus placebo,
Outcome 13 Neurological function: mean scores at end of treatment.
Study or subgroup Pharmacotherapy Placebo Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.13.1 Chinese Stroke Scale (high score = more impairment)  
Huang 2002 40 4 (1.9) 40 8.6 (3.6) 25% -1.56[-2.06,-1.06]
Jiang 2001a 30 3.2 (2.4) 15 5.2 (3.3) 21.58% -0.72[-1.36,-0.08]
Wang 2005 52 5.8 (6.6) 54 13.9 (7.9) 27.4% -1.1[-1.51,-0.69]
Subtotal *** 122   109   73.98% -1.15[-1.59,-0.72]
Heterogeneity: Tau2=0.08; Chi2=4.34, df=2(P=0.11); I2=53.94%  
Test for overall effect: Z=5.22(P<0.0001)  
   
1.13.2 National Institutes of Health Stroke Scale (high score = more impairment  
Kong 2007 37 8.6 (6.4) 36 11.2 (6.4) 26.02% -0.4[-0.87,0.06]
Subtotal *** 37   36   26.02% -0.4[-0.87,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.7(P=0.09)  
   
Total *** 159   145   100% -0.95[-1.44,-0.45]
Heterogeneity: Tau2=0.19; Chi2=11.98, df=3(P=0.01); I2=74.95%  
Test for overall effect: Z=3.76(P=0)  
Test for subgroup differences: Chi2=5.37, df=1 (P=0.02), I2=81.39%  
Favours Pharmacotherapy 52.5-5 -2.5 0 Favours Placebo
 
 
Analysis 1.14.   Comparison 1 Pharmacological interventions versus placebo, Outcome 14 Adverse events: death.
Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.14.1 At end of treatment  
Andersen 1994 2/33 2/33 37.81% 1[0.15,6.68]
Favours Pharmacotherapy 500.02 100.1 1 Favours Placebo
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Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Fruehwald 2003 1/28 0/26 13.69% 2.79[0.12,65.66]
Gao 2017a 1/91 1/45 18.06% 0.49[0.03,7.73]
Huang 2002 0/40 0/40   Not estimable
Li 2008 0/60 0/30   Not estimable
Lipsey 1984 0/17 2/22 15.44% 0.26[0.01,5]
Murray 2002 0/62 2/61 15% 0.2[0.01,4.02]
Ponzio 2001 0/112 0/117   Not estimable
Wiart 2000 0/16 0/15   Not estimable
Subtotal (95% CI) 459 389 100% 0.64[0.2,2.07]
Total events: 4 (Pharmacotherapy), 7 (Placebo)  
Heterogeneity: Tau2=0; Chi2=2.05, df=4(P=0.73); I2=0%  
Test for overall effect: Z=0.74(P=0.46)  
   
Total (95% CI) 459 389 100% 0.64[0.2,2.07]
Total events: 4 (Pharmacotherapy), 7 (Placebo)  
Heterogeneity: Tau2=0; Chi2=2.05, df=4(P=0.73); I2=0%  
Test for overall effect: Z=0.74(P=0.46)  
Favours Pharmacotherapy 500.02 100.1 1 Favours Placebo
 
 
Analysis 1.15.   Comparison 1 Pharmacological interventions versus placebo, Outcome 15 Adverse events: all.
Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.15.1 Central nervous system events (e.g. confusion, sedation,
tremor)
 
Andersen 1994 2/33 0/33 1.28% 5[0.25,100.32]
Lipsey 1984 4/17 0/22 1.12% 11.5[0.66,199.99]
Murray 2002 33/62 28/61 72.27% 1.16[0.81,1.66]
Ponzio 2001 17/112 8/117 20.04% 2.22[1,4.94]
Wiart 2000 3/16 2/15 5.29% 1.41[0.27,7.28]
Subtotal (95% CI) 240 248 100% 1.55[1.12,2.15]
Total events: 59 (Pharmacotherapy), 38 (Placebo)  
Heterogeneity: Tau2=0; Chi2=5.78, df=4(P=0.22); I2=30.84%  
Test for overall effect: Z=2.64(P=0.01)  
   
1.15.2 Psychiatric events (e.g. anxiety, increased depression)  
Fruehwald 2003 0/28 1/26 31.97% 0.31[0.01,7.3]
Li 2008 0/60 1/30 40.93% 0.17[0.01,4.04]
Lipsey 1984 0/17 1/22 27.1% 0.43[0.02,9.85]
Subtotal (95% CI) 105 78 100% 0.28[0.05,1.7]
Total events: 0 (Pharmacotherapy), 3 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.17, df=2(P=0.92); I2=0%  
Test for overall effect: Z=1.38(P=0.17)  
   
1.15.3 Recurrent stroke  
Andersen 1994 1/33 0/33 20.16% 3[0.13,71.07]
Li 2008 2/60 0/30 26.73% 2.54[0.13,51.31]
Lipsey 1984 0/17 1/22 53.11% 0.43[0.02,9.85]
Favours Pharmacotherapy 5000.002 100.1 1 Favours Placebo
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Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Subtotal (95% CI) 110 85 100% 1.51[0.29,7.76]
Total events: 3 (Pharmacotherapy), 1 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.92, df=2(P=0.63); I2=0%  
Test for overall effect: Z=0.49(P=0.62)  
   
1.15.4 Vascular events - not stroke (e.g. dizziness, palpitation)  
Andersen 1994 1/33 1/33 3.5% 1[0.07,15.33]
Fruehwald 2003 1/28 0/26 1.81% 2.79[0.12,65.66]
Jiang 2001a 7/30 0/15 2.31% 7.74[0.47,127.11]
Lipsey 1984 2/17 1/22 3.05% 2.59[0.26,26.22]
Murray 2002 22/62 18/61 63.43% 1.2[0.72,2.01]
Ponzio 2001 9/112 6/117 20.51% 1.57[0.58,4.26]
Wiart 2000 0/16 1/15 5.4% 0.31[0.01,7.15]
Subtotal (95% CI) 298 289 100% 1.44[0.94,2.22]
Total events: 42 (Pharmacotherapy), 27 (Placebo)  
Heterogeneity: Tau2=0; Chi2=3.29, df=6(P=0.77); I2=0%  
Test for overall effect: Z=1.68(P=0.09)  
   
1.15.5 Gastrointestinal effects (e.g. constipation, diarrhoea)  
Li 2008 6/60 2/30 6.53% 1.5[0.32,6.99]
Murray 2002 44/62 27/61 66.7% 1.6[1.16,2.22]
Ponzio 2001 17/112 8/117 19.18% 2.22[1,4.94]
Wiart 2000 1/16 3/15 7.59% 0.31[0.04,2.68]
Subtotal (95% CI) 250 223 100% 1.62[1.19,2.19]
Total events: 68 (Pharmacotherapy), 40 (Placebo)  
Heterogeneity: Tau2=0; Chi2=2.86, df=3(P=0.41); I2=0%  
Test for overall effect: Z=3.09(P=0)  
   
1.15.6 Other events - not listed above (e.g. dysuria, eye discomfort)  
Andersen 1994 1/33 0/33 0.89% 3[0.13,71.07]
Fruehwald 2003 0/28 1/26 2.76% 0.31[0.01,7.3]
Jiang 2001a 2/30 0/15 1.17% 2.58[0.13,50.6]
Li 2008 4/60 1/30 2.37% 2[0.23,17.12]
Murray 2002 37/62 26/61 46.64% 1.4[0.98,2]
Ponzio 2001 29/112 26/117 45.25% 1.17[0.73,1.85]
Wiart 2000 1/16 0/15 0.92% 2.82[0.12,64.39]
Subtotal (95% CI) 341 297 100% 1.32[1,1.75]
Total events: 74 (Pharmacotherapy), 54 (Placebo)  
Heterogeneity: Tau2=0; Chi2=2.02, df=6(P=0.92); I2=0%  
Test for overall effect: Z=1.93(P=0.05)  
   
1.15.7 Protocol violation (e.g. refused treatment, withdrew consent)  
Andersen 1994 1/33 0/33 5.65% 3[0.13,71.07]
Kong 2007 4/48 4/42 48.18% 0.88[0.23,3.28]
Lipsey 1984 0/17 3/22 34.71% 0.18[0.01,3.31]
Wang 2005 2/54 0/54 5.65% 5[0.25,101.77]
Wiart 2000 1/16 0/15 5.82% 2.82[0.12,64.39]
Subtotal (95% CI) 168 166 100% 1.1[0.45,2.68]
Total events: 8 (Pharmacotherapy), 7 (Placebo)  
Heterogeneity: Tau2=0; Chi2=3.3, df=4(P=0.51); I2=0%  
Test for overall effect: Z=0.21(P=0.83)  
Favours Pharmacotherapy 5000.002 100.1 1 Favours Placebo
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Analysis 1.16.   Comparison 1 Pharmacological interventions versus placebo,
Outcome 16 Adverse events: leaving the study early (including death).
Study or subgroup Pharma-
cotherapy
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.16.1 All dropouts and withdrawals  
Andersen 1994 7/33 2/33 3.05% 3.5[0.78,15.62]
Fruehwald 2003 2/28 2/26 1.92% 0.93[0.14,6.12]
Gao 2017a 6/85 2/43 2.81% 1.52[0.32,7.21]
Huang 2002 0/40 0/40   Not estimable
Kong 2007 11/37 6/36 8.75% 1.78[0.74,4.31]
Li 2008 2/60 1/15 1.25% 0.5[0.05,5.15]
Lipsey 1984 6/17 7/22 8.65% 1.11[0.46,2.7]
Murray 2002 24/62 30/61 41.77% 0.79[0.53,1.18]
Ponzio 2001 20/112 20/117 21.5% 1.04[0.59,1.83]
Robinson 2008a 7/48 3/28 4.23% 1.36[0.38,4.85]
Robinson 2008b 9/55 3/28 4.54% 1.53[0.45,5.2]
Wang 2005 2/54 0/54 0.75% 5[0.25,101.77]
Wiart 2000 2/16 0/15 0.78% 4.71[0.24,90.69]
Subtotal (95% CI) 647 518 100% 1.07[0.82,1.39]
Total events: 98 (Pharmacotherapy), 76 (Placebo)  
Heterogeneity: Tau2=0; Chi2=9.38, df=11(P=0.59); I2=0%  
Test for overall effect: Z=0.49(P=0.62)  
Favours Pharmacotherapy 100.1 50.2 20.5 1 Favours Placebo
 
 
Comparison 2.   Non-invasive brain stimulation versus sham non-invasive brain stimulation and/or usual care





Statistical method Effect size
1 Depression: meeting study criteria
for depression at end of treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Depression: < 50% reduction in
scale scores at end of treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
2.1 HDRS 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Depression: mean scores at end of
treatment
8 495 Mean Difference (IV, Random, 95% CI) -6.63 [-9.71, -3.55]
3.1 HDRS (high score = more de-
pressed)
8 495 Mean Difference (IV, Random, 95% CI) -6.63 [-9.71, -3.55]
4 Depression: mean scores at end of
follow-up
3 170 Mean Difference (IV, Random, 95% CI) -2.60 [-3.33, -1.87]
4.1 HDRS (high score = more de-
pressed)
3 170 Mean Difference (IV, Random, 95% CI) -2.60 [-3.33, -1.87]
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Statistical method Effect size
5 Activities of daily living: mean
scores at end of treatment
2 208 Std. Mean Difference (IV, Random, 95% CI) 1.84 [-1.40, 5.08]
5.1 Barthel Index (high score = more
dependent)
1 108 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.18, 0.57]
5.2 ADL (high score = more impair-
ment)
1 100 Std. Mean Difference (IV, Random, 95% CI) 3.50 [2.87, 4.13]
6 Neurological function: average
change in scores between baseline
and end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
6.1 Chinese Stroke Scale (high score =
more impairment)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Neurological function: mean scores
at end of treatment
3 290 Std. Mean Difference (IV, Random, 95% CI) -2.21 [-3.32, -1.09]
7.1 Chinese Stroke Scale (high score =
more impairment)
2 190 Std. Mean Difference (IV, Random, 95% CI) -1.79 [-2.94, -0.64]
7.2 National Institutes of Health
Stroke Scale (high score = more im-
pairment)
1 100 Std. Mean Difference (IV, Random, 95% CI) -3.04 [-3.63, -2.46]
8 Adverse events: death 2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 At end of treatment 2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events: all 2 496 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Central nervous system events
(e.g. confusion, sedation, tremor)
2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Gastrointestinal effects (e.g. con-
stipation, diarrhoea)
2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Recurrent stroke 2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.4 Other events - not listed above
(e.g. dysuria, eye discomfort)
2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events: leaving the study
early (including death)
2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 All dropouts and withdrawals 2 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 2.2.   Comparison 2 Non-invasive brain stimulation versus sham non-invasive brain stimulation
and/or usual care, Outcome 2 Depression: < 50% reduction in scale scores at end of treatment.
Study or subgroup Non-invasive stimulation Sham or usual care Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
2.2.1 HDRS  
Zheng 2016 39/41 29/41 1.34[1.09,1.66]




Analysis 2.3.   Comparison 2 Non-invasive brain stimulation versus sham non-invasive brain
stimulation and/or usual care, Outcome 3 Depression: mean scores at end of treatment.
Study or subgroup Non-invasive
stimulation
Sham or usual care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.3.1 HDRS (high score = more depressed)  
Chen 2005a 16 15.4 (6.7) 16 22.4 (7.1) 10.44% -7[-11.78,-2.22]
Gu 2016 12 6.8 (0.6) 12 10.3 (0.6) 13.91% -3.5[-3.98,-3.02]
Jiang 2014a 50 7 (0.9) 50 17 (1.1) 13.93% -10[-10.39,-9.61]
Meng 2015 54 14.3 (4.5) 54 19.2 (3.1) 13.54% -4.9[-6.36,-3.44]
Yang 2013 19 12.9 (2.3) 19 15.1 (3.3) 13.32% -2.19[-3.99,-0.39]
Yang 2014a 37 7.4 (2.8) 19 18.5 (9.1) 11.1% -11.06[-15.24,-6.88]
Yang 2014b 37 8.6 (3.1) 18 18.5 (9.1) 10.95% -9.9[-14.22,-5.58]
Zheng 2016 41 13.3 (5.6) 41 19.2 (5.8) 12.81% -5.9[-8.37,-3.43]
Subtotal *** 266   229   100% -6.63[-9.71,-3.55]
Heterogeneity: Tau2=17.7; Chi2=467.16, df=7(P<0.0001); I2=98.5%  
Test for overall effect: Z=4.22(P<0.0001)  
   
Total *** 266   229   100% -6.63[-9.71,-3.55]
Heterogeneity: Tau2=17.7; Chi2=467.16, df=7(P<0.0001); I2=98.5%  
Test for overall effect: Z=4.22(P<0.0001)  
Favours Non-invasive stimulation 105-10 -5 0 Favours Sham or usual care
 
 
Analysis 2.4.   Comparison 2 Non-invasive brain stimulation versus sham non-invasive brain
stimulation and/or usual care, Outcome 4 Depression: mean scores at end of follow-up.
Study or subgroup Non-invasive
stimulation
Sham or usual care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 HDRS (high score = more depressed)  
Gu 2016 12 7.8 (1.1) 12 10.3 (1.1) 69.27% -2.5[-3.38,-1.62]
Meng 2015 54 9.3 (2.2) 54 12 (6) 18.42% -2.7[-4.41,-0.99]
Yang 2013 19 7.1 (3.4) 19 10.1 (3.2) 12.32% -3.02[-5.11,-0.93]
Subtotal *** 85   85   100% -2.6[-3.33,-1.87]
Heterogeneity: Tau2=0; Chi2=0.22, df=2(P=0.9); I2=0%  
Test for overall effect: Z=6.96(P<0.0001)  
   
Total *** 85   85   100% -2.6[-3.33,-1.87]
Heterogeneity: Tau2=0; Chi2=0.22, df=2(P=0.9); I2=0%  
Test for overall effect: Z=6.96(P<0.0001)  
Favours Non-invasive stimulation 105-10 -5 0 Favours Sham or usual care
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Analysis 2.5.   Comparison 2 Non-invasive brain stimulation versus sham non-invasive brain
stimulation and/or usual care, Outcome 5 Activities of daily living: mean scores at end of treatment.
Study or subgroup Non-invasive
stimulation
Sham or usual care Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.5.1 Barthel Index (high score = more dependent)  
Meng 2015 54 76.8 (20.4) 54 72.9 (19.3) 50.3% 0.2[-0.18,0.57]
Subtotal *** 54   54   50.3% 0.2[-0.18,0.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
   
2.5.2 ADL (high score = more impairment)  
Jiang 2014a 50 78 (5.1) 50 60 (5.1) 49.7% 3.5[2.87,4.13]
Subtotal *** 50   50   49.7% 3.5[2.87,4.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=10.87(P<0.0001)  
   
Total *** 104   104   100% 1.84[-1.4,5.08]
Heterogeneity: Tau2=5.4; Chi2=77.54, df=1(P<0.0001); I2=98.71%  
Test for overall effect: Z=1.11(P=0.27)  
Test for subgroup differences: Chi2=77.54, df=1 (P<0.0001), I2=98.71%  
Favours Non-invasive stimulation 52.5-5 -2.5 0 Favours Sham or usual care
 
 
Analysis 2.6.   Comparison 2 Non-invasive brain stimulation versus sham non-invasive brain stimulation and/or
usual care, Outcome 6 Neurological function: average change in scores between baseline and end of treatment.
Study or subgroup Non-invasive stimulation Sham or usual care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.6.1 Chinese Stroke Scale (high score = more impairment)  
Meng 2015 54 9.3 (2.8) 54 12.2 (1.8) -2.9[-3.79,-2.01]




Analysis 2.7.   Comparison 2 Non-invasive brain stimulation versus sham non-invasive brain
stimulation and/or usual care, Outcome 7 Neurological function: mean scores at end of treatment.
Study or subgroup Non-invasive
stimulation
Sham or usual care Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.7.1 Chinese Stroke Scale (high score = more impairment)  
Meng 2015 54 9.3 (2.8) 54 12.2 (1.8) 34.32% -1.22[-1.64,-0.81]
Zheng 2016 41 3.7 (1.9) 41 9.2 (2.6) 32.89% -2.39[-2.97,-1.82]
Subtotal *** 95   95   67.21% -1.79[-2.94,-0.64]
Heterogeneity: Tau2=0.62; Chi2=10.54, df=1(P=0); I2=90.52%  
Test for overall effect: Z=3.06(P=0)  
   
2.7.2 National Institutes of Health Stroke Scale (high score = more impairment)  
Jiang 2014a 50 8 (1.2) 50 12 (1.4) 32.79% -3.04[-3.63,-2.46]
Favours Non-invasive stimulation 105-10 -5 0 Favours Sham or usual care
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Study or subgroup Non-invasive
stimulation
Sham or usual care Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 50   50   32.79% -3.04[-3.63,-2.46]
Heterogeneity: Not applicable  
Test for overall effect: Z=10.25(P<0.0001)  
   
Total *** 145   145   100% -2.21[-3.32,-1.09]
Heterogeneity: Tau2=0.9; Chi2=27.77, df=2(P<0.0001); I2=92.8%  
Test for overall effect: Z=3.87(P=0)  
Test for subgroup differences: Chi2=3.66, df=1 (P=0.06), I2=72.67%  
Favours Non-invasive stimulation 105-10 -5 0 Favours Sham or usual care
 
 
Analysis 2.8.   Comparison 2 Non-invasive brain stimulation versus sham non-
invasive brain stimulation and/or usual care, Outcome 8 Adverse events: death.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.8.1 At end of treatment  
Gu 2016 0/12 0/12   Not estimable
Jiang 2014a 0/50 0/50   Not estimable
Subtotal (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Non-invasive stimulation 1000.01 100.1 1 Favours Sham or usual care
 
 
Analysis 2.9.   Comparison 2 Non-invasive brain stimulation versus sham non-
invasive brain stimulation and/or usual care, Outcome 9 Adverse events: all.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.9.1 Central nervous system events (e.g. confusion, sedation, tremor)  
Gu 2016 0/12 0/12   Not estimable
Jiang 2014a 0/50 0/50   Not estimable
Subtotal (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.9.2 Gastrointestinal effects (e.g. constipation, diarrhoea)  
Gu 2016 0/12 0/12   Not estimable
Favours Non-invasive stimulation 1000.01 100.1 1 Favours Sham or usual care
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Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Jiang 2014a 0/50 0/50   Not estimable
Subtotal (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.9.3 Recurrent stroke  
Gu 2016 0/12 0/12   Not estimable
Jiang 2014a 0/50 0/50   Not estimable
Subtotal (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.9.4 Other events - not listed above (e.g. dysuria, eye discomfort)  
Gu 2016 0/12 0/12   Not estimable
Jiang 2014a 0/50 0/50   Not estimable
Subtotal (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 248 248 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours Non-invasive stimulation 1000.01 100.1 1 Favours Sham or usual care
 
 
Analysis 2.10.   Comparison 2 Non-invasive brain stimulation versus sham non-invasive brain
stimulation and/or usual care, Outcome 10 Adverse events: leaving the study early (including death).




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.10.1 All dropouts and withdrawals  
Gu 2016 0/12 0/12   Not estimable
Jiang 2014a 0/50 0/50   Not estimable
Subtotal (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 62 62 Not estimable
Total events: 0 (Non-invasive stimulation), 0 (Sham or usual care)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Non-invasive stimulation 1000.01 100.1 1 Favours Sham or usual care
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Comparison 3.   Psychological therapy versus usual care and/or attention control





Statistical method Effect size
1 Depression: meeting study criteria
for depression at end of treatment
6 521 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.62, 0.95]
1.1 GHQ-28 (high score = greater
psychological distress)
1 254 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.76, 1.05]
1.2 HDRS (high score = more de-
pressed)
4 225 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.54, 0.88]
1.3 HADS (high score = more de-
pressed)
1 42 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.16, 16.85]
2 Depression: < 50% reduction in
scale scores at end of treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Depression: average change in
scores between baseline and end of
treatment
3 189 Mean Difference (IV, Random, 95% CI) -6.20 [-8.24,
-4.16]
3.1 HDRS (high score = more de-
pressed)
3 189 Mean Difference (IV, Random, 95% CI) -6.20 [-8.24,
-4.16]
4 Depression: mean scores at end of
treatment
10   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
4.1 BDI (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 WDI (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 HDRS (high score = more de-
pressed)
5   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 SAD-Q 21-item (high score =
more depressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Zung SDS (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 MADRS (high score= more de-
pressed
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 HADS (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.8 Visual Analog Mood Scale (high
score = more depressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.9 AHI (high score = more de-
pressed
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
4.10 DASS-21 (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Depression: meeting study criteria
for depression at end of follow-up
3 201 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.59, 1.21]
5.1 HDRS (high score = more de-
pressed)
3 201 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.59, 1.21]
6 Depression: average change in
scores between baseline and end of
follow-up
1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
6.1 HDRS (high score = more de-
pressed)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Depression: mean scores at end of
follow-up
5   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
7.1 BDI (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 WDI (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 SAD-Q 21-item (high score =
more depressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 HDRS (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.5 HADS (high score = more de-
pressed)
2   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.6 MADRS (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.7 VAMS (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.8 PHQ-9 (high score = more de-
pressed)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Psychological distress: average
change in scores between baseline
and end of treatment
2 377 Mean Difference (IV, Random, 95% CI) -0.21 [-1.89, 1.48]
8.1 GHQ-28 (high score = greater
psychological distress)
2 377 Mean Difference (IV, Random, 95% CI) -0.21 [-1.89, 1.48]
9 Psychological distress: mean
scores at end of treatment
2 377 Mean Difference (IV, Random, 95% CI) -0.43 [-2.17, 1.31]
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Statistical method Effect size
9.1 GHQ-28 (high score = greater
psychological distress)
2 377 Mean Difference (IV, Random, 95% CI) -0.43 [-2.17, 1.31]
10 Anxiety: meeting study criteria
for anxiety at end of treatment
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
10.1 HADS Anxiety (high score =
more anxious)
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Anxiety: mean scores at end of
treatment
2   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
11.1 HADS Anxiety (high score =
more anxious)
2   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 State Trait Anxiety Inventory-
Trait (high score = more anxious)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.3 State Trait Anxiety Inventory-
State (high score = more anxious)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Anxiety: mean scores at end of
follow-up
1   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
12.1 State Trait Anxiety Inventory -
Trait (high score = more anxious)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 State Trait Anxiety Inventory -
State (high score = more anxious)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Activities of daily living: average
change in scores from baseline to
end of treatment
2 377 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.24, 0.18]
13.1 Nottingham EADL (high score =
more independent)
1 123 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.48, 0.28]
13.2 Barthel Index (high score =
more dependent)
1 254 Std. Mean Difference (IV, Random, 95% CI) 0.0 [-0.25, 0.25]
14 Activities of daily living: mean
scores at end of treatment
8   Std. Mean Difference (IV, Random, 95% CI) Totals not select-
ed
14.1 Barthel Index (high score =
more dependent)
8   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Nottingham EADL (high score =
more independent)
1   Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Activities of daily living: mean
scores at end of follow-up
1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
15.1 Modified Barthel Index (high
score = more dependent)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
16 Disability: mean scores at end of
treatment
2 162 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.48, 0.17]
16.1 WHODAS-II total 1 24 Std. Mean Difference (IV, Random, 95% CI) -0.51 [-1.33, 0.30]
16.2 FIM Motor 1 138 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.44, 0.27]
17 Adverse events: death 8   Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 At end of treatment 8 831 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.26, 1.66]
18 Adverse events: all 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 Recurrent stroke 1 254 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.24, 103.12]
18.2 Vascular events - not stroke
(e.g. transient ischaemic attack)
1 254 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.23, 2.19]
18.3 Other events - not listed above
(e.g. too ill)
2 206 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.15, 6.81]
18.4 Protocol violation (e.g. refused
treatment, withdrew consent)
3 250 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.21, 5.50]
19 Adverse events: leaving the study
early (including death)
8   Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 All dropouts and withdrawals 8 784 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.42, 1.63]
 
 
Analysis 3.1.   Comparison 3 Psychological therapy versus usual care and/or attention
control, Outcome 1 Depression: meeting study criteria for depression at end of treatment.
Study or subgroup Psychotherapy Usual care/
attention cont
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 GHQ-28 (high score = greater psychological distress)  
Watkins 2007 85/127 95/127 39.68% 0.89[0.76,1.05]
Subtotal (95% CI) 127 127 39.68% 0.89[0.76,1.05]
Total events: 85 (Psychotherapy), 95 (Usual care/attention cont)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.38(P=0.17)  
   
3.1.2 HDRS (high score = more depressed)  
Alexopoulos 2012 4/12 10/12 5.58% 0.4[0.17,0.93]
Kirkness 2017a 20/35 9/14 13.75% 0.89[0.55,1.44]
Kirkness 2017b 21/37 10/14 16.05% 0.79[0.51,1.23]
Mitchell 2002 24/48 43/53 24.12% 0.62[0.45,0.84]
Subtotal (95% CI) 132 93 59.51% 0.69[0.54,0.88]
Total events: 69 (Psychotherapy), 72 (Usual care/attention cont)  
Favours Psychotherapy 1000.01 100.1 1 Favours Usual care/attention cont
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Study or subgroup Psychotherapy Usual care/
attention cont
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.01; Chi2=3.65, df=3(P=0.3); I2=17.82%  
Test for overall effect: Z=2.93(P=0)  
   
3.1.3 HADS (high score = more depressed)  
Fang 2017 2/23 1/19 0.81% 1.65[0.16,16.85]
Subtotal (95% CI) 23 19 0.81% 1.65[0.16,16.85]
Total events: 2 (Psychotherapy), 1 (Usual care/attention cont)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.67)  
   
Total (95% CI) 282 239 100% 0.77[0.62,0.95]
Total events: 156 (Psychotherapy), 168 (Usual care/attention cont)  
Heterogeneity: Tau2=0.02; Chi2=7.83, df=5(P=0.17); I2=36.16%  
Test for overall effect: Z=2.44(P=0.01)  
Test for subgroup differences: Chi2=3.33, df=1 (P=0.19), I2=39.98%  
Favours Psychotherapy 1000.01 100.1 1 Favours Usual care/attention cont
 
 
Analysis 3.3.   Comparison 3 Psychological therapy versus usual care and/or attention control,
Outcome 3 Depression: average change in scores between baseline and end of treatment.
Study or subgroup Psychotherapy Usual care/
attention cont
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.3.1 HDRS (high score = more depressed)  
Kirkness 2017a 31 -40.2 (25.3) 13 -33.2 (22.5) 1.82% -7.02[-22.15,8.11]
Kirkness 2017b 34 -38.4 (27.8) 13 -33.2 (22.5) 1.76% -5.21[-20.6,10.18]
Mitchell 2002 45 -9.8 (4.9) 53 -3.6 (5.6) 96.42% -6.2[-8.28,-4.12]
Subtotal *** 110   79   100% -6.2[-8.24,-4.16]
Heterogeneity: Tau2=0; Chi2=0.03, df=2(P=0.99); I2=0%  
Test for overall effect: Z=5.95(P<0.0001)  
   
Total *** 110   79   100% -6.2[-8.24,-4.16]
Heterogeneity: Tau2=0; Chi2=0.03, df=2(P=0.99); I2=0%  
Test for overall effect: Z=5.95(P<0.0001)  
Favours Psychotherapy 105-10 -5 0 Favours Usual care/attention cont
 
 
Analysis 3.4.   Comparison 3 Psychological therapy versus usual care and/
or attention control, Outcome 4 Depression: mean scores at end of treatment.
Study or subgroup Psychotherapy Usual care/attention cont Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.4.1 BDI (high score = more depressed)  
Lincoln 2003 39 15.2 (10.1) 84 15 (8.4) 0.02[-0.36,0.4]
   
3.4.2 WDI (high score = more depressed)  
Lincoln 2003 39 19 (8.3) 84 19 (7.1) -0[-0.38,0.38]
Favours Psychotherapy 52.5-5 -2.5 0 Favours Usual care/at-
tention cont
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Study or subgroup Psychotherapy Usual care/attention cont Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
   
3.4.3 HDRS (high score = more depressed)  
Alexopoulos 2012 12 8.2 (6.6) 12 13.2 (5.4) -0.8[-1.64,0.04]
Cao 2009b 72 36.2 (5) 72 38.8 (5.7) -0.48[-0.81,-0.15]
Gao 2017b 92 8.5 (2.7) 46 8.5 (3.4) 0[-0.35,0.35]
Mitchell 2002 48 10.3 (5.3) 53 16.2 (7) -0.94[-1.35,-0.53]
Zhao 2004 35 14.4 (3.1) 35 21.1 (2.5) -2.35[-2.97,-1.73]
   
3.4.4 SAD-Q 21-item (high score = more depressed)  
Thomas 2007 51 16.9 (10.2) 54 19.2 (9.6) -0.23[-0.61,0.15]
   
3.4.5 Zung SDS (high score = more depressed)  
Wang 2004a 35 40.2 (7.6) 35 44.2 (8.4) -0.48[-0.96,-0.01]
   
3.4.6 MADRS (high score= more depressed  
Hoffmann 2015 12 19.4 (1.2) 10 18.5 (0.7) 0.85[-0.03,1.74]
   
3.4.7 HADS (high score = more depressed)  
Hoffmann 2015 12 8.2 (1.4) 10 8.2 (0.9) 0.01[-0.83,0.85]
   
3.4.8 Visual Analog Mood Scale (high score = more depressed)  
Thomas 2007 51 26.5 (22.3) 54 36.3 (28.4) -0.38[-0.77,0.01]
   
3.4.9 AHI (high score = more depressed  
Cullen 2018 12 2.7 (0.6) 12 2.1 (0.6) 0.99[0.13,1.85]
   
3.4.10 DASS-21 (high score = more depressed)  
Cullen 2018 12 13.5 (11.5) 12 28.5 (11.6) -1.26[-2.15,-0.37]




Analysis 3.5.   Comparison 3 Psychological therapy versus usual care and/or attention
control, Outcome 5 Depression: meeting study criteria for depression at end of follow-up.
Study or subgroup Psychotherapy Usual care/
attention cont
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.5.1 HDRS (high score = more depressed)  
Kirkness 2017a 13/35 5/14 17.04% 1.04[0.46,2.37]
Kirkness 2017b 15/37 4/14 14.02% 1.42[0.57,3.54]
Mitchell 2002 23/48 35/53 68.94% 0.73[0.51,1.03]
Subtotal (95% CI) 120 81 100% 0.85[0.59,1.21]
Total events: 51 (Psychotherapy), 44 (Usual care/attention cont)  
Heterogeneity: Tau2=0.02; Chi2=2.25, df=2(P=0.32); I2=11.17%  
Test for overall effect: Z=0.91(P=0.36)  
   
Total (95% CI) 120 81 100% 0.85[0.59,1.21]
Total events: 51 (Psychotherapy), 44 (Usual care/attention cont)  
Heterogeneity: Tau2=0.02; Chi2=2.25, df=2(P=0.32); I2=11.17%  
Test for overall effect: Z=0.91(P=0.36)  
Favours Psychotherapy 1000.01 100.1 1 Favours Usual care/attention cont
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Analysis 3.6.   Comparison 3 Psychological therapy versus usual care and/or attention control,
Outcome 6 Depression: average change in scores between baseline and end of follow-up.
Study or subgroup Psychotherapy Usual care/attention cont Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
3.6.1 HDRS (high score = more depressed)  
Mitchell 2002 48 -9.2 (5.7) 53 -6.2 (6.4) -3[-5.36,-0.64]




Analysis 3.7.   Comparison 3 Psychological therapy versus usual care and/
or attention control, Outcome 7 Depression: mean scores at end of follow-up.
Study or subgroup Psychotherapy Usual care/attention cont Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.7.1 BDI (high score = more depressed)  
Lincoln 2003 39 14.3 (8) 84 15.3 (8.7) -0.12[-0.5,0.26]
   
3.7.2 WDI (high score = more depressed)  
Lincoln 2003 39 19.2 (7.3) 84 19.7 (8.8) -0.06[-0.44,0.32]
   
3.7.3 SAD-Q 21-item (high score = more depressed)  
Thomas 2007 51 17.4 (10) 54 21.9 (9.5) -0.46[-0.85,-0.07]
   
3.7.4 HDRS (high score = more depressed)  
Mitchell 2002 48 8.7 (6) 53 11.3 (6.3) -0.41[-0.81,-0.02]
   
3.7.5 HADS (high score = more depressed)  
Hoffmann 2015 12 4.6 (2.7) 10 8.9 (1.7) -1.78[-2.81,-0.76]
Kerr 2018 4 4.5 (3.9) 6 7 (2.7) -0.7[-2.03,0.62]
   
3.7.6 MADRS (high score = more depressed)  
Hoffmann 2015 12 19.8 (1.8) 10 18.7 (1.1) 0.73[-0.14,1.6]
   
3.7.7 VAMS (high score = more depressed)  
Thomas 2007 51 25.5 (21.5) 54 32.1 (29.3) -0.25[-0.64,0.13]
   
3.7.8 PHQ-9 (high score = more depressed)  
Kerr 2018 4 1.7 (2.9) 6 6 (7.4) -0.64[-1.95,0.68]




Analysis 3.8.   Comparison 3 Psychological therapy versus usual care and/or attention control,
Outcome 8 Psychological distress: average change in scores between baseline and end of treatment.
Study or subgroup Psychotherapy Usual care/
attention cont
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.8.1 GHQ-28 (high score = greater psychological distress)  
Lincoln 2003 39 -6.2 (15.3) 84 -7 (15.3) 8.38% 0.82[-4.99,6.63]
Favours Psychotherapy 105-10 -5 0 Favours Usual care/attention cont
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Study or subgroup Psychotherapy Usual care/
attention cont
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Watkins 2007 127 -1.3 (7.1) 127 -1 (7.2) 91.62% -0.3[-2.06,1.46]
Subtotal *** 166   211   100% -0.21[-1.89,1.48]
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
   
Total *** 166   211   100% -0.21[-1.89,1.48]
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
Favours Psychotherapy 105-10 -5 0 Favours Usual care/attention cont
 
 
Analysis 3.9.   Comparison 3 Psychological therapy versus usual care and/or attention
control, Outcome 9 Psychological distress: mean scores at end of treatment.
Study or subgroup Psychotherapy Usual care/
attention cont
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.9.1 GHQ-28 (high score = greater psychological distress)  
Lincoln 2003 39 28.8 (16.7) 84 27 (15.2) 7.93% 1.79[-4.38,7.96]
Watkins 2007 127 9 (7.7) 127 9.6 (7) 92.07% -0.62[-2.43,1.19]
Subtotal *** 166   211   100% -0.43[-2.17,1.31]
Heterogeneity: Tau2=0; Chi2=0.54, df=1(P=0.46); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
   
Total *** 166   211   100% -0.43[-2.17,1.31]
Heterogeneity: Tau2=0; Chi2=0.54, df=1(P=0.46); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
Favours Psychotherapy 105-10 -5 0 Favours Usual care/attention cont
 
 
Analysis 3.10.   Comparison 3 Psychological therapy versus usual care and/or attention
control, Outcome 10 Anxiety: meeting study criteria for anxiety at end of treatment.
Study or subgroup Psychotherapy Usual care/attention cont Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
3.10.1 HADS Anxiety (high score = more anxious)  
Fang 2017 4/23 2/19 1.65[0.34,8.06]




Analysis 3.11.   Comparison 3 Psychological therapy versus usual care and/
or attention control, Outcome 11 Anxiety: mean scores at end of treatment.
Study or subgroup Psychotherapy Usual care/attention cont Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.11.1 HADS Anxiety (high score = more anxious)  
Hoffmann 2015 12 8.1 (1) 10 7.6 (0.5) 0.61[-0.25,1.48]
Favours Psychotherapy 105-10 -5 0 Favours Usual care/at-
tention cont
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Study or subgroup Psychotherapy Usual care/attention cont Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Kerr 2018 4 4.5 (4) 6 8.2 (4.8) -0.74[-2.07,0.59]
   
3.11.2 State Trait Anxiety Inventory- Trait (high score = more anxious)  
Hoffmann 2015 12 46.2 (1.1) 10 43.6 (0.6) 2.84[1.59,4.1]
   
3.11.3 State Trait Anxiety Inventory- State (high score = more anxious)  
Hoffmann 2015 12 45 (2.3) 10 45.8 (1.3) -0.41[-1.26,0.44]




Analysis 3.12.   Comparison 3 Psychological therapy versus usual care and/
or attention control, Outcome 12 Anxiety: mean scores at end of follow-up.
Study or subgroup Psychotherapy Usual care/attention cont Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.12.1 State Trait Anxiety Inventory - Trait (high score = more anxious)  
Hoffmann 2015 12 44.7 (1.4) 10 43.9 (0.8) 0.6[-0.26,1.46]
   
3.12.2 State Trait Anxiety Inventory - State (high score = more anxious)  
Hoffmann 2015 12 46.3 (3.3) 10 44.9 (1.9) 0.46[-0.39,1.32]




Analysis 3.13.   Comparison 3 Psychological therapy versus usual care and/or attention control,
Outcome 13 Activities of daily living: average change in scores from baseline to end of treatment.
Study or subgroup Psychotherapy Usual care/
attention cont
Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.13.1 Nottingham EADL (high score = more independent)  
Lincoln 2003 39 -5.4 (13.3) 84 -4 (14.7) 29.53% -0.1[-0.48,0.28]
Subtotal *** 39   84   29.53% -0.1[-0.48,0.28]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.5(P=0.62)  
   
3.13.2 Barthel Index (high score = more dependent)  
Watkins 2007 127 -1.4 (3.9) 127 -1.4 (4.4) 70.47% 0[-0.25,0.25]
Subtotal *** 127   127   70.47% 0[-0.25,0.25]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 166   211   100% -0.03[-0.24,0.18]
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=0.27(P=0.78)  
Test for subgroup differences: Chi2=0.18, df=1 (P=0.67), I2=0%  
Favours Psychotherapy 21-2 -1 0 Favours Usual care/attention cont
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Analysis 3.14.   Comparison 3 Psychological therapy versus usual care and/or attention
control, Outcome 14 Activities of daily living: mean scores at end of treatment.
Study or subgroup Psychotherapy Usual care/attention cont Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.14.1 Barthel Index (high score = more dependent)  
Cao 2009b 72 42.7 (8.3) 72 36.3 (7.5) 0.8[0.46,1.14]
Gao 2017b 92 69.3 (16.9) 46 72.3 (15.9) -0.18[-0.53,0.17]
Hoffmann 2015 12 68.2 (2.8) 10 70.2 (2.1) -0.78[-1.66,0.09]
Kerr 2018 4 95.7 (7.2) 6 97.8 (7.1) -0.27[-1.54,1.01]
Kirkness 2017a 35 94.7 (15) 14 91.7 (17.3) 0.19[-0.43,0.81]
Kirkness 2017b 37 91.2 (18.2) 14 91.7 (17.3) -0.03[-0.64,0.59]
Mitchell 2002 48 85.5 (25.1) 53 86.7 (17.9) -0.06[-0.45,0.34]
Watkins 2007 127 16.2 (4.3) 127 16.8 (3.8) -0.15[-0.39,0.1]
   
3.14.2 Nottingham EADL (high score = more independent)  
Hoffmann 2015 12 34.7 (6.5) 10 39.7 (3.5) -0.89[-1.78,-0]




Analysis 3.15.   Comparison 3 Psychological therapy versus usual care and/or attention
control, Outcome 15 Activities of daily living: mean scores at end of follow-up.
Study or subgroup Psychotherapy Usual care/attention cont Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
3.15.1 Modified Barthel Index (high score = more dependent)  
Hoffmann 2015 2 76.3 (5.6) 5 76.4 (4.3) -0.12[-8.73,8.49]




Analysis 3.16.   Comparison 3 Psychological therapy versus usual care and/
or attention control, Outcome 16 Disability: mean scores at end of treatment.
Study or subgroup Psychotherapy Usual care/
attention cont
Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.16.1 WHODAS-II total  
Alexopoulos 2012 12 24.5 (8.5) 12 29.5 (10.2) 15.85% -0.51[-1.33,0.3]
Subtotal *** 12   12   15.85% -0.51[-1.33,0.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.24(P=0.22)  
   
3.16.2 FIM Motor  
Gao 2017b 92 69.9 (18.1) 46 71.5 (17.6) 84.15% -0.09[-0.44,0.27]
Subtotal *** 92   46   84.15% -0.09[-0.44,0.27]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
   
Total *** 104   58   100% -0.16[-0.48,0.17]
Heterogeneity: Tau2=0; Chi2=0.88, df=1(P=0.35); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
Favours Psychotherapy 21-2 -1 0 Favours Usual care/attention cont
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Study or subgroup Psychotherapy Usual care/
attention cont
Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for subgroup differences: Chi2=0.88, df=1 (P=0.35), I2=0%  
Favours Psychotherapy 21-2 -1 0 Favours Usual care/attention cont
 
 
Analysis 3.17.   Comparison 3 Psychological therapy versus usual
care and/or attention control, Outcome 17 Adverse events: death.
Study or subgroup Psychotherapy Usual care/
attention cont
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.17.1 At end of treatment  
Alexopoulos 2012 2/12 0/12 10.03% 5[0.27,94.34]
Fang 2017 0/23 0/19   Not estimable
Gao 2017b 1/92 1/46 11.45% 0.5[0.03,7.81]
Lincoln 2003 0/39 2/84 9.53% 0.43[0.02,8.65]
Mitchell 2002 2/48 0/53 9.54% 5.51[0.27,111.97]
Thomas 2007 0/51 1/54 8.57% 0.35[0.01,8.46]
Towle 1989 0/21 0/23   Not estimable
Watkins 2007 3/127 8/127 50.89% 0.38[0.1,1.38]
Subtotal (95% CI) 413 418 100% 0.65[0.26,1.66]
Total events: 8 (Psychotherapy), 12 (Usual care/attention cont)  
Heterogeneity: Tau2=0; Chi2=4.8, df=5(P=0.44); I2=0%  
Test for overall effect: Z=0.9(P=0.37)  
Favours Psychotherapy 1000.01 100.1 1 Favours Usual care/attention cont
 
 
Analysis 3.18.   Comparison 3 Psychological therapy versus usual
care and/or attention control, Outcome 18 Adverse events: all.
Study or subgroup Psychotherapy Usual care/
attention cont
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.18.1 Recurrent stroke  
Watkins 2007 2/127 0/127 100% 5[0.24,103.12]
Subtotal (95% CI) 127 127 100% 5[0.24,103.12]
Total events: 2 (Psychotherapy), 0 (Usual care/attention cont)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
3.18.2 Vascular events - not stroke (e.g. transient ischaemic attack)  
Watkins 2007 5/127 7/127 100% 0.71[0.23,2.19]
Subtotal (95% CI) 127 127 100% 0.71[0.23,2.19]
Total events: 5 (Psychotherapy), 7 (Usual care/attention cont)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
3.18.3 Other events - not listed above (e.g. too ill)  
Mitchell 2002 1/48 0/53 35.75% 3.31[0.14,79.28]
Favours Psychotherapy 2000.005 100.1 1 Favours Usual care/attention cont
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Study or subgroup Psychotherapy Usual care/
attention cont
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Thomas 2007 1/51 2/54 64.25% 0.53[0.05,5.66]
Subtotal (95% CI) 99 107 100% 1.02[0.15,6.81]
Total events: 2 (Psychotherapy), 2 (Usual care/attention cont)  
Heterogeneity: Tau2=0; Chi2=0.82, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
   
3.18.4 Protocol violation (e.g. refused treatment, withdrew consent)  
Mitchell 2002 1/48 3/53 30.46% 0.37[0.04,3.42]
Thomas 2007 9/51 3/54 50.12% 3.18[0.91,11.08]
Towle 1989 0/21 1/23 19.42% 0.36[0.02,8.47]
Subtotal (95% CI) 120 130 100% 1.08[0.21,5.5]
Total events: 10 (Psychotherapy), 7 (Usual care/attention cont)  
Heterogeneity: Tau2=0.97; Chi2=3.69, df=2(P=0.16); I2=45.78%  
Test for overall effect: Z=0.09(P=0.92)  
Favours Psychotherapy 2000.005 100.1 1 Favours Usual care/attention cont
 
 
Analysis 3.19.   Comparison 3 Psychological therapy versus usual care and/or attention
control, Outcome 19 Adverse events: leaving the study early (including death).
Study or subgroup Psychotherapy Usual care/
attention cont
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.19.1 All dropouts and withdrawals  
Alexopoulos 2012 3/12 1/12 10.22% 3[0.36,24.92]
Gao 2017b 5/92 3/46 23.81% 0.83[0.21,3.34]
Kirkness 2017a 4/35 1/14 10.37% 1.6[0.2,13.09]
Kirkness 2017b 3/37 1/14 9.66% 1.14[0.13,10.02]
Lincoln 2003 1/39 4/84 9.84% 0.54[0.06,4.66]
Mitchell 2002 1/48 0/53 4.54% 3.31[0.14,79.28]
Towle 1989 0/21 1/23 4.62% 0.36[0.02,8.47]
Watkins 2007 3/127 8/127 26.94% 0.38[0.1,1.38]
Subtotal (95% CI) 411 373 100% 0.83[0.42,1.63]
Total events: 20 (Psychotherapy), 19 (Usual care/attention cont)  
Heterogeneity: Tau2=0; Chi2=4.44, df=7(P=0.73); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
Favours Psychotherapy 1000.01 100.1 1 Favours Usual care/attention cont
 
 
Comparison 4.   Pharmacological intervention and psychotherapy (combination) versus a pharmacological
intervention and usual care or attention control (single)





Statistical method Effect size
1 Depression: meeting study criteria
for depression at end of treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
2 Depression: < 50% reduction in
scale scores at end of treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Depression: mean scores at end of
treatment
2 198 Mean Difference (IV, Fixed, 95% CI) -1.53 [-2.10, -0.96]
3.1 HDRS (high score = more de-
pressed)
2 198 Mean Difference (IV, Fixed, 95% CI) -1.53 [-2.10, -0.96]
4 Anxiety: mean scores at end of
treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 HAMA (high score = more anxious) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Activities of daily living: mean
scores at end of treatment
2 198 Mean Difference (IV, Random, 95% CI) 11.83 [0.27, 23.40]
5.1 Barthel Index (high score = more
dependent)
2 198 Mean Difference (IV, Random, 95% CI) 11.83 [0.27, 23.40]
6 Neurological function: mean scores
at end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Scandinavian Stroke Scale (low
score = more neurological deficit)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Adverse events: death 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 At end of treatment 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse events: all 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Gastrointestinal effects (e.g. con-
stipation, diarrhoea)
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events: leaving the study
early (including death)
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 All dropouts and withdrawals 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 4.3.   Comparison 4 Pharmacological intervention and psychotherapy
(combination) versus a pharmacological intervention and usual care or attention
control (single), Outcome 3 Depression: mean scores at end of treatment.
Study or subgroup Combination
treatment
Single treatment Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
4.3.1 HDRS (high score = more depressed)  
Cao 2009a 72 26.7 (5) 72 30.2 (4.2) 14.22% -3.5[-5.01,-1.99]
Wang 2005a 27 8.9 (1.2) 27 10.1 (1.1) 85.78% -1.2[-1.81,-0.59]
Favours Combination treatment 105-10 -5 0 Favours Single treatment
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Study or subgroup Combination
treatment
Single treatment Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Subtotal *** 99   99   100% -1.53[-2.1,-0.96]
Heterogeneity: Tau2=0; Chi2=7.66, df=1(P=0.01); I2=86.95%  
Test for overall effect: Z=5.26(P<0.0001)  
   
Total *** 99   99   100% -1.53[-2.1,-0.96]
Heterogeneity: Tau2=0; Chi2=7.66, df=1(P=0.01); I2=86.95%  
Test for overall effect: Z=5.26(P<0.0001)  
Favours Combination treatment 105-10 -5 0 Favours Single treatment
 
 
Analysis 4.4.   Comparison 4 Pharmacological intervention and psychotherapy
(combination) versus a pharmacological intervention and usual care or
attention control (single), Outcome 4 Anxiety: mean scores at end of treatment.
Study or subgroup Combination treatment Single treatment Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
4.4.1 HAMA (high score = more anxious)  
Wang 2005a 27 3.8 (1.8) 27 5.4 (1.7) -1.6[-2.53,-0.67]
Favours Combination treatment 105-10 -5 0 Favours Single treatment
 
 
Analysis 4.5.   Comparison 4 Pharmacological intervention and psychotherapy
(combination) versus a pharmacological intervention and usual care or attention
control (single), Outcome 5 Activities of daily living: mean scores at end of treatment.
Study or subgroup Combination
treatment
Single treatment Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.5.1 Barthel Index (high score = more dependent)  
Cao 2009a 72 80.1 (10.3) 72 62.4 (13) 50.28% 17.7[13.87,21.53]
Wang 2005a 27 90.2 (7.3) 27 84.3 (8.4) 49.72% 5.9[1.7,10.1]
Subtotal *** 99   99   100% 11.83[0.27,23.4]
Heterogeneity: Tau2=65.42; Chi2=16.56, df=1(P<0.0001); I2=93.96%  
Test for overall effect: Z=2.01(P=0.04)  
   
Total *** 99   99   100% 11.83[0.27,23.4]
Heterogeneity: Tau2=65.42; Chi2=16.56, df=1(P<0.0001); I2=93.96%  
Test for overall effect: Z=2.01(P=0.04)  
Favours Combination treatment 10050-100 -50 0 Favours Single treatment
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Analysis 4.6.   Comparison 4 Pharmacological intervention and psychotherapy
(combination) versus a pharmacological intervention and usual care or attention
control (single), Outcome 6 Neurological function: mean scores at end of treatment.
Study or subgroup Combination treatment Single treatment Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
4.6.1 Scandinavian Stroke Scale (low score = more neurological deficit)  
Wang 2005a 27 5 (1.8) 27 6.5 (1.6) -1.5[-2.41,-0.59]
Favours Combination treatment 105-10 -5 0 Favours Single treatment
 
 
Analysis 4.7.   Comparison 4 Pharmacological intervention and psychotherapy (combination) versus a
pharmacological intervention and usual care or attention control (single), Outcome 7 Adverse events: death.
Study or subgroup Combination treatment Single treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
4.7.1 At end of treatment  
Wang 2005a 0/27 0/27 Not estimable
Favours Combination treatment 1000.01 100.1 1 Favours Single treatment
 
 
Analysis 4.8.   Comparison 4 Pharmacological intervention and psychotherapy (combination) versus a
pharmacological intervention and usual care or attention control (single), Outcome 8 Adverse events: all.
Study or subgroup Combination treatment Single treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
4.8.1 Gastrointestinal effects (e.g. constipation, diarrhoea)  
Wang 2005a 10/27 9/27 1.11[0.54,2.3]
Favours Combination treatment 1000.01 100.1 1 Favours Single treatment
 
 
Analysis 4.9.   Comparison 4 Pharmacological intervention and psychotherapy
(combination) versus a pharmacological intervention and usual care or attention
control (single), Outcome 9 Adverse events: leaving the study early (including death).
Study or subgroup Combination treatment Single treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
4.9.1 All dropouts and withdrawals  
Wang 2005a 0/27 0/27 Not estimable
Favours Combination treatment 1000.01 100.1 1 Favours Single treatment
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Comparison 5.   Non-invasive brain stimulation and a pharmacological intervention (combination) versus a
pharmacological intervention and sham stimulation or usual care (single)





Statistical method Effect size
1 Depression: meeting the crite-
ria for depression at end of treat-
ment
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 HDRS (high score = more de-
pressed)
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Depression: < 50% reduction in
scale scores at end of treatment
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 HDRS 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Depression: mean scores at end
of treatment
9 685 Mean Difference (IV, Random, 95% CI) -4.09 [-5.61, -2.57]
3.1 HDRS (high score = more de-
pressed)
9 685 Mean Difference (IV, Random, 95% CI) -4.09 [-5.61, -2.57]
4 Depression: mean scores at end
of follow-up
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 HDRS (high score = more de-
pressed)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Cognitive function: mean scores
at end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 MMSE (low score = cognitive
impairment)
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Activities of daily living: mean
scores at end of treatment
5 403 Std. Mean Difference (IV, Random, 95% CI) 2.03 [1.21, 2.85]
6.1 Barthel Index (high score =
more dependent)
3 243 Std. Mean Difference (IV, Random, 95% CI) 2.49 [1.78, 3.19]
6.2 ADL (high score = more im-
pairment)
2 160 Std. Mean Difference (IV, Random, 95% CI) 1.33 [-0.28, 2.94]
7 Disability: mean scores at end
of treatment
2 180 Mean Difference (IV, Random, 95% CI) -10.02 [-20.14, 0.11]
7.1 SDS (high score = more dis-
ability
2 180 Mean Difference (IV, Random, 95% CI) -10.02 [-20.14, 0.11]
8 Neurological function: mean
scores at end of treatment
4 280 Mean Difference (IV, Random, 95% CI) -2.78 [-4.13, -1.44]
8.1 NIHSS (high score = more im-
pairment)
4 280 Mean Difference (IV, Random, 95% CI) -2.78 [-4.13, -1.44]
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Statistical method Effect size
9 Adverse events: death 3 220 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 At end of treatment 3 220 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events: all 2 120 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.38, 129.93]
10.1 Other events - not listed
above (e.g. insomnia, discomfort,
headaches)
2 120 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.38, 129.93]
11 Adverse events: leaving the
study early (including death)
4 300 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.32, 5.58]
11.1 All dropouts and with-
drawals
4 300 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.32, 5.58]
 
 
Analysis 5.1.   Comparison 5 Non-invasive brain stimulation and a pharmacological intervention
(combination) versus a pharmacological intervention and sham stimulation or usual care
(single), Outcome 1 Depression: meeting the criteria for depression at end of treatment.
Study or subgroup Combination treatment Single treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
5.1.1 HDRS (high score = more depressed)  
Du 2005 10/30 14/30 0.71[0.38,1.35]
Favours Combination treatment 1000.01 100.1 1 Favours Single treatment
 
 
Analysis 5.2.   Comparison 5 Non-invasive brain stimulation and a pharmacological intervention
(combination) versus a pharmacological intervention and sham stimulation or usual
care (single), Outcome 2 Depression: < 50% reduction in scale scores at end of treatment.
Study or subgroup Favours Combi-
nation treatment
Single treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
5.2.1 HDRS  
Li 2013 26/30 21/30 1.24[0.94,1.63]
Favours Combination treatment 1000.01 100.1 1 Favours Single treatment
 
 
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)









Cochrane Database of Systematic Reviews
Analysis 5.3.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and sham stimulation
or usual care (single), Outcome 3 Depression: mean scores at end of treatment.
Study or subgroup Combination
treatment
Single treatment Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.3.1 HDRS (high score = more depressed)  
Du 2005 30 6 (5) 30 13 (7) 8.61% -7[-10.08,-3.92]
Fan 2014 45 15.3 (2.4) 45 16.7 (2.7) 12.53% -1.39[-2.43,-0.35]
Jin 2013 30 14.1 (3.7) 30 19.8 (2.9) 11.46% -5.71[-7.38,-4.04]
Li 2013 30 13.3 (3.6) 30 14.7 (3.9) 11.02% -1.44[-3.34,0.46]
Li 2014 47 7.2 (3.6) 46 11.2 (3.2) 12% -4.04[-5.41,-2.67]
Liu 2015 30 13.5 (3.1) 30 19.8 (2.8) 11.77% -6.33[-7.83,-4.83]
Lu 2016 40 16.4 (7) 40 24.5 (6.8) 8.7% -8.05[-11.08,-5.02]
Sun 2013 50 19.8 (3.3) 50 21.2 (3.3) 12.13% -1.44[-2.74,-0.14]
Zhang 2013 41 9.5 (3.5) 41 12.8 (3.5) 11.78% -3.33[-4.83,-1.83]
Subtotal *** 343   342   100% -4.09[-5.61,-2.57]
Heterogeneity: Tau2=4.53; Chi2=64.31, df=8(P<0.0001); I2=87.56%  
Test for overall effect: Z=5.26(P<0.0001)  
   
Total *** 343   342   100% -4.09[-5.61,-2.57]
Heterogeneity: Tau2=4.53; Chi2=64.31, df=8(P<0.0001); I2=87.56%  
Test for overall effect: Z=5.26(P<0.0001)  
Favours Combination treatment 105-10 -5 0 Favours Single treatment
 
 
Analysis 5.4.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and sham stimulation
or usual care (single), Outcome 4 Depression: mean scores at end of follow-up.
Study or subgroup Combination treatment Single treatment Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
5.4.1 HDRS (high score = more depressed)  
Jiang 2014b 50 5 (0.8) 50 8 (1.2) -3[-3.4,-2.6]
Favours Combination treatment 105-10 -5 0 Favours Single treatment
 
 
Analysis 5.5.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and sham stimulation
or usual care (single), Outcome 5 Cognitive function: mean scores at end of treatment.
Study or subgroup Combination treatment Single treatment Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
5.5.1 MMSE (low score = cognitive impairment)  
Du 2005 30 24 (7) 30 18 (6) 6[2.7,9.3]
Favours Combination treatment 10050-100 -50 0 Favours Single treatment
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Analysis 5.6.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and sham stimulation
or usual care (single), Outcome 6 Activities of daily living: mean scores at end of treatment.
Study or subgroup Combination
treatment
Single treatment Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.6.1 Barthel Index (high score = more dependent)  
Du 2005 30 78 (2) 30 53 (10) 18.24% 3.42[2.61,4.23]
Fan 2014 45 79.4 (6.4) 45 66.7 (5.6) 20.39% 2.1[1.58,2.62]
Li 2014 47 78.3 (6.3) 46 65.6 (5.5) 20.42% 2.14[1.63,2.65]
Subtotal *** 122   121   59.05% 2.49[1.78,3.19]
Heterogeneity: Tau2=0.29; Chi2=8.24, df=2(P=0.02); I2=75.72%  
Test for overall effect: Z=6.93(P<0.0001)  
   
5.6.2 ADL (high score = more impairment)  
Jiang 2014b 50 87 (6.2) 50 75 (4.8) 20.53% 2.15[1.65,2.64]
Li 2013 30 67.5 (5.4) 30 64.5 (6.1) 20.42% 0.51[-0.01,1.02]
Subtotal *** 80   80   40.95% 1.33[-0.28,2.94]
Heterogeneity: Tau2=1.28; Chi2=20.28, df=1(P<0.0001); I2=95.07%  
Test for overall effect: Z=1.62(P=0.11)  
   
Total *** 202   201   100% 2.03[1.21,2.85]
Heterogeneity: Tau2=0.79; Chi2=44.09, df=4(P<0.0001); I2=90.93%  
Test for overall effect: Z=4.86(P<0.0001)  
Test for subgroup differences: Chi2=1.67, df=1 (P=0.2), I2=40.03%  
Favours Combination treatment 52.5-5 -2.5 0 Favours Single treatment
 
 
Analysis 5.7.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and sham stimulation
or usual care (single), Outcome 7 Disability: mean scores at end of treatment.
Study or subgroup Combination
treatment
Single treatment Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.7.1 SDS (high score = more disability  
Lu 2016 40 47.5 (9.3) 40 62.9 (12.2) 47.64% -15.43[-20.18,-10.68]
Sun 2013 50 26.6 (4.2) 50 31.7 (4.9) 52.36% -5.09[-6.87,-3.31]
Subtotal *** 90   90   100% -10.02[-20.14,0.11]
Heterogeneity: Tau2=50.11; Chi2=15.97, df=1(P<0.0001); I2=93.74%  
Test for overall effect: Z=1.94(P=0.05)  
   
Total *** 90   90   100% -10.02[-20.14,0.11]
Heterogeneity: Tau2=50.11; Chi2=15.97, df=1(P<0.0001); I2=93.74%  
Test for overall effect: Z=1.94(P=0.05)  
Favours Combination treatment 10050-100 -50 0 Favours Single treatment
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Analysis 5.8.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and sham stimulation
or usual care (single), Outcome 8 Neurological function: mean scores at end of treatment.
Study or subgroup Combination
treatment
Single treatment Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.8.1 NIHSS (high score = more impairment)  
Jiang 2014b 50 5 (0.9) 50 9 (1.5) 30.48% -4[-4.48,-3.52]
Jin 2013 30 6.1 (2.1) 30 8.6 (3.1) 24.09% -2.54[-3.89,-1.19]
Li 2013 30 10.3 (2.5) 30 11.5 (3.1) 23.55% -1.18[-2.59,0.23]
Liu 2015 30 6.1 (3) 30 9.2 (3.3) 21.88% -3.08[-4.68,-1.48]
Subtotal *** 140   140   100% -2.78[-4.13,-1.44]
Heterogeneity: Tau2=1.48; Chi2=16.68, df=3(P=0); I2=82.02%  
Test for overall effect: Z=4.05(P<0.0001)  
   
Total *** 140   140   100% -2.78[-4.13,-1.44]
Heterogeneity: Tau2=1.48; Chi2=16.68, df=3(P=0); I2=82.02%  
Test for overall effect: Z=4.05(P<0.0001)  
Favours Combination treatment 105-10 -5 0 Favours Single treatment
 
 
Analysis 5.9.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and
sham stimulation or usual care (single), Outcome 9 Adverse events: death.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.9.1 At end of treatment  
Du 2005 0/30 0/30   Not estimable
Jiang 2014b 0/50 0/50   Not estimable
Liu 2015 0/30 0/30   Not estimable
Subtotal (95% CI) 110 110 Not estimable
Total events: 0 (Combination treatment), 0 (Single treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 110 110 Not estimable
Total events: 0 (Combination treatment), 0 (Single treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Combination treatment 1000.01 100.1 1 Favours Single treatment
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Analysis 5.10.   Comparison 5 Non-invasive brain stimulation and a pharmacological intervention (combination)
versus a pharmacological intervention and sham stimulation or usual care (single), Outcome 10 Adverse events: all.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.10.1 Other events - not listed above (e.g. insomnia, discomfort,
headaches)
 
Du 2005 0/30 0/30   Not estimable
Liu 2015 3/30 0/30 100% 7[0.38,129.93]
Subtotal (95% CI) 60 60 100% 7[0.38,129.93]
Total events: 3 (Combination treatment), 0 (Single treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
   
Total (95% CI) 60 60 100% 7[0.38,129.93]
Total events: 3 (Combination treatment), 0 (Single treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
Favours Combination treatment 5000.002 100.1 1 Favours Single treatment
 
 
Analysis 5.11.   Comparison 5 Non-invasive brain stimulation and a pharmacological
intervention (combination) versus a pharmacological intervention and sham stimulation or
usual care (single), Outcome 11 Adverse events: leaving the study early (including death).




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.11.1 All dropouts and withdrawals  
Du 2005 0/30 0/30   Not estimable
Jiang 2014b 0/50 0/50   Not estimable
Liu 2015 0/30 0/30   Not estimable
Lu 2016 4/40 3/40 100% 1.33[0.32,5.58]
Subtotal (95% CI) 150 150 100% 1.33[0.32,5.58]
Total events: 4 (Combination treatment), 3 (Single treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.69)  
   
Total (95% CI) 150 150 100% 1.33[0.32,5.58]
Total events: 4 (Combination treatment), 3 (Single treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.69)  
Favours Combination treatment 1000.01 100.1 1 Favours Single treatment
 
 
A D D I T I O N A L   T A B L E S
 
Study ID Methods Participants Interventions Out-
comes
Notes
Table 1.   Characteristics of 'dropout' studies 
Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression aer stroke (Review)





























Number of participants: 30
Stroke criteria: acute stroke
Method of stroke diagnosis: not re-
ported
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: not reported
Total number included in this trial:
unclear (63% men, mean age 72.2, SD
not reported for the overall cohort)
Number included in treatment
group: unclear
Number included in control group:
unclear









































Number of participants: 16
Stroke criteria: ischaemic strokes
Method of stroke diagnosis: diagnosis
confirmed by imaging
Inclusion criteria: not reported
Exclusion criteria: (1) history of men-
tal illness; (2) cognitive impairment;
(3) severe aphasia; (4) > 2 weeks post
stroke
Depression criteria: Chinese version
of HDRS score ≥ 35
Total number included in this trial:
16 (% men and age unknown)
Number included in treatment
group: 8
Number included in control group: 8
Treatment: REBT + usual care.
REBT counselling therapy (1 to 2
hour sessions/week) consisting of a
knowledge component (education
about health psychology and recov-
ery from hemiplegic stroke) and a
behavioural training component
(belief changes, forgiveness train-
ing, anger management)
Administered by: a trained psy-
chology graduate (regular care ad-
ministered by hospital nurses)
Supervision: unclear
















































Geographical location: South Korea
Setting: outpatients
Number of participants: 152
Stroke criteria: ischaemic stroke
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Method of stroke diagnosis: diagno-
sis via CT and MRI scans; interview per-
formed on average of 14 months after
stroke
Inclusion criteria: not reported
Exclusion criteria: (1) did not undergo
imaging (CT/MRI) studies; (2) SAH; (3)
had TIA without progression to stroke;
(4) severe communication problems
(aphasia, dementia, or dysarthria);
(5) scored < 23 on MMSE; (6) history of
depression or psychiatric illness be-
fore onset of stroke; (7) already treat-
ed with psychiatric regimens; (8) lived
alone
Depression criteria: psychiatric inter-
view, BDI score > 13
Total number included in this trial:
152
Number included in treatment
group: 76 (75% men, mean age 58
years, SD 9)
Number included in control group:










































+ 1 × 125
Geographical location: Iran
Setting: inpatient
Number of participants: 78
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: not re-
ported
Inclusion criteria: (1) only patients
with limb (arm or leg) paresis
Exclusion criteria: (1) unable to re-
spond or directly consent; (2) comor-
bidities requiring strict blood pressure
control and put at risk by the poten-
tial of hypertension from MPH therapy
(history of haemorrhagic stroke, recent
myocardial infarction within 4-week
period, decompensated cardiac insuf-
ficiency, tachycardia, uncontrolled hy-
pertension, unstable metabolic dis-
ease, glaucoma); (3) potential for ad-
verse outcomes from stimulant effects
of MPH, including seizure and agita-
tion major cognitive deficits prevent-
ing adequate study participation; (4)
currently taking alpha-adrenergic ag-
onists, antagonists, neuroleptics, ben-
zodiazepines, MAO inhibitors, or anti-
depressants; (5) known hypersensitivi-
ty to MPH or LD
Treatment A: 2 × 10 mg
methylphenidate + 125 mg placebo
(content unknown)
Treatment B: 1 × 12.5 mg levodopa
+ 2 × 10 mg placebo
Treatment C: 2 × 10 mg
methylphenidate + 1 × 125 mg lev-
odopa
Control: 2 × 10 mg placebo + 1 × 125
mg placebo
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mg place-
bo
Depression criteria: GDS < 7.8
Total number included in this trial:
78
Number included in Treatment A: 19
(47% men, mean age 64.05, SD 10.8)
Number included in Treatment B: 20
(70% men, mean age 66.3, SD 9.5)
Number included in Treatment C: 19
(58% men, 60.2, SD 9.1)
Number included in control group:

























Number of participants: 62
Stroke criteria: not reported
Method of stroke diagnosis: not re-
ported
Inclusion criteria: (1) lived at home;
(2) had an informal carer; (3) stroke
increase in mRS; (4) poststroke mRS
score of 2 to 5
Exclusion criteria: (1) not living at
home; (2) not having an informal carer;
(3) having no increase in disability or
change in lifestyle/dependency
Total number included in this trial:
62
Number included in treatment 1: 22
(50% men, age not reported)
Number included in treatment 2: 22
(55% men, age not reported)
Number included in control group:
18 (44% men, age not reported)
Treatment 1: information plus
counselling. Egan's problem-solving
approach, individual is helped to ex-
plore concerns, clarify problems, set
goals, and take appropriate action.
Protocol discussed first and formu-
lated into a counsellor/client con-
tract. Information pack containing
information on physical, cognitive,
behavioural, and emotional effects
of stroke, carer well-being, and local
services
Treatment 2: information only: in-
formation pack containing infor-
mation on physical, cognitive, be-
havioural, and emotional effects of
stroke, carer well-being, and local
services
Control: standard care, no visit(s) or
information pack provided
Duration: information session con-
sisted of 1 visit and provision of the
information pack. Counselling con-
sisted of up to 8 counselling ses-
sions over 4 to 6 months














































Stroke criteria: first-time diagnosis of
ischaemic stroke < 48 hours
Method of stroke diagnosis: not re-
ported
Inclusion criteria: (1) Mini-Cog score
of 3; ≥ 50 years of age; (2) able to read
and write in English
Exclusion criteria: (1) previous histo-
ry of mental health problems; (2) diag-
nosis of severe aphasia as identified by
Treatment: 1-on-1 problem-solv-
ing therapy sessions lasting 1 to 2
hours. Therapy entails providing
patient information on impact and
guidance to enable the patient to
identify and define the problem;
brainstorm all potential solutions;
select the most appropriate and
feasible solution; create and im-
plement a SMART (Specific, Mea-
sureable, Achievable, Realistic, and
Timely) goal; evaluate and review
progress in follow-up sessions
Administered by: a doctoral nurs-
ing student who received PST train-
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a speech pathologist; (3) haemorrhag-
ic stroke or transient ischaemic attack;
(4) medical instability requiring trans-
fer to critical care
Depression criteria: CES-D score mea-
sured at baseline but patients recruit-
ed regardless of their CES-D score. If
CES-D score > 10, or suicidal ideation,
the primary physician was notified
Total number included in this trial:
22
Number included in treatment
group: 11 (18% men, mean age 73)
Number included in control group:
11 (45% men, mean age 69)
gram adapted from standard 3-day
in-person training
Supervision: principal Investigator
who had undergone in-person PST
training
Intervention fidelity: not reported
Control: weekly telephone calls to
assess CES-D and FIM scores






















Number of participants: 20
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: clini-
cal diagnosis of ischaemic stroke con-
firmed by imaging
Inclusion criteria: not reported
Exclusion criteria: (1) haemorrhag-
ic stroke; (2) clinical evidence of de-
mentia MMSE scores < 23; (3) apha-
sia with severe language comprehen-
sion deficits; (4) alcohol or drug abuse
during past 12 months; (5) severe sys-
temic disease or ongoing neoplasia;
(6) neurodegenerative disorders such
as Parkinson's disease or Alzheimer's
disease; (7) contraindications to rTMS
including prior occurrence of induced
seizures; major head trauma; or his-
tory of idiopathic epilepsy; presence
of metal in the skull, cranial cavity, or
brain parenchyma; cardiac pacemaker,
implanted defibrillator, or intracardiac
lines
Depression criteria: psychiatric di-
agnosis (i.e. depression due to stroke
with major depressive-like episode or
research criteria for minor depression)
was made using symptoms elicited by
a version of the Present State Examina-
tion modified to identify DSM-IV symp-
toms of depression and anxiety dis-
order; evidence that depression was
unresponsive to at least 2 treatments
with antidepressants given in ade-
quate doses; clear clinical indication
Treatment: rTMS delivered over the
le( pre-frontal cortex at frequen-
cy of 10 Hz, intensity of 110% of the
motor threshold, duration of 5 sec-
onds, and total of 20 trains separat-
ed by 60-second pauses. Cumulative
rTMS exposure for the 10-Hz stim-
uli was 5 seconds × 20 per session ×
10 sessions × 1000 seconds of cumu-
lative exposure or a total of 10,000
magnetic pulses
Control: sham stimulation: similar
stimulation parameters to the rTMS
stated but with the coil angled oN
the head, to produce a 67% to 73%
reduction in the magnetic field
Administered by: investigators at
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of a significant change in the course or
severity of depressive disorder after
stroke
Total number included in this trial:
20
Number included in treatment
group: 10 (60% men; mean age 63.1,
SD 8.1)
Number included in control group:

















































Number of participants: unclear
Stroke criteria: not an entry criteria.
Includes patients with clinical diagno-
sis of vascular depression
Inclusion criteria: not reported
Exclusion criteria: (1) presence of se-
vere heart or respiratory failure or re-
nal or hepatic failure, or occurrence of
ongoing neoplastic process; (2) neu-
rodegenerative disorders such as idio-
pathic Parkinson's disease or proba-
ble Alzheimer's disease and clinical ev-
idence of dementia (Clinical Dementia
Rating Scale score 0.5); (3) depressed
patients who were actively suicidal,
who presented with prominent psy-
chotic features, or with comorbid al-
cohol or other drug abuse that was ac-
tive within 2 years before the study; (4)
prior occurrence of induced seizures,
major head trauma, and history of
epilepsy; (5) metal in the skull, cranial
cavity, or brain parenchyma; cardiac
pacemaker, implanted defibrillator, or
medication pump
Depression criteria: diagnosis of ma-
jor depression during current depres-
sive episode
Total number included in this trial:
number of stroke patients unclear
Treatment A: 10 rTMS sessions in
the le( DLPFC at frequency of 10 Hz
and intensity of 110% of the motor
threshold during a 6-second period,
with a total of 20 trains separated
by 1-minute pauses. Treatment was
administered during a 10-day pe-
riod for a TCD of 12,000 pulses (i.e.
TCD-12K group)
Treatment B: 15 rTMS sessions in
the le( pre-frontal cortex at fre-
quency of 10 Hz and intensity of
110% of the motor threshold during
a 6-second period, with a total of 20
trains separated by 1-minute paus-
es. Treatment was administered
during a 10-day period with 2 ses-
sions per day for 5 days to achieve
a TCD of 18,000 pulses (i.e. TCD-18K
group)
Control A: 10 sham stimulation ses-
sions with matched pulses but per-
formed with a specially designed
coil that looks exactly like the stan-
dard stimulating coil but produces
scalp sensation without actual corti-
cal stimulation
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Number included in treatment
group: number of stroke patients un-
clear
Number included in control group:
number of stroke patients unclear













Geographical location: South Korea
Setting: unclear
Number of participants: 478
Stroke criteria: ischaemic stroke or in-
tracerebral haemorrhage
Method of diagnosis: diagnosis con-
firmed by MRI or CT
Inclusion criteria: (1) acute ischaemic
stroke or intracerebral haemorrhage
within previous 21 days
Exclusion criteria: (1) history of diag-
nosed depression or other psychiatric
diseases before index stroke; (2) severe
dementia, defined as requiring assis-
tance from others to maintain activ-
ities of daily living because of cogni-
tive dysfunction (stages 5 to 7 of the
Global Deterioration Scale); (3) apha-
sia resulting in communication diffi-
culties regardless of reasons; (4) ex-
hibiting strong suicidal thoughts (com-
bined MADRS score > 8 on ninth and
tenth questions); (5) seizures; (6) histo-
ry of other brain disease or head trau-
ma within 30 days before screening; (7)
abnormal blood tests such as abnor-
mal liver function test or renal insuffi-
ciency; (8) pregnant or lactating
Depression criteria: none
Total number included in this trial:
478
Number included in treatment
group: 241 (57% men, mean age 63.6,
SD 12.6)
Number included in control group:
237 (65% men, mean age 63.5, SD 12.0)
Treatment: escitalopram (5 mg
daily as a starting dose, dose in-
creased to 10 mg daily from the sec-































































Georgraphical location: South Korea
Setting: inpatient
Number of participants: 44
Stroke criteria: right hemisphere is-
chaemic or haemorrhagic stroke
Method of stroke diagnosis: unclear
Treatment: rTMS. rTMS stimulus
was targeted at P3, over the le(
parieto-occipital cortex, and at P4,
over the right parieto-occipital cor-
tex. To set the motor threshold be-
fore stimulation, a cotton cap with
a grid (1 × 1 cm2) was fixed to the
scalp from the nasion to the inion,
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Inclusion criteria: (1) diagnosis of
right hemisphere ischaemic or haem-
orrhagic stroke
Exclusion criteria: (1) severe cognitive
impairment that made it difficult to
understand instructions; (2) seizures;
(3) severe head trauma; (4) metal skull
implant; (5) pacemaker
Depression criteria: none
Total number included in this trial:
44
Number included in treatment
group: 22 (82% men, mean age 52.6,
SD 10.6)
Number included in control group:
22 (59% men, mean age 64.3, SD 11.5)
the cranium, and motor-evoked po-
tentials were measured. Low-fre-
quency rTMS stimulation was ap-
plied to P3 on the le(, healthy side,
using a 1-Hz stimulus at 90% motor
threshold, 4 times, for 5 minutes at
a time, separated by 1-minute in-
tervals. High-frequency rTMS was
applied to P4 on the right, affected
side, using a 5-Hz stimulus at 90%
motor threshold, 20 times, for 5 sec-
onds at a time, separated by 55-sec-
ond intervals
Control: sham rTMS. Mock stimu-
lus used the same protocol as low-
frequency rTMS, except that the coil
was not placed against the skull,
































Geographical location: The Nether-
lands
Setting: outpatient
Number of participants: 61
Stroke criteria: all subtypes
Method of stroke diagnosis: clinically
confirmed stroke
Inclusion criteria: (1) sustained any
type of clinically confirmed stroke at
least 3 months earlier; (2) only mild
cognitive impairment (MMSE score);
(3) scoring positively on communica-
tion-related items of NIHSS; (4) master
Dutch language
Exclusion criteria: (1) pre-stroke ma-
jor depression requiring psychiatric
care; (2) poststroke major depression
requiring a start with medication; (3)
pre-morbid disability as reflected in a
BI score < 19 (out of 20); (4) severe co-
morbidity that might affect mood (e.g.
cancer)
Depression criteria: HADS score > 7
Total number included in this trial:
61
Number included in treatment
group: 31 (61.3% men, mean age 61,
SD not reported)
Treatment: tailored cognitive-be-
havioural therapy. Each session
consisted of 2 × 20 to 25-minute
blocks divided by a 10 to 15-minute
break. Therefore, each session last-
ed approximately 1 hour. Goals for
attaining daily life activities were
primarily set together by the patient
and the therapist using pictures
from the Activity Card Sort. Concur-
rently with psychological sessions,
the CBT intervention was augment-
ed with 3 sessions of occupational
therapy or movement therapy. Dur-
ing these sessions, an occupational
or movement therapist helped pa-
tients in establishing and attaining
goals aimed at meaningful activi-
ties and social participation. These
goals were attuned to the content of
the psychological sessions
Administered by: certified health-
care psychologist (therapist)
Supervision: not reported
Intervention fidelity: not reported
Control: computer cognitive train-
ing. A desktop was set up with
headphones and a keyboard with
coloured patches attached to 2
keys. Patients could select any (or
a combination) of 4 specific cogni-
tive domains for training (i.e. atten-
tion, memory, executive function-
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Number included in control group:
30 (63.3%, mean age 61, SD not report-
ed)
improved, the Cogniplus Program
adjusted the level of difficulty for
each training task accordingly. In
this way, each patient trained at his/
her individual level and pace
Administered by: self-adminis-
tered, but cognitive trainers or psy-
chological assistants were present




















Number of participants: unclear
Stroke criteria: ischaemic stroke
Method of diagnosis: unclear
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: GDS (15 item)
score > 4
Total number included in this trial:
unclear
Number included in treatment
group: unclear






































Number of participants: unclear
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: unclear
Inclusion criteria: not reported
Exclusion criteria: (1) moderate to
severe dementia; (2) severe aphasia,
communication difficulties; (3) poorly
controlled epilepsy
Depression criteria: GDS (15 item)
score > 4
Total number included in this trial:
unclear
Number included in treatment: un-
clear
Number included in control group:
unclear
Treatment: sertraline, 50 mg daily.
Dose escalation to 100 mg for non-
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Number of participants: 188
Stroke criteria: all subtypes
Method of stroke diagnosis: diagnosis
via clinical signs and CT
Inclusion criteria: (1) > 40 years of
age, high blood pressure (> 160/90
mmHg), and hypertensive changes on
fundoscopy changes; (2) stable neu-
roleptic, minor tranquilliser, antide-
pressant, brain metabolic activators,
cerebro-vasodilators washed out for 3
to 7 days before randomisation
Exclusion criteria: (1) severe aphasia;
(2) severe dementia; (3) drug depen-
dence; (4) inadequate conditions for
the study
Depression criteria: not reported
Total number included in this trial:
288
Number included in treatment
group: 141 (54% men, mean age not
reported)
Number included in control group:
147 (61% men, mean age not reported)
Treatment: tiapride, 75 mg daily for
1 week, dose escalation to 150 to











































Number of participants: 159
Stroke criteria: not reported
Method of stroke diagnosis: not re-
ported
Inclusion criteria: not reported
Exclusion criteria: (1) history of psy-
chopathology for patient or caregiver;
(2) globally aphasic preventing com-
munication and consent; (3) patient or
caregiver has comorbidity that would
take priority over stroke rehabilitation;
(4) life expectancy < 6 months
Depression criteria: depression not
an entry criterion
Total number included in this trial:
159
Number included in treatment
group: 80 (69% men, mean age 66.98,
SD 9.04)
Treatment: home visits from a mul-
ti-disciplinary therapy team to pro-
vide education, support, skill train-
ing, counselling, and linkages to
social and community resources +
mailed information. Average dose
36.7 hours
Administered by: advanced prac-
tice nurses, occupational and physi-
cal therapists
Supervision: not reported
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Number included in control group:


















Number of participants: 22
Stroke criteria: unclear
Method of stroke diagnosis: not re-
ported
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: ZDS
Total number included in this trial:
22
Number included in treatment
group: 11 (45.4% men, mean age 69.5,
SD 2.3)
Number included in control group:
11 (72.7% men, mean age 70.4, SD 3.0)
Treatment: trazodone 300 mg/d
Control: placebo

















































Stroke criteria: infarction and haem-
orrhage
Method of stroke diagnosis: not re-
ported
Inclusion criteria: (1) acute stroke
within 6 months of onset of the study;
(2) taking antidepressants other than
fluoxetine at the time of enrolment
and allowed to stop antidepressants
for a 2-week washout period before
the study; (3) patient's immediate fam-
ily and treating physician agree to the
patient’s participation
Exclusion criteria: (1) severe compre-
hension
deficit that precluded a verbal inter-
view (defined as failing part 1 of the
Token Test); (2) any other significant
medical illness that would threaten life
or recovery from stroke; (3) prior his-
tory of head injury; (4) prior history of
other brain disease with the exception
of prior stroke
Treatment 1: nortriptyline (SN-
RI). Doses of 25 mg/d gradually in-
creased to 100 mg/d
Treatment 2: fluoxetine (SSRI). Dos-
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Depression criteria: DSM-IV and HDRS
Total number included in this trial:
unclear
Number included in treatment group
1: unclear (74% men, mean age 65, SD
14)
Number included in treatment group
2: unclear (31% men, mean age 64, SD
10)
Number included in control group:
























Number of participants: 60
Stroke criteria: all ischaemic and
haemorrhagic strokes
Method of stroke diagnosis: diagnosis
consistent with diagnostic criteria for
stroke reported in Chinese Journal of
Neurology and Psychiatry in 1988 and
confirmation by brain CT or MRI
Inclusion criteria: not reported
Exclusion criteria: (1) severe cognitive
impairment; (2) obvious consciousness
disturbance
Depression criteria: none
Total number included in this trial:
60
Number included in treatment
group: 30 (60% men, mean age 56.5,
SD 13.4, 53.3% ischaemic)
Number included in control group:
30 (63% men, 55.9, SD 14.3, 56.7% is-
chaemic)
Treatment: add-on psychothera-
py entailing understanding the pa-
tient's reaction to sudden illness
and letting the patient talk about
concerns in mind, to give sympathy,
care, and support; inducing correct
understanding of the illness by the
patient, helping him/her to analyse
current problems and building con-
fidence to overcome the disease;
promoting the family’s help and co-
operation; giving praise, encourage-
ment, or small prizes for patient im-
provement
Administered by: not reported
Supervision: not reported



































Number of participants: 48
Stroke criteria: ischaemic and PICH
stroke
Method of stroke diagnosis: diagnosis
was confirmed with brain CT or MRI
Inclusion criteria: (1) aged 30 to 60
years; (2) first stroke only; (3) time
since stroke < 5 years
Treatment: active tDCS. 12 times of
30-minute sessions of 2 mA anodal
le(/cathodal right dorsolateral pre-
frontal tDCS administered (once dai-
ly on weekdays for 2 weeks, then 1
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sham tD-
CS
Exclusion criteria: (1) on antide-
pressants, antipsychotics, benzodi-
azepines, or diazepam; (2) dementia
and epilepsy, life-threatening condi-
tion, suicide risk (score ≤ 2 on third
item HDRS)
Depression criteria: depression diag-
nosed by a trained psychiatrist with
the MINI for DSM-IV psychiatric disor-
ders
Total number included in this trial:
48
Number included in treatment
group: 24 (50% men, mean age 62.2,
SD not reported)
Number included in control group:
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BDI: Beck Depression Inventory.
BI: Barthel Index.
CES-D: Centre for Epidemiologic Studies Depression Scale.
CT: computed tomography.
DLPFC: dorsolateral pre-frontal cortex.
DSM- IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
ECT: electroconvulsive therapy.
EQ5D: EuroQoL 5-dimension.
FIM: Functional Independence Measure.
GDS: Geriatric Depression Scale.
HADS: Hospital Anxiety and Depression Scale.
HARS: Hamilton Anxiety Rating Scale.
HDRS: Hamilton Depression Rating Scale.
Hz: hertz.
LD: levodopa.
MADRS: Montgomery Asberg Depression Rating Scale.
MAO: monoamine oxidase.
MINI: Mini-International Neuropsychiatry Interview.
MMSE: Mini Mental State Examination.
MPH: methylphenidate.
MRI: magnetic resonance imaging.
mRS: modified Rankin Scale.
NIHSS: National Institute of Health Stroke Scale.
PICH: primary intracerebral haemorrhage.
PHQ-9: 9-item Patient Health Questionnaire.




SNRI: selective nortriptyline reuptake inhibitor.
SSRI: selective serotonin reuptake inhibitor.
TIA: transient ischaemic attack.
tDCS: transcranial direct current stimulation.
ZDS: Zung Depression Scale.
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A P P E N D I C E S
Appendix 1. Search review - 2008
Electronic searches
Cochrane Stroke Trial Register - searched October 2007; Cochrane Anxiety and Neurosis Trial Register - searched February 2008.
The remaining databases were searched May 2006.





• Applied Science and Technology Plus
• Arts and Humanities Index
• Biological Abstracts
• BIOSIS Previews
• General Science Plus
• Science Citation Index
• Social Sciences Citation Index
• ISI Web of Science
• Dissertations and Theses
The following search strategy with a combination of controlled vocabulary and free-text terms for MEDLINE and CINAHL (Ovid), and
modified to suit the other databases.
1 exp cerebrovascular disorders/
2 (stroke$ or poststroke$ or cva$).tw.
3 (cerebrovascular$ or cerebral vascular).tw.
4 (cerebral or cerebellar or brain$ or vertebrobasilar).tw.
5 (infarct$ or isch?emi$ or thrombo$ or emboli$ or apoplexy).tw.
6 (cerebral or intracerebral or intracranial or brain$).tw.
7 (haemorrhage or hemorrhage or bleed$).tw.
8 4 and 5
9 6 and 7
10 1 or 2 or 3 or 8 or 9
11 Depression/
12 Depression, involutional/ or Depressive disorder/ or Dysthymic disorder/
13 (depress$ or dysthymi$).tw.
14 11 or 12 or 13
15 10 and 14
16 randomized controlled trial.pt.
17 randomized controlled trials/
18 controlled clinical trial.pt.





24 exp clinical trials/
25 (clin$ adj25 trial$).tw.
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31 clinical trial phase ii.pt.
32 clinical trial phase iii.pt.













46 (versus or sham or intervention group or comparative stud$).tw.
47 or/16-46
48 15 and 47
49 limit 48 to human
Additional searches
The following conference abstracts and proceedings were searched.
• European Stroke Conferences (2000 to 2007)
• Stroke Society of Australasia Annual Scientific Meetings (1999 to 2007)






Reference lists of relevant studies were searched to identify studies not already included.
Personal communication
Professional bodies, authors of included studies, and pharmaceutical companies were contacted for information on published and
unpublished information.
Appendix 2. Search review 2018 - CENTRAL
Search strategy for CENTRAL, August 2018
 
# Query
#1 [mh ^"cerebrovascular disorders"] or [mh "basal ganglia cerebrovascular disease"] or [mh "brain
ischemia"] or [mh "carotid artery diseases"] or [mh "intracranial arterial diseases"] or [mh "in-
tracranial embolism and thrombosis"] or [mh "intracranial hemorrhages"] or [mh ^stroke] or [mh
"brain infarction"] or [mh ^"stroke, lacunar"] or [mh ^"vasospasm, intracranial"] or [mh ^"vertebral
artery dissection"]
#2 stroke or poststroke or "post-stroke" or cerebrovasc* or brain next vasc* or cerebral next vasc* or
cva* or apoplex* or SAH:ti,ab,kw (Word variations have been searched)
#3 (brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch*emi* or infarct* or throm-
bo* or emboli* or occlus*):ti,ab,kw (Word variations have been searched)
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#4 (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemor-
rhage* or hemorrhage* or haematoma* or hematoma* or bleed*):ti,ab,kw (Word variations have
been searched)
#5 [mh hemiplegia] or [mh paresis]
#6 hemipleg* or hemipar* or paresis or paretic:ti,ab,kw (Word variations have been searched)
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 [mh ^"depressive disorder"] or [mh ^"depressive disorder, major"] or [mh ^"depressive disorder,
treatment-resistant"] or [mh ^"dysthymic disorder"] or [mh ^depression] or [mh "antidepressive
agents"]
#9 depress* or dysthymi*or dysphor*or antidepress*or anti-depress*:ti,ab,kw (Word variations have
been searched)
#10 #8 or #9
#11 #7 and #10
  (Continued)
 
Appendix 3. Search review 2018 - MEDLINE
Search strategy for MEDLINE, August 2018
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or stroke/ or exp brain
infarction/ or stroke, lacunar/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. depressive disorder/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or Depression/
or exp Antidepressive Agents/
9. (depress$ or dysthymi$ or dysphor$ or antidepress$ or anti-depress$).tw.
10. 8 or 9
11. Randomized Controlled Trials as Topic/
12. random allocation/
13. Controlled Clinical Trials as Topic/
14. control groups/
15. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical









24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
27. (random$ or RCT or RCTs).tw.
28. (controlled adj5 (trial$ or stud$)).tw.
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29. (clinical$ adj5 trial$).tw.
30. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
31. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
32. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
33. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
34. (cross-over or cross over or crossover).tw.
35. (placebo$ or sham).tw.
36. trial.ti.
37. (assign$ or allocat$).tw.
38. or/11-37
39. 7 and 10 and 38
40. exp animals/ not humans.sh.
41. 39 not 40
Appendix 4. Search review 2018 - Embase
Search strategy for Embase, August 2018
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/ or
exp brain ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp intracranial aneurysm/
or exp occlusive cerebrovascular disease/
2. stroke patient/ or stroke unit/
3. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
5. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
6. hemiparesis/ or hemiplegia/
7. (hemipleg$ or hemipar$ or paresis or paretic).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. depression/ or agitated depression/ or atypical depression/ or dysphoria/ or dysthymia/ or endogenous depression/ or involutional
depression/ or late life depression/ or major depression/ or masked depression/ or reactive depression/ or recurrent brief depression/ or
treatment resistant depression/
10. exp antidepressant agent/
11. (depress$ or dysthymi$ or dysphor$ or antidepress$ or anti-depress$).tw.
12. 9 or 10 or 11
13. Randomized Controlled Trial/ or "randomized controlled trial (topic)"/
14. Randomization/
15. Controlled clinical trial/ or "controlled clinical trial (topic)"/
16. control group/ or controlled study/
17. clinical trial/ or "clinical trial (topic)"/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
18. Crossover Procedure/
19. Double Blind Procedure/
20. Single Blind Procedure/ or triple blind procedure/
21. placebo/ or placebo eNect/
22. (random$ or RCT or RCTs).tw.
23. (controlled adj5 (trial$ or stud$)).tw.
24. (clinical$ adj5 trial$).tw.
25. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
26. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
27. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
28. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
29. (cross-over or cross over or crossover).tw.
30. (placebo$ or sham).tw.
31. trial.ti.
32. (assign$ or allocat$).tw.
33. or/13-32
34. 8 and 12 and 33
35. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not (human/
or normal human/ or human cell/)
36. 34 not 35
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Appendix 5. Search review 2018 - PsycINFO
Search strategy for PsycINFO, August 2018
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular
accidents/ or subarachnoid hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. major depression/ or dysthymic disorder/ or endogenous depression/ or reactive depression/ or recurrent depression/ or treatment
resistant depression/ or atypical depression/ or "depression (emotion)"/
9. exp antidepressant drugs/
10. (depress$ or dysthymi$ or dysphor$ or antidepress$ or anti-depress$).tw.
11. 8 or 9 or 10
12. clinical trials/ or treatment eNectiveness evaluation/ or placebo/
13. treatment outcome clinical trial.md.
14. (random$ or RCT or RCTs).tw.
15. (controlled adj5 (trial$ or stud$)).tw.
16. (clinical$ adj5 trial$).tw.
17. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
18. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
19. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
20. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
21. (cross-over or cross over or crossover).tw.
22. (placebo$ or sham).tw.
23. trial.ti.
24. (assign$ or allocat$).tw.
25. or/12-24
26. 7 and 11 and 25
Appendix 6. Search review 2018 - CINAHL
Search strategy for CINAHL, August 2018
 
# Query
S1 (MH "Cerebrovascular Disorders") OR (MH "Basal Ganglia Cerebrovascular Disease+") OR (MH
"Carotid Artery Diseases+") OR (MH "Cerebral Ischemia+") OR (MH "Cerebral Vasospasm") OR (MH
"Intracranial Arterial Diseases+") OR (MH "Intracranial Embolism and Thrombosis") OR (MH "In-
tracranial Hemorrhage+") OR (MH "Stroke") OR (MH "Vertebral Artery Dissections")
S2 (MH "Stroke Patients") OR (MH "Stroke Units")
S3 TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or
apoplex or SAH ) or AB ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cere-
bral vasc or cva or apoplex or SAH )
S4 TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cere-
bell* or intracran* or intracerebral )
S5 TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or ischae-
mi* or infarct* or thrombo* or emboli* or occlus* )
S6 S4 and S5
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S7 TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid ) or AB ( brain* or
cerebr* or cerebell* or intracerebral or intracranial or subarachnoid )
S8 TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemor-
rhage* or hemorrhage* or haematoma* or hematoma* or bleed* )
S9 S7 and S8
S10 (MH "Hemiplegia")
S11 TI ( hemipleg* or hemipar* or paresis or paretic ) or AB ( hemipleg* or hemipar* or paresis or paret-
ic )
S12 S1 or S2 or S3 or S6 or S9 or S10 or S11
S13 (MH "Depression") OR (MH "Depression, Reactive") OR (MH "Dysthymic Disorder")
S14 (MH "Antidepressive Agents+")
S15 TI ( depress* or dysthymi*or dysphor*or antidepress*or anti-depress* ) OR AB ( depress* or dysthy-
mi*or dysphor*or antidepress*or anti-depress* )
S16 S13 OR S14 OR S15
S17 (MH "Randomized Controlled Trials") or (MH "Random Assignment") or (MH "Random Sample+")
S18 (MH "Clinical Trials") or (MH "Intervention Trials") or (MH "Therapeutic Trials")
S19 (MH "Double-Blind Studies") or (MH "Single-Blind Studies") or (MH "Triple-Blind Studies")
S20 (MH "Control (Research)") or (MH "Control Group") or (MH "Placebos") or (MH "Placebo Effect")
S21 (MH "Crossover Design") OR (MH "Quasi-Experimental Studies")
S22 PT (clinical trial or randomized controlled trial)
S23 TI (random* or RCT or RCTs) or AB (random* or RCT or RCTs)
S24 TI (controlled N5 (trial* or stud*)) or AB (controlled N5 (trial* or stud*))
S25 TI (clinical* N5 trial*) or AB (clinical* N5 trial*)
S26 TI ((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*)) or AB
((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*))
S27 TI ((control or experiment* or conservative) N5 (treatment or therapy or procedure or manage*)) or
AB ((control or experiment* or conservative) N5 (treatment or therapy or procedure or manage*))
S28 TI ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*)) or AB ((singl* or doubl* or tripl* or tre-
bl*) N5 (blind* or mask*))
S29 TI (cross-over or cross over or crossover) or AB (cross-over or cross over or crossover)
S30 TI (placebo* or sham) or AB (placebo* or sham)
S31 TI trial
  (Continued)
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S32 TI (assign* or allocat*) or AB (assign* or allocat*)
S33 TI controls or AB controls
S34 TI (quasi-random* or quasi random* or pseudo-random* or pseudo random*) or AB (quasi-ran-
dom* or quasi random* or pseudo-random* or pseudo random*)
S35 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR
S30 OR S31 OR S32 OR S33 OR S34 S36 .S12 AND S16 AND S35
S36 S6 AND S16 AND S35
  (Continued)
 
Appendix 7. Search review 2018 - Web of Science
Search strategy for Web of Science, August 2018
The following indexes Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), and Arts &
Humanities Citation Index (A&HCI) within Web of Science were searched from January 2002 to August 2018.
 
# Query
#1 TS=(stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or
apoplex* or SAH)
#2 TS=((brain* or cerebr* or cerebell* or intracran* or intracerebral) NEAR/5 (isch*emi* or infarct* or
thrombo* or emboli* or occlus*))
#3 TS=((brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) NEAR/5 (haem-
orrhage* or hemorrhage* or haematoma* or hematoma* or bleed*))
#4 TS=(hemipleg* or hemipar* or paresis or paretic or hemineglect or hemi-neglect)
#5 TS=((unilateral or spatial or hemi*spatial or visual) NEAR/5 neglect)
#6 #5 OR #4 OR #3 OR #2 OR #1
#7 TS=(depress* or dysthymi*or dysphor*or antidepress*or anti-depress*)
#8 TS=(random* or RCT or RCTs)
#9 TS=(controlled NEAR/5 (trial* or stud*))
#10 TS=(clinical* NEAR/5 trial*)
#11 TS=((control or treatment or experiment* or intervention) NEAR/5 (group* or subject* or patient*))
#12 TS=(quasi-random* or quasi random* or pseudo-random* or pseudo random*)
#13 TS=((control or experiment* or conservative) NEAR/5 (treatment or therapy or procedure or man-
age*))
#14 TS=((singl* or doubl* or tripl* or trebl*) NEAR/5 (blind* or mask*))
#15 TS=(cross-over or cross over or crossover)
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#16 TS=(placebo* or sham)
#17 TI=trial
#18 TS=(assign* or allocat*)
#19 TS=controls
#20 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 or #19
#21 #6 AND #7 AND #20
  (Continued)
 
Appendix 8. Search review 2018 - other sources
Additional searches
The following conference abstracts and proceedings were searched.
1. European Stroke Conference (2011- 2018)
2. Stroke Society of Australasia Annual Scientific Meetings (2011- 2017)
3. World Stroke Congress (2000-2016)
4. Asia Pacific Stroke Conference (2011-2017)
Online clinical trials and research registers were also searched August 2018.
• www.ClinicalTrials.gov (https://clinicaltrials.gov/)
(depression OR low mood) AND (Brain Infarction OR Intracranial Hemorrhages OR Carotid Artery Diseases OR Brain Ischemia OR Cerebral
Hemorrhage OR Cerebrovascular Disorders OR Stroke)
• WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/search/en/)
Condition: stroke AND depression OR low mood
Recruitment status is: ALL
Phases are: ALL
Hide synonyms
- 9-52 DEPRESSIVE DISORDERS, BEREAVEMENT, DEPRESSED, DEPRESSED - SYMPTOM, DEPRESSED MOOD, DEPRESSED MOOD (FINDING),
DEPRESSED MOOD (PHYSICAL FINDING), DEPRESSED STATE, DEPRESSIVE DIS, DEPRESSIVE DISORDER, DEPRESSIVE DISORDER
(DISORDER), DEPRESSIVE DISORDER [DISEASE/FINDING], DEPRESSIVE DISORDER NOS, DEPRESSIVE DISORDER, NOS, DEPRESSIVE
DISORDERS, DEPRESSIVE DISORDERS NOS, DEPRESSIVE ILLNESS, DEPRESSIVE NEUROSES, DEPRESSIVE NEUROSIS, DEPRESSIVE
STATE, DEPRESSIVE STATE NOS, DEPRESSIVE; DISORDER, DEPRESSIVE; NEUROSIS, DEPRESSIVE; STATE, DISORDER, DEPRESSIVE,
DISORDER; DEPRESSIVE, DISORDERS, DEPRESSIVE, DYSTHYMIC DISORDER, FEELING BLUE, FEELING DOWN, FEELING;DOWN, LOW
MOOD, MELANCHOLY, MISERABLE, MOOD DEPRESSED, MOOD DISORDER OF DEPRESSED TYPE, MOOD DISORDER OF DEPRESSED TYPE
(DISORDER), MOROSE MOOD, NEUROSES, DEPRESSIVE, NEUROSIS, DEPRESSIVE, NEUROSIS; DEPRESSIVE, PUSH DOWN OR DEPRESS,
STATE; DEPRESSIVE, depression - DEPRESSED, DEPRESSED MOOD, DEPRESSED MOOD (FINDING), DEPRESSED MOOD (PHYSICAL
FINDING), FEELING BLUE, FEELING DOWN, FEELING;DOWN, MELANCHOLY, MOOD DEPRESSED, MOOD DEPRESSION, MOOD DEPRESSIONS,
MOROSE MOOD, low mood - ACCIDENT CEREBROVASCULAR, ACCIDENT; CEREBRAL, ACCIDENT; CEREBROVASCULAR, APOPLEXY,
APOPLEXY, CEREBROVASCULAR, APOPLEXY; CEREBRAL, BRAIN ATTACK, BRAIN VASCULAR ACCIDENT, BRAIN VASCULAR ACCIDENTS,
CEREBRAL VASCULAR ACCIDENT, CEREBRAL VASCULAR EVENTS, CEREBRAL; ACCIDENT, CEREBRAL; APOPLEXY, CEREBROVASCULAR
ACCIDENT, CEREBROVASCULAR ACCIDENT (DISORDER), CEREBROVASCULAR ACCIDENT NOS, CEREBROVASCULAR ACCIDENT, NOS,
CEREBROVASCULAR ACCIDENTS, CEREBROVASCULAR APOPLEXY, CEREBROVASCULAR; ACCIDENT, CVA, CVA (CEREBRAL VASCULAR
ACCIDENT), CVA (CEREBROVASCULAR ACCIDENT), CVA NOS, CVAS (CEREBROVASCULAR ACCIDENT), NEURO: CEREBROVASCULAR
ACCIDENT, VASCULAR ACCIDENT, BRAIN, VASCULAR ACCIDENTS, BRAIN, stroke
W H A T ' S   N E W
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Date Event Description
13 August 2018 New search has been performed New interventions are included: combination psychological and
pharmacological interventions vs a single intervention, and non-
invasive brain stimulation interventions
Thirty-three new trials (39 comparisons) with 2753 participants
are included in the review. A total of 49 trials (56 comparisons)
with 3342 participants are included in the review. Data were
available for 20 pharmacological comparisons, 8 non-invasive
brain stimulation comparisons, 16 psychological therapy com-
parisons, and 12 combination therapy trials
Covidence was used to collate and screen identified titles and
abstracts
MH extracted additional data from previously included trials
Searches for the review were completed to 13 August 2018
13 August 2018 New citation required and conclusions
have changed
New data are included. New authors are included
 
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 3, 2004
 
Date Event Description
28 March 2008 Amended Review was converted to new review format
14 March 2008 New search has been performed Searches for the review were completed to February 2008
Seven new trials have been added: 6 pharmacological interven-
tions, making a total of 13, and 2 psychological interventions,
making a total of 4 comparisons. A total of 16 trials with 1655
participants are now included
Eight trials require more information before they can be as-
sessed for inclusion in the review (down from 14 in the previous
version). Nine trials appear to meet the review inclusion criteria,
but information is not available in a format suitable for pooling.
Three studies are ongoing (up from 0 in the previous version)
14 March 2008 New citation required and conclusions
have changed
This version of the review found a small but significant effect of
pharmacotherapy (not psychotherapy) on treating depression
and reducing depressive symptoms in stroke patients
There has been a change in authorship
 
C O N T R I B U T I O N S   O F   A U T H O R S
SA: contributed to writing the review, completed title screening and inclusion/exclusion review, extracted data, performed meta-analyses
and GRADE assessment.
KC: completed title screening and inclusion/exclusion review and data extraction.
CFH: assisted with obtaining, translating, and extracting data from Chinese studies for the current updated review.
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HL: completed title screening and cross-checked data extraction.
AH: conceived the idea for the review; contributed to development, writing, and editing of the protocol; and undertook the work necessary
to complete the 2004 and 2008 reviews.
MH: contributed to development, writing, and editing of the protocol; undertook the work necessary to complete the 2004 and 2008
reviews; and oversaw each version of the review updates.
All review authors read and edited this update.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In this update, the review was expanded to include other non-invasive brain stimulation interventions such as (1) transcranial magnetic
stimulation or repetitive transcranial magnetic stimulation (TMS or rTMS, where a magnetic 'coil' is placed near the head of the person
receiving treatment without making physical contact); (2) transcranial direct current stimulation (tDCS, where a constant, low current is
delivered directly to the brain area of interest via small electrodes); (3) cranial electrotherapy stimulation (CES, where a small, pulsed
electrical current is applied across a patient's head); and (4) magnetic seizure therapy (MST), a type of convulsive therapy that involves
replacing the electrical stimulation used in ECT with a rapidly alternating strong magnetic stimulation; and (5) combinations of all included
interventions compared with a single intervention plus a respective control.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents  [adverse eNects]  [therapeutic use];  Anxiety  [chemically induced];  Depression  [*therapy];  Psychotherapy; 
Randomized Controlled Trials as Topic;  Stroke  [*psychology]
MeSH check words
Humans
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